



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number: WO 99/14235 (43) International Publication Date: 25 March 1999 (25.03.99)
C07K 14/475, 16/26, C12N 15/18, 15/85, 15/63, C07H 21/00, A61K 38/18, 48/00, C12Q 1/68, G01N 33/53, C12P 19/34		
(21) International Application Number: PCT/US98/19163		Alto, CA 94301 (US). DeSAUVAGE, Fred [BE/US]; 166 Beach Park Boulevard, Foster City, CA 94404 (US).
(22) International Filing Date: 15 September 1998 (15.09.98)		
(30) Priority Data: 08/931,858 16 September 1997 (16.09.97) US		(74) Agents: HOLLAND, Donald, R. et al.; Howell & Haferkamp, L.C., Suite 1400, 7733 Forsyth Boulevard, St. Louis, MO 63105-1817 (US).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/931,858 (CON) Filed on 16 September 1997 (16.09.97)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US).		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): JOHNSON, Eugene, M. [US/US]; 13233 Amiot Drive, St. Louis, MO 63146 (US). MILBRANDT, Jeffrey, D. [US/US]; 75 Aberdeen Place, St. Louis, MO 63105 (US). KOTZBAUER, Paul, T. [US/US]; 17 Bishops Drive, Aston, PA 19014 (US). LAMPE, Patricia, A. [US/US]; 10323 Grant Forest Lane, St. Louis, MO 63123 (US). KLEIN, Robert [US/US]; 1044 Webster Street, Palo		
(54) Title: PERSEPHIN AND RELATED GROWTH FACTORS		
(57) Abstract		
		<p>A novel growth factor, persephin, which belongs to the GDNF/neurturin family of growth factors, is disclosed. The human, mouse and rat amino acid sequences have been identified. Human, mouse and rat persephin genomic DNA sequences have been cloned and sequenced and the respective cDNA sequences identified. In addition, methods for treating degenerative conditions using persephin, methods for detecting persephin gene alterations and methods for detecting and monitoring patient levels of persephin are provided. Methods for identifying additional members of the persephin-neurturin-GDNF family of growth factors are also provided.</p>

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Latvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece	<b>ML</b>	Mali	<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>MN</b>	Mongolia	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MR</b>	Mauritania	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MW</b>	Malawi	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MX</b>	Mexico	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>NE</b>	Niger	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NL</b>	Netherlands	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NO</b>	Norway	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NZ</b>	New Zealand	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>PL</b>	Poland		
<b>CM</b>	Cameroon	<b>KR</b>	Republic of Korea	<b>PT</b>	Portugal		
<b>CN</b>	China	<b>KZ</b>	Kazakhstan	<b>RO</b>	Romania		
<b>CU</b>	Cuba	<b>LC</b>	Saint Lucia	<b>RU</b>	Russian Federation		
<b>CZ</b>	Czech Republic	<b>LI</b>	Liechtenstein	<b>SD</b>	Sudan		
<b>DE</b>	Germany	<b>LK</b>	Sri Lanka	<b>SE</b>	Sweden		
<b>DK</b>	Denmark	<b>LR</b>	Liberia	<b>SG</b>	Singapore		

PERSEPHIN AND RELATED GROWTH FACTORSReference to Government Grant

This invention was made with government support under Grant Numbers NS24679 and CA53524. The government  
5 has certain rights in this invention.

Related Applications

This application is a continuation-in-part of Application Serial No. 08/881,172 filed June 23, 1997  
10 which is a continuation-in-part of Application Serial No. 08/615,944 filed March 14, 1996 and a continuation-in part of Application PCT/US97/03461 filed March 14, 1997.

Background of the Invention

## 15 (1) Field of the Invention

This invention relates generally to trophic or growth factors and, more particularly, to novel growth factors of the neurturin-GDNF family of growth factors.

## (2) Description of the Related Art

20 The development and maintenance of tissues in complex organisms requires precise control over the processes of cell proliferation, differentiation, survival and function. A major mechanism whereby these processes are controlled is through the actions of  
25 polypeptides known as "growth factors". These structurally diverse molecules act through specific cell surface receptors to produce these actions.

Growth factors, termed "neurotrophic factors"  
30 promote the differentiation, growth and survival of neurons and reside in the nervous system or in innervated tissues. Nerve growth factor (NGF) was the first neurotrophic factor to be identified and characterized (Levi-Montalcini et al., J. Exp. Zool. 116:321, 1951

which is incorporated by reference). NGF exists as a non-covalently bound homodimer that promotes the survival and growth of sympathetic, neural crest-derived sensory, and basal forebrain cholinergic neurons. In sympathetic neurons this substance produces neurite outgrowth *in vitro* and increased axonal and dendritic growth *in vivo*. (See Levi-Montalcini and Booker, *Proc Nat'l Acad Sci* 46:384-391, 1960; Johnson et al. *Science* 210: 916-918, 1980; Crowley et al., *Cell* 76:1001-12, 1994 which are incorporated by reference). NGF has effects on cognition and neuronal plasticity, and can promote the survival of neurons that have suffered damage due to a variety of mechanical, chemical, viral, and immunological insults (Snider and Johnson, *Ann Neurol* 26:489-506, 1989; Hefti, *J Neurobiol* 25:1418-35, 1994 which are incorporated by reference). NGF also is known to extensively interact with the endocrine system and in immune and inflammatory processes. (Reviewed in Scully and Otten, *Cell Biol Int* 19:459-469, 1995; Otten and Gadiant, *Int. J. Devl Neurosci* 13:147-151, 1995 which are incorporated by reference). For example, NGF promotes the survival of mast cells. (Horigome et al. *J Biol Chem* 269:2695-2707, 1994 which is incorporated by reference).

In recent years it has become apparent that growth factors fall into classes, i.e. families or superfamilies based upon the similarities in their amino acid sequences. These families include, for example, the fibroblast growth factor family, the neurotrophin family and the transforming growth factor-beta (TGF- $\beta$ ) family. As an example of family member sequence similarities, TGF- $\beta$  family members have 7 canonical framework cysteine residues which identify members of this superfamily.

NGF is the prototype of such a family of growth factors. Brain-derived neurotrophic factor (BDNF), the second member of this family to be discovered, was shown to be related to NGF by virtue of the conservation of all

six cysteines that form the three internal disulfides of the NGF monomer (Barde, *Prog Growth Factor Res* 2:237-248, 1990 and Liebrock et al. *Nature* 341:149-152, 1989 which are incorporated by reference). By utilizing the  
5 information provided by BDNF of the highly conserved portions of two factors, additional members (NT-3, NT-4/5) of this neurotrophin family were rapidly found by several groups (Klein, *FASEB J* 8:738-44, 1994 which is incorporated by reference).

10       Neurotrophic factors structurally unrelated to NGF have been recently identified. These include factors originally isolated based upon a "neurotrophic action" such as ciliary neurotrophic factor (CNTF) (Lin et al., *Science* 246:1023-5, 1989 which is incorporated by  
15 reference) along with others originally isolated as a result of non-neuronal activities (e.g. fibroblast growth factors (Cheng and Mattson *Neuron* 1:1031-41, 1991 which is incorporated by reference), IGF-I (Kanje et al, *Brain Res* 486:396-398, 1989 which is incorporated by reference)  
20 leukemia inhibitory factor (Kotzbauer et al, *Neuron* 12:763-773, 1994 which is incorporated by reference).

          Glial-derived neurotrophic factor (GDNF), is one such neurotrophic factor structurally unrelated to NGF. GDNF was, thus, a unique factor, which, up until now, was  
25 not known to be a member of any subfamily of factors. The discovery, purification and cloning of GDNF resulted from a search for factors crucial to the survival of midbrain dopaminergic neurons, which degenerate in Parkinson's disease. GDNF was purified from rat B49  
30 glial cell conditioned media (Lin et al., *Science* 260:1130-2, 1993 which is incorporated by reference). Sequence analysis revealed it to be a distant member of the TGF- $\beta$  superfamily of growth factors, having approximately 20% identity based primarily on the  
35 characteristic alignment of the 7 canonical framework cysteine residues (Lin et al., *Science* 260:1130-2, 1993

which is incorporated by reference). Thus, GDNF could possibly have represented a new subfamily within the TGF- $\beta$  superfamily.

Recombinant GDNF produced in bacteria specifically  
5 promotes the survival and morphological differentiation  
of dopaminergic neurons (Lin et al., *Science* 260:1130-2,  
1993); Tomac et al., *Nature* 373:335-9, 1995; Beck et al.,  
*Nature* 373:339-41, 1995 and Ebendal et al., *J Neurosci  
Res* 40:276-84, 1995 which are incorporated by reference)  
10 and motor neurons (Henderson et al., *Science* 266:1062-4,  
1994; Yan et al., *Nature* 373:341-4, 1995; and Oppenheim  
et al., *Nature* 373:344-6, 1995 which are incorporated by  
reference). Overall, GDNF was a more potent factor for  
promoting the survival of motor neurons than the other  
15 factors, and it was the only factor that prevented  
neuronal atrophy in response to these lesions, thereby  
positioning it as a promising therapeutic agent for motor  
neuron diseases.

It is now generally believed that neurotrophic  
20 factors regulate many aspects of neuronal function,  
including survival and development in fetal life, and  
structural integrity and plasticity in adulthood. Since  
both acute nervous system injuries as well as chronic  
neurodegenerative diseases are characterized by  
25 structural damage and, possibly, by disease-induced  
apoptosis, it is likely that neurotrophic factors play  
some role in these afflictions. Indeed, a considerable  
body of evidence suggests that neurotrophic factors may  
be valuable therapeutic agents for treatment of these  
30 neurodegenerative conditions, which are perhaps the most  
socially and economically destructive diseases now  
afflicting our society. Nevertheless, because different  
neurotrophic factors can potentially act preferentially  
through different receptors and on different neuronal or  
35 non-neuronal cell types, there remains a continuing need  
for the identification of new members of neurotrophic

factor families for use in the diagnosis and treatment of a variety of acute and chronic diseases of the nervous system.

5 Summary of the Invention:

Briefly, therefore, the present invention is directed to the identification and isolation of substantially purified factors that promote the survival and growth of neurons as well as non-neuronal cells.

10 Accordingly, the inventors herein have succeeded in discovering novel protein growth factors belonging to a family of growth factors for which GDNF was the first known member. The first such newly discovered family member was neurturin and this is the subject of copending application serial Number 08/519,777. Based upon the sequence of GDNF and neurturin the inventors herein have discovered another member of the GDNF-Neurturin family of growth factors referenced herein as persephin (PSP).

15 This growth factor is believed to show at least 75% sequence identity among homologous sequences from different mammalian species although sequence homology may be as low as 65% in non-mammalian species such as avian species. Indeed, the mouse, rat and human mature persephin sequences show from about 80% to about 94%

20 sequence identity. Mature persephin proteins identified herein comprise mouse sequences as set forth in SEQ ID NOS:79 and 187 (Figure 17B amino acids 66 through 154 and 61 through 156, respectively), rat sequences as set forth in SEQ ID NOS:82 and 196 (Figure 18B amino acids 6

25 through 94 and 1 through 96, respectively), and human sequences as set forth in SEQ ID NOS:221 and 223 (Figure 24; amino acids 61-156 and 66-154, respectively).

30

35

Persephin has been identified and obtained by a method based upon the conserved regions of the GDNF-Neurturin family discovered by the inventors herein. Accordingly, a new method has been devised that utilizes

degenerate primers constructed from the sequences of these conserved regions for use in the polymerase chain reaction procedure. By utilizing this method the mouse, rat and human orthologs of the new family member, 5 persephin, have been identified and obtained.

The present invention thus provides both amino acid sequences and nucleotide sequences that encode mouse, rat and human persephin including amino acid sequences of SEQ ID NOS:79, 82, 187, 196, 221 and 223 and 10 nucleotide sequences of SEQ ID NOS: 183, 193 and 199 and 201 as well as the complements of such nucleotide sequences (SEQ ID NOS:184, 194, 200 and 202). In addition, the present invention includes pre-, pro- and prepro- regions as well as pre-pro persephin amino acid 15 and nucleotide sequences.

Expression vectors and stably transformed cells comprising persephin polynucleotides are also within the scope of this invention. The transformed cells can be used in a method for producing persephin.

20 In another embodiment, the present invention provides a method for preventing or treating cellular degeneration comprising administering to a patient in need thereof a therapeutically effective amount of persephin. A patient may also be treated by implanting 25 transformed cells which express persephin or a DNA sequence which encodes persephin into a patient, or cells cultured and expanded by growth in persephin.

The present invention also provides compositions and methods for detecting persephin. One method is based 30 upon persephin antibodies and other methods are based upon detecting mRNA or cDNA or genomic DNA encoding persephin using recombinant DNA techniques.

In still further embodiments, the present invention includes pan-growth factors comprising a 35 segment of a persephin sequence and a segment of at least one growth factor other than persephin. Also included

are polynucleotides encoding the pan-growth factors, vectors containing such polynucleotides and host cells comprising the polynucleotides.

Among the several advantages found to be achieved  
5 by the present invention, therefore, may be noted the provision of a new growth factor, persephin, for use in preventing the atrophy, degeneration or death of certain cells, in particular neurons; the provision of human persephin; the provision of other members of the  
10 neuriturin-persephin-GDNF family of growth factors by making available new methods capable of obtaining other family members; the provision of methods for obtaining persephin by recombinant techniques; the provision of methods for preventing or treating diseases producing  
15 cellular degeneration and, particularly neuronal degeneration; the provision of methods that can detect and monitor persephin levels in a patient; and the provision of methods that can detect alterations in the persephin gene.

20

Brief Description of the Drawings

Figure 1 illustrates the purification scheme for preparing neuriturin from CHO cells;

Figure 2 illustrates the characterization of  
25 fractions eluted from Mono S column in purifying neuriturin showing (a) electrophoresis of each fraction on a SDS-polyacrylamide gel and visualization of the proteins by silver stain and (b) the neurotrophic activity present in each fraction in the superior  
30 cervical ganglion survival assay;

Figure 3 illustrates the ability of neuriturin to maintain survival of superior cervical ganglionic cells in culture showing (a) positive control cells maintained with nerve growth factor (NGF) (b) negative control cells  
35 treated with anti-NGF antibodies showing diminished survival and (c) cells treated with anti-NGF and

neurturin (approximately 3 ng/ml) showing survival of neurons;

Figure 4 illustrates the concentration-response effect of neurturin in the superior cervical ganglion  
5 survival assay;

Figure 5 illustrates the homology of the amino acid sequences for the mature growth factors, human neurturin (hNTN), mouse neurturin (mNTN), rat GDNF (rGDNF), mouse GDNF (mGDNF) and human GDNF (hGDNF) with  
10 identical amino acid residues enclosed in boxes;

Figure 6 illustrates the tissue distribution of neurturin mRNA and the mRNA for GDNF using RT/PCR analysis on RNA samples obtained from embryonic day 21 (E21) and adult rats;

15 Figure 7 illustrates the cDNA and encoded amino acid sequence of human pre-pro neurturin (SEQ ID NO:11) showing the pre- region from nucleic acid 1 through 57 (SEQ ID NO:17), the pro- region from nucleic acid 58 through 285 (SEQ ID NO:20), human neurturin from nucleic  
20 acid 286 through 591 (SEQ ID NO:9) and the splice site between nucleic acids 169 and 170 which defines the coding sequence portion of two exons from nucleic acids 1 through 169 (SEQ ID NO:27) and 170 through 594 (SEQ ID NO:28);

25 Figure 8 illustrates the cDNA and encoded amino acid sequence of mouse pre-pro neurturin (SEQ ID NO:12) showing the pre- region from nucleic acid 1 through 57 (SEQ ID NO:18), the pro- region from nucleic acid 58 through 285 (SEQ ID NO:21), mouse neurturin from nucleic  
30 acid 286 through 585 (SEQ ID NO:10) and the splice site between nucleic acids 169 and 170 which defines the coding sequence portion of two exons from nucleic acids 1 through 169 (SEQ ID NO:29) and 170 through 588 (SEQ ID NO:30);

35 Figure 9 illustrates the mouse cDNA sequence containing a 5' non-coding region (SEQ ID NO:13) and a 3'

non-coding region (SEQ ID NO:14) each of which are contiguous to the coding region of pre-pro neuriturin;

Figure 10 illustrates the percent neuronal survival in E18 rat nodose ganglia neurons treated 24 hours post-plating for NTN, GDNF, BDNF, NGF and AMO;

Figure 11 illustrates the nucleotide and amino acid sequence of murine persephin (SEQ ID NOS:79, 80 and 81; amino acid residues 52 through 140, 47 through 142, and 9 through 142, respectively);

Figure 12 illustrates the family member sequence identity in the region between the first and seventh canonical framework cysteine residues aligned beginning with the first canonical framework cysteine for murine GDNF (SEQ ID NO:87), murine neuriturin (NTN) (SEQ ID NO:88) and murine persephin (PSP) (SEQ ID NO:89);

Figure 13 illustrates the partial sequence of rat persephin cDNA (SEQ ID NO:97) obtained by the technique of rapid amplification of cDNA ends;

Figure 14 illustrates the partial sequence beginning with the first canonical framework cysteine for rat persephin (SEQ ID NO:83) and the corresponding polynucleotide sequence (SEQ ID NO:86);

Figure 15 shows (A) the family member aligned partial amino acid sequences from the first through the seventh canonical framework cysteine residues illustrating family member sequence homology of the mature growth factors, human GDNF (SEQ ID NO:240), rat GDNF (SEQ ID NO:241), mouse GDNF (SEQ ID NO:242), human neuriturin (NTN (human); SEQ ID NO:31), mouse neuriturin (NTN (mouse); SEQ ID NO:32), rat persephin (PSP (rat); SEQ ID NO:79), and mouse persephin (PSP(mouse); SEQ ID NO:82) in which boxes enclose the 28 conserved amino acid residues present in all and (B) the aligned sequences of mature mouse persephin (mPSP; SEQ ID NO:187), mature rat persephin (mPSP; SEQ ID NO:198) and mature human persephin (hPSP; SEQ ID NO:221);

Figure 16 illustrates the sequences of TGF- $\beta$  superfamily members aligned using the Clustal method, from the first canonical framework cysteine to the end of the sequence for transforming growth factor- $\beta$ 1 (TGFB1), 5 transforming growth factor- $\beta$ 2 (TGFB2), transforming growth factor- $\beta$ 3 (TGFB3), inhibin  $\beta$  A (INH $\beta$ A), inhibin  $\beta$  B (INH $\beta$ B), the nodal gene (NODAL), bone morphogenetic proteins 2 and 4 (BMP2 and BMP4), the *Drosophila* decapentaplegic gene (*dpp*), bone morphogenetic proteins 10 5-8 (BMP5, BMP6, BMP7 and BMP8), the *Drosophila* 60A gene family (60A), bone morphogenetic protein 3 (BMP3), the Vgl gene, growth differentiation factors 1 and 3 (GDF1 and GDF3), dorsalin (drsln), inhibin  $\alpha$  (INH $\alpha$ ), the MIS gene (MIS), growth factor 9 (GDF-9), glial-derived 15 neurotropic growth factor (GDNF) and neurturin (NTN);

Figure 17 illustrates (A) full length murine persephin gene (SEQ ID NO:177) with arrows indicating an 88 nt intron from positions 155-242 and (B) the nucleotide sequence of murine pre-pro persephin (SEQ ID 20 NO:179) with encoded amino acid sequence (SEQ ID NO:185);

Figure 18 illustrates (A) full length rat persephin gene (SEQ ID NO:188) with arrows indicating an 88 nt intron from positions 155-242 and (B) the nucleotide sequence of rat pre-pro persephin (SEQ ID 25 NO:190) with encoded amino acid sequence (SEQ ID NO:196);

Figure 19 illustrates a western blot analysis using anti-persephin antibodies to detect persephin protein in cell lysates from COS monkey cells transfected with the murine persephin gene (lane 2) or the rat 30 persephin gene (lane 3) compared to cells transfected with the non-recombinant vector alone (pCB6, lane 4) and the mature protein produced by *E. Coli* (lane 1);

Figure 20 illustrates the murine chimeric molecules (A) PSP/NTN containing the persephin fragment 35 (residues 1-63) and the neurturin fragment (residues 68-100) and (B) NTN/PSP containing the neurturin fragment

(residues 1-67) and the persephin fragment (residues 64-96) with the arrow indicating the crossover point in each;

Figure 21 illustrates the survival promoting  
5 effect of persephin in murine embryonic day-14  
mesencephalic cells cultured for three days (a) in the  
absence of persephin where almost all of the cells are  
dead and (b) in the presence of persephin (100 ng/ml)  
where substantial neuronal cell survival is evident;

10 Figure 22 illustrates the survival promoting  
effect of persephin (PSP) in murine embryonic day-14  
mesencephalic cells compared to effects of neurturin  
(NTN) and GDNF, measured by the number of cells stained  
with tyrosine hydroxylase (TOH);

15 Figure 23 illustrates RT/PCT survey for persephin  
expression in adult mouse tissues showing persephin  
expression by Kidney cells; and

Figure 24 illustrates the cDNA sequence of human  
pre-pro persephin (SEQ ID NO:203) with two silent  
20 mutations indicated at positions 30 and 360 and the  
encoded amino acid sequence (SEQ ID NO:217) with the  
first amino acid of the pro- region indicated by the  
double asterisks (\*\*) at amino acid position 24 and the  
first amino acid of mature human persephin indicated by  
25 the single asterisk (\*) at amino acid position 61.

#### Description of the Preferred Embodiments

The present invention is based upon the  
identification, isolation and sequencing of a DNA  
30 molecule that encodes a new growth factor, persephin.  
Persephin promotes cell survival and, in particular, the  
survival of neuronal cells. Prior to this invention,  
persephin was unknown and had not been identified as a  
discrete biological substance nor had it been isolated in  
35 pure form.

The growth factor, neuriturin (NTN) was identified and isolated as set forth in copending application Serial Number 08/519,777 filed August 28, 1995, which is incorporated in its entirety by reference. From the 5 sequence of neuriturin and the sequence of the closely related growth factor, glial-derived neurotrophic factor (GDNF), the inventors herein have devised and pursued strategies to find additional related factors. Neurturin is approximately 40% identical to GDNF, but less than 20% 10 identical to any other member of the TGF- $\beta$  superfamily. Together these two proteins define a new subfamily within the TGF- $\beta$  superfamily. Several sequence regions within neuriturin and GDNF were identified that are highly conserved, such that they are likely to be present in any 15 additional members of this subfamily. This sequence information can, therefore, be used to isolate previously unknown members of this subfamily by designing degenerate oligonucleotides to be used as either primers in PCR reactions or as probes in hybridization studies.

20 Using the new degenerate primer PCR strategy described in Example 11 of copending application Serial Number 08/519,777, the inventors herein have succeeded in identifying a third factor, persephin, that is approximately 40-50% identical to both GDNF and 25 neuriturin. Primers corresponding to the amino acid sequence from conserved regions of neuriturin and GDNF (SEQ ID NO:42 and SEQ ID NO:44) were used to amplify a 77 nt fragment from rat genomic DNA. The resulting products were subcloned into the Bluescript KS plasmid and 30 sequenced. The sequence of one of the amplified products predicted amino acid sequence data internal to the PCR primers that was different from that of GDNF or neuriturin but had more than 20% identity with GDNF and neuriturin, whereas the sequences of other amplified products we 35 obtained corresponded to GDNF or neuriturin, as would be expected. The 22 nucleotide sequence (SEQ ID NO:90) was

then aligned with the rat sequences of GDNF and neurturin and found to be unique. This novel sequence, thus, suggested that we had identified a new family member referenced herein as persephin.

5 To obtain additional persephin sequence information, primers containing the unique 22 nucleotide sequence of the amplified fragment were used in the rapid amplification of cDNA ends (RACE) technique (Frohman, M.A. Methods in Enzymology 218:340-356, 1993) using cDNA 10 obtained from neonatal rat brain. An approximately 350 nt fragment was obtained from this PCR reaction which constituted a partial rat persephin cDNA sequence of approximately 350 nucleotides (SEQ ID NO:106). The predicted amino acid sequence of this cDNA was compared 15 to that of GDNF and neurturin, and found to have approximately 40% identity with each of these proteins. Importantly, the characteristic spacing of the canonical framework cysteine residues in members of the TGF- $\beta$  superfamily was present. Furthermore, in addition to the 20 region of similarity encoded by the degenerate primers used to isolate persephin, another region of high homology shared between GDNF and neurturin, but absent in other members of the TGF- $\beta$  superfamily, was also present in persephin

25  
GDNF ACCRPVAFDDDLFLDD (aa 60-76) (SEQ ID NO:98)  
NTN PCCRPTAYEDEVSKD (aa 61-77) (SEQ ID NO:99)  
PSP PCCQPTSYAD-VTFLDD (aa 57-72) (SEQ ID NO:100)

30 (Amino acid numbering uses the first Cys residue as amino acid 1).

With the confirmation that persephin was indeed a new member of the GDNF/NTN subfamily, we isolated murine 35 genomic clones of persephin to obtain additional sequence information. Primers corresponding to rat cDNA sequence were used in a PCR reaction to amplify a 155 nucleotide (nt) fragment from mouse genomic DNA which was homologous to the rat persephin cDNA sequence. These primers were

then used to obtain murine persephin genomic clones from a mouse 129/Sv library in a P1 bacteriophage vector (library screening service of Genome Systems, Inc., St. Louis, MO).

5        Restriction fragments (3.4 kb Nco I and a 3.3 kb Bam H1) from this P1 clone containing the persephin gene were identified by hybridization with a 210 nt fragment of persephin obtained by PCR using mouse genomic DNA and persephin-specific primers. The Nco I and Bam H1  
10      fragments were sequenced and found to encode a stretch of amino acids corresponding to that present in the rat persephin RACE product, as well as being homologous to the mature regions of both neurturin and GDNF (Figure 11).

15      Human persephin was obtained in a manner similar to that of mouse persephin. Degenerate PCR primers were used to amplify human genomic DNA and one clone was determined to have a sequence homologous to mouse persephin. Primers based upon the identified sequence  
20      were then used to screen cDNA libraries. Positive clones were identified by hybridization with a DNA probe derived from the identified sequence and these clones were then sequenced.

When the amino acid sequences of mature murine GDNF,  
25 NTN and PSP are aligned using the first canonical framework cysteine as the starting point, which is done because alterations in the cleavage sites between family members creates variability in the segments upstream of the first cysteine, persephin (91 amino acids) is  
30 somewhat smaller than either neurturin (95 amino acids) or GDNF (94 amino acids). The overall identity within this region is about 50% with neurturin and about 40% with GDNF (Figure 12).

Further nucleotide sequencing of the murine  
35 persephin NcoI fragment revealed the nucleotide sequence of the entire murine persephin gene as shown in Figure

17. In addition, the entire rat persephin gene has been determined by sequencing a PCR amplified fragment of rat genomic DNA as shown in Figure 18. In both the murine and rat persephin gene, an open reading frame extends  
5 from the sequence coding for an initiator methionine up to a stop codon at positions 244-246. However, somewhere in this sequence an apparent anomaly was found to occur such that the sequence encoding the RXXR cleavage site (positions 257-268) and the sequence corresponding to the  
10 mature persephin protein (positions 269-556) are not co-linear with this open reading frame. Instead, a second reading frame encodes the cleavage site and the mature persephin. Irrespective of this apparent anomaly, mammalian cells were found to express persephin from  
15 either the murine or rat full length genomic sequence (see Example 14 below).

To pursue the genesis of this anomaly, we prepared mammalian expression vectors for both murine and rat persephin. To construct the murine plasmid, a P1 clone  
20 containing the murine persephin gene was used as a template in a PCR assay. Primers were designed such that the resulting fragment would contain the persephin gene extending from the initiator Methionine to the stop codon. The PCR reaction utilized a forward primer M3175  
25 [5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA] and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]. To construct the analogous rat plasmid, rat genomic DNA was used as a template in a PCR assay. The PCR reaction utilized a forward primer M3175 [5'-  
30 TGCTGTCACCATGGCTGCAGGAAGACTTCGGA] and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]. The amplified products were cloned into BSKS and sequenced to verify that the correct clone had been obtained. The rat and murine persephin fragments were excised using Sma I  
35 and Hind III and cloned into a Asp718 (blunted) and Hind III sites of the mammalian expression vector pCB6.

COS monkey cells were transfected with either the rat or murine persephin expression vectors or the non-recombinant vector (pCB6) itself. Forty eight hr later the cells were lysed, the samples were loaded onto a 15% SDS-polyacrylamide gel, and the proteins were separated by electrophoresis. The proteins were then transferred to nitrocellulose by electroblotting. This nitrocellulose membrane was incubated with anti-persephin antibodies (which we raised to mature persephin produced in bacteria from a pET plasmid) to detect the presence of persephin in the lysates. Lysates from cells transfected with either the rat or murine persephin expression vectors, but not the lysate from cells transfected with pCB6, contain high amounts of persephin. The size of the persephin detected was 10-15 kD, consistent with the size predicted for the processed (i.e. mature form of persephin). Conditioned media harvested from these cells also contained mature persephin. These results demonstrate that both the murine and rat persephin genes are capable of directing the synthesis of a properly processed persephin molecule.

To pursue the mechanism by which this occurred, we isolated RNA from cells transfected with either rat or murine persephin expression vector. RT/PCR analysis was performed using primers corresponding to the initiator Met and the stop codon. We detected two fragments: one corresponding to the predicted size of the persephin gene and the other somewhat smaller, suggesting that RNA splicing had occurred. We confirmed this with a number of other primer pairs. Both the large and small persephin fragments were cloned and sequenced. As expected, the larger fragment corresponded to the persephin gene. The small fragment corresponded to a spliced version of persephin. A small 88 nt intron within the pro-domain (situated 154 nt downstream of the start codon) had been spliced out. After this splicing

event, the "frameshift" was no longer present (i.e. the initiator Met and the mature region are in-frame) in either rat or mouse persephin.

The N-terminus of persephin was predicted by reference to the N-terminal regions of neurturin or GDNF. Using neurturin sequence homology and cleavage signals, a characteristic RXXR cleavage motif is present beginning 9 residues upstream of the first canonical framework cysteine of persephin which would suggest that mature murine persephin would contain 5 amino acids (ALAGS) (SEQ ID NO:103) upstream of this cysteine (as does neurturin). The corresponding 5 amino acids in rat persephin are ALPGL (SEQ ID NO:112) and those in human persephin are ALSGP (SEQ ID NO:224). Using these parameters, mature persephin would consist of 96 amino acids and have a predicted molecular mass of 10.4 kD.

By "mature" growth factor reference is made to the secreted form of the growth factor in which any pre- or pro- regions have been cleaved and which may exist as a monomer or, by analogy to other members of the TGF- $\beta$  superfamily, in the form of a homodimer linked by disulfide bonds.

The discovery of the new growth factor, persephin, as described above is a result of the prior discovery by the inventors herein of neurturin. Thus, the experiments leading to the discovery of neurturin are relevant to the current discovery of persephin as well as to the biological activity of persephin. The isolation, identification and characterization of neurturin is described in detail in Examples 1-5 below.

Reference to persephin herein is intended to be construed to include growth factors of any origin which are substantially homologous to and which are biologically equivalent to the persephin characterized and described herein. Such substantially homologous growth factors may be native to any tissue or species

and, similarly, biological activity can be characterized in any of a number of biological assay systems. Reference to pre-pro persephin is intended to be construed to include pre-pro growth factors containing a 5 pre- or leader or signal sequence region, a pro- sequence region and persephin as defined herein.

The terms "biologically equivalent" are intended to mean that the compositions of the present invention are capable of demonstrating some or all of the same growth 10 promoting properties in a similar fashion, although not necessarily to the same degree as the recombinantly produced human, mouse or rat persephin as identified herein.

By "substantially homologous" it is meant that the 15 degree of sequence identity of persephin orthologs including human, mouse and rat persephin as well as persephin from any other species, is greater than that between paralogs such as persephin and neurturin or persephin and GDNF, and greater than that reported 20 previously for members of the TGF- $\beta$  superfamily (For discussion of homology of TGF- $\beta$  superfamily members see Kingsley, *Genes and Dev* 8:133-46, 1994 which is incorporated by reference).

Sequence identity or percent identity is intended to 25 mean the percentage of same residues between two sequences. The reference sequence is human persephin when determining percent identity with mouse or rat persephin and with the non-persephin growth factors, human neurturin or human GDNF. The reference sequence is 30 mouse persephin when determining percent identity with mouse GDNF and mouse neurturin and rat persephin when determining percent identity with rat GDNF and rat neurturin. Referencing is to human neurturin when determining percent identity with non-human neurturin and 35 to human GDNF. In all of the above comparisons, the two sequences being compared are aligned using the Clustal

method (Higgins et al, *Cabios* 8:189-191, 1992) of multiple sequence alignment in the Lasergene biocomputing software (DNASTAR, INC, Madison, WI). In this method, multiple alignments are carried out in a progressive manner, in which larger and larger alignment groups are assembled using similarity scores calculated from a series of pairwise alignments. Optimal sequence alignments are obtained by finding the maximum alignment score, which is the average of all scores between the separate residues in the alignment, determined from a residue weight table representing the probability of a given amino acid change occurring in two related proteins over a given evolutionary interval. Penalties for opening and lengthening gaps in the alignment contribute to the score. The default parameters used with this program are as follows: gap penalty for multiple alignment = 10; gap length penalty for multiple alignment = 10; k-tuple value in pairwise alignment = 1; gap penalty in pairwise alignment = 3; window value in pairwise alignment = 5; diagonals saved in pairwise alignment = 5. The residue weight table used for the alignment program is PAM250 (Dayhoff et al., in *Atlas of Protein Sequence and Structure*, Dayhoff, Ed., NBRF, Washington, Vol. 5, suppl. 3, p. 345, 1978).

Percent conservation is calculated from the above alignment by adding the percentage of identical residues to the percentage of positions at which the two residues represent a conservative substitution (defined as having a log odds value of greater than or equal to 0.3 in the PAM250 residue weight table). Using this criterion, preferred conservative amino acid changes are: R-K; E-D, Y-F, L-M; V-I, Q-H. Conservation is referenced to human persephin when determining percent conservation with persephin from other species or with non-persephin growth factors; referenced to human neurturin when determining

percent conservation with non-human neurturin or with non-persephin, non-neurturin growth factors.

Table 1 shows the calculations of identity (I) and conservation (C) for comparisons of mature persephin, 5 mature neurturin and mature GDNF from various species. Comparisons were made between mature human persephin (hPSP) and mature mouse and rat persephin (mPSP and rPSP, respectively) and between mature human persephin and mature human GDNF or neurturin (hGDNF and hNTN 10 respectively). Neurturin comparisons were between mature human and mature mouse neurturin (hNTN and mNTN, respectively) and between each of these and mature human, rat and mouse GDNF (hGDNF, rGDNF and mGDNF, respectively) as shown in the table.

15

Table 1.

	COMPARISON	% IDENTITY	% CONSERVATION
20	hPSP v. mPSP	81	81
	hPSP v. rPSP	80	81
	mPSP v. rPSP	94	96
	hPSP v. hNTN	49	50
	hPSP v. hGDNF	40	43
25	hNTN v. mNTN	90	93
	hNTN v. rGDNF	44	53
	hNTN v. mGDNF	43	52
	hNTN v. hGDNF	43	53
	mNTN v. rGDNF	42	52
30	mNTN v. mGDNF	41	51
	mNTN v. hGDNF	41	52

35 The degree of homology between the human persephin and mouse or rat persephin is about 80% whereas the degree of homology between mouse and rat persephin is about 94%. The neurturin comparisons as shown in Table 1 indicate mature mouse and human neurturin proteins have 40 about 90% sequence identity. Furthermore, all persephin and neurturin homologs of non-human mammalian species are believed to similarly have at least about 75% sequence

identity with human persephin, human neurturin, or human GDNF. For non-mammalian species such as avian species, it is believed that the degree of homology with persephin is at least about 65% identity with human persephin, or 5 neurturin human neurturin or human GDNF. By way of comparison, the variations between family members of the neurturin-persephin-GDNF family of growth factors can be seen by the comparison of persephin and GDNF or neurturin and GDNF. Human persephin has about 40% sequence 10 identity and about 43% sequence conservation with human GDNF; and about 49% sequence identity and about 50% sequence conservation with human neurturin. Similarly, human neurturin has about 40% sequence identity and about 50% sequence conservation with human GDNF. It is 15 believed that the different family members also have a similar sequence identity of about 40% of that of neurturin, about 40% of that of persephin or about 40% of that of GDNF and within a range of about 30% to about 75% identity with neurturin, within a range of about 30% to 20 about 75% identity with persephin or within a range of about 30% to about 75% sequence identity with GDNF.

Thus, a given member of the GDNF-neurturin-persephin family would be expected to have lesser sequence identity with any other family member of the same species than is 25 present in orthologs of that family member in other species just as human GDNF and human neurturin are more closely related to mouse GDNF and mouse neurturin, respectively, than to each other or to GDNF and any given family member would be expected to have greater sequence 30 identity with another family member than to any other known member of the TGF- $\beta$  superfamily (Kingsley, *supra*).

Homologs of pre-pro persephin in non-human mammalian species can be identified by virtue of the persephin portion of the amino acid sequence having at least about 35 75% sequence identity with human persephin and homologs of pre-pro persephin in non-mammalian species can be

identified by virtue of the persephin portion of the amino acid sequence having at least about 65% identity with human persephin.

Persephin as used herein, can also include hybrid 5 and modified forms of persephin, respectively, including fusion proteins and persephin fragments and hybrid and modified forms in which certain amino acids have been deleted or replaced and modifications such as where one or more amino acids have been changed to a modified amino 10 acid or unusual amino acid and modifications such as glycosolations so long as the hybrid or modified form retains the biological activity of persephin. By retaining the biological activity, it is meant that neuronal survival is promoted, although not necessarily 15 at the same level of potency as that of the human, mouse or rat persephin identified herein.

Also included within the meaning of substantially homologous is any persephin which may be isolated by virtue of cross-reactivity with antibodies to the 20 persephin or whose encoding nucleotide sequences including genomic DNA, mRNA or cDNA may be isolated through hybridization with the complementary sequence of genomic or subgenomic nucleotide sequences or cDNA of the persephin or fragments thereof. It will also be 25 appreciated by one skilled in the art that degenerate DNA sequences can encode human persephin and these are also intended to be included within the present invention as are allelic variants of persephin.

Conservatively substituted persephin proteins are 30 also within the scope of the present invention. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. Conservatively substituted amino acids can be grouped according to the chemical properties of their 35 side chains. For example, one grouping of amino acids includes those amino acids have neutral and hydrophobic

side chains (A, V, L, I, P, W, F, and M); another grouping is those amino acids having neutral and polar side chains (G, S, T, Y, C, N, and Q); another grouping is those amino acids having basic side chains (K, R, and H); another grouping is those amino acids having acidic side chains (D and E); another grouping is those amino acids having aliphatic side chains (G, A, V, L, and I); another grouping is those amino acids having aliphatic-hydroxyl side chains (S and T); another grouping is those amino acids having amine-containing side chains (N, Q, K, R, and H); another grouping is those amino acids having aromatic side chains (F, Y, and W); and another grouping is those amino acids having sulfur-containing side chains (C and M). Preferred conservative amino acid substitutions groups are: R-K; E-D, Y-F, L-M; V-I, and Q-H. In addition, Q-R-H and A-V are believed to be preferred substitutions for persephin inasmuch as they occur among the human, mouse and rat paralogs of persephin (see Figure 15B).

In the case of pre-pro neuriturin, alternatively spliced protein products, resulting from an intron located in the coding sequence of the pro region, may exist. The intron is believed to exist in the genomic sequence at a position corresponding to that between nucleic acids 169 and 170 of the cDNA which, in turn, corresponds to a position within amino acid 57 in both the mouse and human pre-pro neuriturin sequences (see Figures 7 and 8). Thus, alternative splicing at this position might produce a sequence that differs from that identified herein for human and mouse pre-pro neuriturin (SEQ ID NO:11 and SEQ ID NO:12, respectively) at the identified amino acid site by addition and/or deletion of one or more amino acids. Any and all alternatively spliced pre-pro neuriturin proteins are intended to be included within the terms pre-pro neuriturin and, similarly, any and all alternatively spliced pre-pro

persephin proteins are also intended to be included within the terms pre-pro persephin as used herein.

Although it is not intended that the inventors herein be bound by any theory, it is thought that the 5 human, mouse and rat persephin proteins identified herein as well as homologs from other tissues and species may exist as dimers in their biologically active form in a manner consistent with what is known for other factors of the TGF- $\beta$  superfamily.

10 In addition to homodimers, the monomeric units of the dimers of persephin can be used to construct stable growth factor heterodimers or heteromultimers comprising at least one monomer unit derived from persephin. This can be done by dissociating a homodimer of persephin into 15 its component monomeric units and reassociating in the presence of a monomeric unit of a second or subsequent homodimeric growth factor. This second or subsequent homodimeric growth factor can be selected from a variety of growth factors including neurturin, GDNF, a member of 20 the NGF family such as NGF, BDNF, NT-3 and NT-4/5, a member of the TGF- $\beta$  superfamily, a vascular endothelial growth factor, a member of the CNTF/LIF family and the like.

Growth factors are thought to act at specific 25 receptors. For example, the receptors for TGF- $\beta$  and activins have been identified and make up a family of Ser/Thr kinase transmembrane proteins (Kingsley, *Genes and Dev* 8:133-146, 1994; Bexk et al *Nature* 373:339-341, 1995 which are incorporated by reference). In the NGF 30 family, NGF binds to the TrkA receptor in peripheral sensory and sympathetic neurons and in basal forebrain neurons; BDNF and NT-4/5 bind to trkB receptors; and NT-3 binds primarily to trkC receptors that possess a distinct distribution within the CNS (Tuszynski et al., *Ann Neurol* 35:S9-S12, 1994). Members of the persephin-neurturin-GDNF family also appear to act through specific receptors

having distinct distributions as has been shown for other growth factor families. Recently, it was shown that GDNF acts through a multicomponent receptor complex in which a transmembrane signal transducing component, the Ret tyrosine kinase protein (Ret PTK), is activated upon the binding of GDNF with another protein, called GDNF Receptor  $\alpha$  (GDNFR- $\alpha$ ) which has no transmembrane domain and is attached to the cell surface via a glycosyl-phosphatidylinositol (GPI) linkage (Durbec et al., *Nature* 381:789-793, 1996; Jing et al., *Cell* 85:1113-1124, 1996; Treanor et al., *Nature* 382:80-83, 1996; Trupp et al., *Nature* 381:785-789, 1996, which are incorporated herein by reference). Furthermore, it has been shown that the signaling of neurturin and GDNF through the Ret tyrosine kinase receptor is mediated by a family of co-receptors, including the co-receptor protein GDNFR- $\alpha$ , also referred to as TrnR1, and the co-receptor protein, TrnR2, either of which can form a functional receptor complex with Ret for both neurturin and GDNF (Baloh et al., *Neuron* 18:793-802, 1997 which is incorporated by reference). By forming heterodimers or heteromultimers of persephin and one or more other growth factors, the resultant growth factor would be expected to be able to bind to at least two distinct receptor types preferentially having a different tissue distribution. The resultant heterodimers or heteromultimers would be expected to show a different and, possibly, an enlarged spectrum of cells upon which it could act or to provide greater potency. It is also possible that the heterodimer or heteromultimer might provide synergistic effects not seen with homodimers or homomultimers. For example, the combination of factors from different classes has been shown to promote long-term survival of oligodendrocytes whereas single factors or combinations of factors within the same class promoted short-term survival (Barres et al., *Development* 118:283-295, 1993).

Heterodimers can be formed by a number of methods. For example, homodimers can be mixed and subjected to conditions in which dissociation/unfolding occurs, such as in the presence of a dissociation/unfolding agent, 5 followed by subjection to conditions which allow monomer reassociation and formation of heterodimers. Dissociation/unfolding agents include any agent known to promote the dissociation of proteins. Such agents include, but are not limited to, guanidine hydrochloride, 10 urea, potassium thiocyanate, pH lowering agents such as buffered HCl solutions, and polar, water miscible organic solvents such as acetonitrile or alcohols such as propanol or isopropanol. In addition, for homodimers linked covalently by disulfide bonds as is the case with 15 TGF- $\beta$  family members, reducing agents such as dithiothreitol and  $\beta$ -mercaptoethanol can be used for dissociation/unfolding and for reassociation/refolding.

Heterodimers can also be made by transfecting a cell with two or more factors such that the transformed cell 20 produces heterodimers as has been done with the neurotrophins. (Heymach and Shooter, *J Biol Chem* 270:12297-12304, 1995).

Another method of forming heterodimers is by combining persephin homodimers and a homodimer from a 25 second growth factor and incubating the mixture at 37°C.

When heterodimers are produced from homodimers, the heterodimers may then be separated from homodimers using methods available to those skilled in the art such as, for example, by elution from preparative, non-denaturing 30 polyacrylamide gels. Alternatively, heterodimers may be purified using high pressure cation exchange chromatography such as with a Mono S cation exchange column or by sequential immunoaffinity columns.

It is well known in the art that many proteins are 35 synthesized within a cell with a signal sequence at the N-terminus of the mature protein sequence and the protein

carrying such a leader sequence is referred to as a preprotein. The pre- portion of the protein is cleaved during cellular processing of the protein. In addition to a pre- leader sequence, many proteins contain a 5 distinct pro sequence that describes a region on a protein that is a stable precursor of the mature protein. Proteins synthesized with both pre- and pro- regions are referred to as preproproteins. In view of the processing events known to occur with other TGF- $\beta$  family members as 10 well as the sequences determined herein, the inventors believe that the form of the persephin protein as synthesized within a cell is the pre-pro persephin. Human pre-pro persephin is believed to contain an N-terminal 23 amino acid signal sequence (human pre- signal sequence, 15 SEQ ID NO:219, Figure 24, amino acids 1 through 23 encoded by SEQ ID NOS:208 and 209, Figure 24, nucleic acids 1 through 69). It is known that the full length of a leader sequence is not necessarily required for the sequence to act as a signal sequence and, therefore, 20 within the definition of pre- region of persephin is included fragments thereof, usually N-terminal fragments, that retain the property of being able to act as a signal sequence, that is to facilitate co-translational insertion into the membranes of one or more cellular 25 organelles such as endoplasmic reticulum, mitochondria, golgi, plasma membrane and the like.

The persephin signal sequence is followed by a pro- domain which contains an RXXR proteolytic processing site immediately before the N-terminal amino acid sequence for 30 the mature persephin. (human pro- region sequence, SEQ ID NO:220, Figure 24, amino acids 24 through 60 encoded by the nucleic acid sequence SEQ ID NO:211, Figure 24 nucleic acids 70 through 180).

The persephin pre- and pro- regions together 35 comprise a pre-pro sequence identified as the human pre- pro region sequence (SEQ ID NO:219, Figure 24, amino

acids 1 through 60 encoded by SEQ ID NOS:213 and 215, nucleic acids 1 through 285). The pre- region sequences and pro- region sequences as well as the pre-pro region sequences can be identified and obtained for non-human 5 mammalian species and for non-mammalian species by virtue of the sequences being contained within the pre-pro persephin as defined herein.

Using the above landmarks, the human persephin cDNA has a 471 bp open reading frame encoding a 156 amino acid 10 long protein (predicted Mr 16.6kDa). Cleavage of the 23 amino acid long predicted signal peptide will lead to a 133 amino acid pro-persephin molecule (Mr 14.2 kDa), Proteolytic cleavage of the pro-persephin at a RXXR consensus sequence should yield a 96 amino acid mature 15 protein with a molecular weight of 10.3 kDa. The mature, secreted persephin molecule is likely to form a disulfide linked homodimer by analogy to other members of the TGF- $\beta$  family.

The nucleotide sequences of persephin pre- and/or 20 pro- regions or similar regions that are believed to be associated with persephin DNA can be used to construct chimeric genes with the coding sequences of other growth factors or proteins. (Booth et al., Gene 146:303-8, 1994; Ibanez, Gene 146:303-8, 1994; Storici et al., FEBS Letters 337:303-7, 1994; Sha et al J Cell Biol 114:827-25 839, 1991 which are incorporated by reference). Such chimeric proteins can exhibit altered production or expression of the active protein species.

A preferred persephin according to the present 30 invention is prepared by recombinant DNA technology although it is believed that persephin can be isolated in purified form from cell-conditioned medium as was done for neurturin.

By "pure form" or "purified form" or "substantially 35 purified form" it is meant that a persephin composition is substantially free of other proteins which are not

persephin. Preferably, a substantially purified persephin composition comprises at least about 50 percent persephin on a molar basis compared to total proteins or other macromolecular species present. More preferably, a 5 substantially purified persephin composition will comprise at least about 80 to about 90 mole percent of the total protein or other macromolecular species present and still more preferably, at least about 95 mole percent or greater.

10 Recombinant persephin may be made by expressing the DNA sequences encoding persephin in a suitable transformed host cell. Using methods well known in the art, the DNA encoding persephin may be linked to an expression vector, transformed into a host cell and 15 conditions established that are suitable for expression of persephin by the transformed cell.

Any suitable expression vector may be employed to produce recombinant human persephin such as, for example, the mammalian expression vector pCB6 (Brewer, *Meth Cell Biol* 43:233-245, 1994) or the *E. coli* pET expression vectors, specifically, pET-30a (Studier et al., *Methods Enzymol* 185:60-89, 1990 which is incorporated by reference) both of which were used herein. Other suitable expression vectors for expression in mammalian 25 and bacterial cells are known in the art as are expression vectors for use in yeast or insect cells. Baculovirus expression systems can also be employed.

Persephin may be expressed in the monomeric units or such monomeric form may be produced by preparation under 30 reducing conditions. In such instances refolding and renaturation can be accomplished using one of the agents noted above that is known to promote dissociation/association of proteins. For example, the monomeric form can be incubated with dithiothreitol 35 followed by incubation with oxidized glutathione disodium

salt followed by incubation with a buffer containing a refolding agent such as urea.

Persephin may exist as a dimer or other multimer and may be glycosylated or chemically modified in other ways.

5 Mature human persephin contains no N-linked glycosylation sites (see Figure 15B and SEQ ID NO:221). Potential O-linked glycosylation sites occur in mature human persephin at positions 3, 10, 12, 14, 24, 36, 43, 67, 70 and 88 in SEQ ID NO:221 (Figure 15B).

10 As noted above, the human nucleic acid sequence suggests that persephin is initially translated as a pre-pro polypeptide and that proteolytic processing of the signal sequence and the "pro" portion of this molecule results in the mature sequence, referenced herein as  
15 "mature persephin" exists in human and in non-human species in homologous form. Therefore, persephin includes any and all "mature persephin" sequences from human and non-human species and any and all pre-pro persephin polypeptides that may be translated from the  
20 persephin gene.

By analogy to the neurturin protein, it is possible that isoforms of persephin may exist. For example, different possible cleavage sites (such as RXXR sites) may be present in the pre-pro neurturin sequence so that  
25 more than one possible isoform of pre-pro neurturin may exist. Thus, the mature neurturin protein may have a variable number of amino acids preceding the first canonical cysteine. Such alternate cleavage sites could be utilized differently among different organisms and  
30 among different tissues of the same organism. The N-terminal amino acids preceding the first of the seven conserved cysteines in the mature forms of members of the TGF- $\beta$  family vary greatly in both length and sequence. Furthermore, insertion of a ten amino acid sequence two  
35 residues upstream of the first conserved cysteine does not affect the known biological activities of one family

member, dorsalin (Basler et al., Cell 73:687-702, 1993). By analogy, it is also possible that persephin proteins containing sequences of different lengths preceding the first canonical cysteine may exist or could be made and 5 that these would retain their biological activity.

The inventors herein believe that at a minimum the sequence of a persephin-neurturin-GDNF growth factor that will show biological activity will contain the sequence from the first through the seventh canonical cysteine. 10 This sequence of human persephin is from cysteine 66 through cysteine 154 as shown in Figure 24 (SEQ ID NO:223). The comparable sequence for murine persephin as shown in Figure 12 is from cysteine 1 through cysteine 87 (SEQ ID NO:79) and that for rat persephin as shown in 15 Figure 14, from cysteine 1 through cysteine 87 (identified as SEQ ID NO:82). Thus, within the scope of persephin proteins of the present invention are amino acid sequences containing SEQ ID NO:223, SEQ ID NO:79 or SEQ ID NO:82 and nucleic acid molecules containing 20 sequences encoding these amino acid sequences.

The present invention also encompasses nucleic acid molecules comprising sequences that encode mouse, rat and human persephin (Figures 11, 14 and 23). Also included within the scope of this invention are sequences that are 25 substantially the same as the nucleic acid sequences encoding persephin. Such substantially the same sequences may, for example, be substituted with codons more readily expressed in a given host cell such as *E. coli* according to well known and standard procedures. 30 Such modified nucleic acid sequences are included within the scope of this invention.

Specific nucleic acid sequences can be modified by those skilled in the art and, thus, all nucleic acid sequences which encode for the amino acid sequences of 35 pre-pro persephin or the pre- region or the pro- region of persephin can likewise be so modified. The present

invention also includes nucleic acid sequence having one or more substitutions, deletions or additions wherein the nucleic acid sequence will hybridize with a persephin nucleic acid sequences -- or complement thereof where 5 appropriate.

Specific hybridization is defined herein as the formation of hybrids between a polynucleotide (e.g. a persephin polynucleotide which may include one or more substitutions, deletions, and/or additions) and a 10 specific reference polynucleotide (e.g. polynucleotides encoding mature persephin and having the sequences of SEQ ID NO:183, 184, 194, 195, 199, 200, 201 or 202) wherein the polynucleotide preferentially hybridizes to the specific reference polynucleotide. For example, a 15 polynucleotide encoding a mature persephin will specifically hybridize to a reference persephin polynucleotide (e.g. SEQ ID NO:183, 184, 194, 195, 199, 200, 201 or 202) and not to a reference neurturin polynucleotide (e.g. SEQ ID NO:9 or 10 or sequences 20 complementary thereto). Specific hybridization is preferably done under high stringency conditions which is well understood by those skilled in the art to be determined by a number of factors during hybridization and during the washing procedure, including temperature, 25 ionic strength, length of time and concentration of formamide (see for example, Sambrook et al., 1989, *supra*).

The present invention also includes nucleic acid sequences which encode for polypeptides that have 30 survival or growth promoting activity and that are recognized by antibodies that bind to persephin.

The present invention also encompasses vectors comprising an expression regulatory element operably linked to any of the nucleic acid sequences included 35 within the scope of the invention. This invention also

includes host cells -- of any variety -- that have been transformed with such vectors.

Methods are also provided herein for producing persephin. Preparation can be by isolation from 5 conditioned medium from a variety of cell types so long as the cell type produces persephin. A second and preferred method involves utilization of recombinant methods by isolating a nucleic acid sequence encoding persephin, cloning the sequence along with appropriate 10 regulatory sequences into suitable vectors and cell types, and expressing the sequence to produce persephin.

A mammalian gene family comprised of four neurotrophic factors has been identified including nerve growth factor (NGF), brain derived neurotrophic factor 15 (BDGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). These factors share approximately 60 percent nucleic acid sequence homology (Tuszynski and Gage, *Ann Neurol* 35:S9-S12, 1994 which is incorporated by reference). The persephin protein and the neuriturin 20 protein display no significant homology to the NGF family of neurotrophic factors. Either persephin or neuriturin shares less than about 20% homology with the TGF- $\beta$  superfamily of growth factors. However, both persephin and neuriturin show approximately 40% sequence identity 25 with GDNF and approximately 50% sequence identity with each other. In particular, the positions of the seven cysteine residues present in persephin, neuriturin and GDNF are nearly exactly conserved. The inventors herein believe that other unidentified genes may exist that 30 encode proteins that have substantial amino acid sequence homology to persephin, neuriturin and GDNF and which function as growth factors selective for the same or different tissues and the same or different biological activities and may act at the same or different 35 receptors. A different spectrum of activity with respect to tissues affected and/or response elicited could result

from preferential activation of different receptors by different family members as is known to occur with members of the NGF family of neurotrophic factors (Tuszynski and Gage, 1994, *supra*).

- 5        As a consequence of members of a particular gene family showing substantial conservation of amino acid sequence among the protein products of the family members, there is considerable conservation of sequences at the DNA level. This forms the basis for a new
- 10      approach for identifying other members of the gene family to which GDNF, neurturin and persephin belong. The method used for such identification is cross-hybridization using nucleic acid probes derived from one family member to form a stable hybrid duplex molecule
- 15      with nucleic acid sequence from different members of the gene family or to amplify nucleic acid sequences from different family members. (see for example, Kaisho et al. *FEBS Letters* 266:187-191, 1990 which is incorporated by reference). The sequence from the different family
- 20      member may not be identical to the probe, but will, nevertheless be sufficiently related to the probe sequence to hybridize with the probe. Alternatively, PCR using primers from one family member can be used to identify additional family members.
- 25      The above approaches have not heretofore been successful in identifying other gene family members because only one family member, GDNF was known. With the identification of neurturin in copending application Serial No. 08/519,777, however, unique new probes and
- 30      primers were made that contain sequences from the conserved regions of this gene family. The same conserved regions are also found in the third family member, persephin. In particular, three conserved regions have been identified herein which can be used as
- 35      a basis for constructing new probes and primers. The new probes and primers made available from the work with

neurturin and persephin make possible this powerful new approach which can now successfully identify other gene family members. Using this new approach, one may screen for genes related to GDNF, neurturin and persephin in sequence homology by preparing DNA or RNA probes based upon the conserved regions in the GDNF and neurturin molecules. Therefore, one embodiment of the present invention comprises probes and primers that are unique to or derived from a nucleotide sequence encoding such 5 conserved regions and a method for identifying further members of the neurturin-persephin-GDNF gene family.

Conserved-region amino acid sequences have been identified herein to include Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser, Thr or Ala and Xaa<sub>2</sub> is Glu or 10 Asp (SEQ ID NO:108); Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>4</sub>-Gly-Xaa<sub>5</sub>-Cys in which Xaa<sub>1</sub> is Thr, Glu or lys, Xaa<sub>2</sub> is Val, Leu or Ile, Xaa<sub>3</sub> is Leu or Ile, Xaa<sub>4</sub> is Ala or Ser, and Xaa<sub>5</sub> is Ala or Ser, (SEQ ID NO:113); and Cys-Cys-Xaa<sub>1</sub>-Pro-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Xaa<sub>5</sub>-Asp-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>-Phe-Leu-Asp-Xaa,<sub>9</sub> 15 in which Xaa<sub>1</sub> is Arg or Gln, Xaa<sub>2</sub> is Thr or Val or Ile, Xaa<sub>3</sub> is Ala or Ser, Xaa<sub>4</sub> is Tyr or Phe, Xaa<sub>5</sub> is Glu, Asp or Ala, Xaa<sub>6</sub> is Glu, Asp or no amino acid, Xaa<sub>7</sub> is val or leu, Xaa<sub>8</sub> is Ser or Thr, and Xaa<sub>9</sub> is Asp or Val (SEQ ID NO:114). Nucleotide sequences containing a coding 20 sequence for the above conserved sequences or fragments of the above conserved sequences can be used as probes. Exemplary probe and primer sequences encoding amino acid sequences and SEQ ID NOS:125-129; primers whose reverse complementary sequences encode amino acid sequences SEQ 25 ID NO:126, SEQ ID NO:127, SEQ ID NO:130; and, in particular, nucleotide sequences, SEQ ID NOS:115-124. Additional primers based upon GDNF and neurturin include nucleic acid sequences encoding amino acid sequences, SEQ 30 ID NO:33, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:41; 35 primers whose reverse complementary sequences encode SEQ

ID NO:37, SEQ ID NO:38 and SEQ ID NO 39; and, in particular, nucleic acid sequences, SEQ ID NOS:42-48.

Hybridization using the new probes from conserved regions of the nucleic acid sequences would be performed under reduced stringency conditions. Factors involved in determining stringency conditions are well known in the art (for example, see Sambrook et al., *Molecular Cloning*, 2nd Ed., 1989 which is incorporated by reference). Sources of nucleic acid for screening would include genomic DNA libraries from mammalian species or cDNA libraries constructed using RNA obtained from mammalian cells cloned into any suitable vector.

PCR primers would be utilized under PCR conditions of reduced annealing temperature which would allow amplification of sequences from gene family members other than GDNF, neurturin and persephin. Sources of nucleic acid for screening would include genomic DNA libraries from mammalian species cloned into any suitable vector, cDNA transcribed from RNA obtained from mammalian cells, and genomic DNA from mammalian species.

DNA sequences identified on the basis of hybridization or PCR assays would be sequenced and compared to GDNF, neurturin and persephin. The DNA sequences encoding the entire sequence of the novel factor would then be obtained in the same manner as described herein. Genomic DNA or libraries of genomic clones can also be used as templates because the intron/exon structures of GDNF and neurturin are conserved and coding sequences of the mature proteins are not interrupted by introns.

Using this approach as described above, the primers designed from the conserved regions of neurturin and GDNF have been used to identify and obtain the sequence of the new family member described herein, persephin.

35 Degenerate primers designed from persephin, neurturin and

GDNF can be further used to identify and obtain additional family members.

It is believed that all GDNF-neurturin-persephin family members will have a high degree of sequence identity with one or more of the three identified family-member consensus regions in the portion of the sequence between the first and seventh canonical framework cysteines (see Figure 12). In particular, a new family member is anticipated to have at least a 62.5% identity with the consensus region octapeptide, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser, Thr or Ala and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:108) or at least a 62.5 percent sequence identity with the consensus region octapeptide, Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys where Xaa<sub>1</sub> and Xaa<sub>2</sub> are alanine or serine (SEQ ID NO:109) or at least a 50 percent sequence identity with the consensus region octapeptide, Asp-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Asp-Xaa<sub>4</sub> where Xaa<sub>1</sub> is aspartic acid or glutamic acid or no amino acid, Xaa<sub>2</sub> is valine or leucine, Xaa<sub>3</sub> is serine or threonine; and Xaa<sub>4</sub> is valine or aspartic acid (SEQ ID NO:110). The inventors herein believed that any new family member will have 28 amino acids in the aligned sequence between the first and seventh canonical framework cysteine residues as set forth in Figure 15 with residues numbered from the N-terminal end of the family member aligned sequence being (1) Cys, (3) Leu, (10) Val, (13) Leu, (14) Gly, (15) Leu, (16) Gly, (17) Tyr, (21) Glu, (25) Phe, (26) Arg, (27) Tyr, (28) Cys, (30) Gly, (32) Cys, (44) Leu, (47) Leu, (58) Cys, (59) Cys (61) Pro, (66) Asp, (69) Phe, (70) Leu, (71) Asp, (83) Ser, (84) Ala, (87) Cys, and (89) Cys, however, it is possible that there may be as many as three mismatches.

On the basis of the structural similarities of persephin to the sequences of neurturin and GDNF, persephin would be expected to promote the survival and growth of neuronal as well as non-neuronal cells. For

example, neurturin has been shown to promote the survival of superior cervical ganglion cells as well as nodose sensory ganglia neurons (see Examples 1-3). Furthermore, GDNF has been shown to act on dopaminergic, sympathetic, 5 motor and several sensory neurons (Henderson et al. *supra*, 1994; Miles et al, *J Cell Biol* 130:137-148, 1995; Yan et al, *Nature* 373:341-344, 1995; Lin et al, *Science* 260:1130-1132, 1993; Trupp et al, *J Cell Biol* 130:137-148, 1995; Martin et al *Brain Res* 683:172-178, 1995;

10 Bowenkamp et al *J Comp Neurol* 355:479-489, 1995 which are incorporated by reference). Moreover, all other growth factors isolated to date have been shown to act on many different cell types (for example see Scully and Otten, *Cell Biol Int* 19:459-469, 1995; Hefti, *Neurotrophic*

15 Factor Therapy 25:1418-1435, 1994 which are incorporated by reference). Thus, it is likely that persephin will show activity on a variety of different neuronal cells, both peripheral and central, as well as on non-neuronal cells. With respect to peripheral neuronal cells, the

20 profile of cells for which persephin will show a survival promoting activity appears to be different from that of neurturin or GDNF. In contrast to the survival-promoting activity produced by neurturin and GDNF in sympathetic and sensory neurons, persephin showed no activity in

25 these tissues at concentrations tested. Nevertheless, persephin showed survival-promoting activity in mesencephalic cells obtained from rat embryo brains. Furthermore, persephin activity on any particular target cell type can be determined by routine experimentation

30 using standard reference models. Moreover, the inventors herein have identified brain and heart tissues as tissues expressing persephin, which further supports the conclusion that persephin can act to promote survival and growth in a variety of neuronal and non-neuronal cells.

35 As an example of the actions of neurotrophic factors on non-neuronal tissues, the prototypical neurotrophic

factor, NGF, also acts upon mast cells to increase their number when injected into newborn rats (Aloe, *J Neuroimmunol* 18:1-12, 1988). In addition, mast cells express the trk receptor and respond to NGF such that NGF 5 is a mast cell secretagogue and survival promoting factor (Horigome et al., *J Biol Chem* 269:2695-2707, 1994 which is incorporated by reference). Moreover, members of the TGF- $\beta$  superfamily act on many cell types of different function and embryologic origin.

10 The inventors herein have identified brain and heart as tissues in which persephin is expressed and it is further believed that persephin is expressed in a number of other neuronal and non-neuronal tissues. The related family member, neurturin, is expressed in a number of 15 non-neuronal tissues including blood, bone marrow, neonatal liver and mast cells. This suggests a role for neurturin in hematopoiesis, inflammation, allergy, and cardiomyopathy. Similarly, persephin may also have a similar profile of activity.

20 Neurotrophic factors of the NGF family are thought to act through factor-specific high affinity receptors (Tuszynski and Gage, 1994, *supra*). Only particular portions of the protein acting at a receptor site are required for binding to the receptor. Such particular 25 portions or discrete fragments can serve as an agonist where the substance activates a persephin receptor to elicit the promoting action on cell survival and growth and antagonists to persephin where they bind to, but do not activate, the receptor or promote survival and 30 growth. Such portions or fragments that are agonists and those that are antagonists are also within the scope of the present invention.

Synthetic, pan-growth factors can also be constructed by combining the active domains of persephin 35 with the active domains of one or more other non-persephin growth factors. (For example, see Ilag et al.,

*Proc Nat'l Acad Sci 92:607-611, 1995 which is incorporated by reference).* These pan-growth factors would be expected to have the combined activities or other advantageous properties of persephin and the one or 5 more other growth factors. As such, these pan-growth factors are believed to be potent and multispecific growth factors that are useful in the treatment of a wide spectrum of degenerative diseases and conditions including conditions that can be treated by any or all of 10 the parent factors from which the active domains were obtained. Such pan-growth factors might also provide synergistic effects beyond the activities of the parent factors (Barres et al., *supra*).

Pan-growth factors within the scope of the present 15 invention can include chimeric or hybrid polypeptides that are constructed from portions of fragments of at least two growth factors. Growth factors of the TGF- $\beta$  superfamily are structurally related having highly conserved sequence landmarks whereby family members are 20 identified. In particular, seven canonical framework cysteine residues are nearly invariant in members of the superfamily (Kingsley, *Genes & Dev 8:133-146, 1994 which is incorporated by reference*) (see Figure 17). Chimeric polypeptide molecules can, therefore, be constructed from 25 a sequence that is substantially identical to a portion of the persephin molecule, up to one or more crossover points, and one or more sequences each of which is substantially identical with a portion of another TGF- $\beta$  superfamily member extending on the other side of the 30 corresponding one or more crossover points. For example, a portion of the amino terminal end of the persephin polypeptide can be combined with a portion of the carboxy terminal end of a neurturin polypeptide or alternatively a portion of the amino terminal end of a neurturin 35 polypeptide can be combined with a portion of the carboxy terminal end of a persephin polypeptide. Such portions

of persephin or neurturin polypeptides are preferably from about 5 to about 95, more preferably from about 10 to about 90, still more preferably from about 20 to about 80 and most preferably from about 30 to about 70

5 contiguous amino acids and such portions of another, non-persephin or, as the case may be, non-neurturin TGF- $\beta$  superfamily member are preferably from about 5 to about 95, more preferably from about 10 to about 90, still more preferably from about 20 to about 80 and most preferably

10 from about 30 to about 70 contiguous amino acids. For example, a particular crossover point might be between the third and fourth canonical framework cysteine residues. One such exemplary construct would contain at the 5' end a sequence comprised of a persephin sequence

15 from residue 1 through the third canonical framework cysteine residue 37 and up to a cross-over point somewhere between residue 37 and residue 63 but not including the fourth canonical framework cysteine residue 64 (for reference, see mature persephin, SEQ ID NO:80).

20 The 3' end of the hybrid construct would constitute a sequence derived from another TGF- $\beta$  superfamily member such as, for example, neurturin which is another TGF- $\beta$  superfamily member that is closely related to persephin. Using neurturin as the other TGF- $\beta$  family member, the

25 hybrid construct beyond the crossover point would be comprised of a sequence beginning at the desired crossover point in the neurturin sequence between the third canonical framework cysteine residue 37 and the fourth canonical framework cysteine residue 67 of

30 neurturin and continuing through residue 100 at the 3' end of neurturin (for alignment, see figure 12). A second exemplary hybrid construct would be comprised of residue 1 through a crossover point between residues 37 and 67 of neurturin contiguously linked with residues

35 from the crossover point between residues 37 and 64 through residue 96 of persephin. The above constructs

with persephin and neurturin are intended as examples only with the particular TGF- $\beta$  family member being selected from family members including but not limited to transforming growth factor- $\beta$ 1 (TGF $\beta$ 1), transforming growth factor- $\beta$ 2 (TGF $\beta$ 2), transforming growth factor- $\beta$ 3 (TGF $\beta$ 3), inhibin  $\beta$  A (INH $\beta$ A), inhibin  $\beta$  B (INH $\beta$ B), the nodal gene (NODAL), bone morphogenetic proteins 2 and 4 (BMP2 and BMP4), the *Drosophila decapentaplegic* gene (*dpp*), bone morphogenetic proteins 5-8 (BMP5, BMP6, BMP7 and BMP8), the *Drosophila 60A* gene family (60A), bone morphogenetic protein 3 (BMP3), the *Vgl* gene, growth differentiation factors 1 and 3 (GDF1 and GDF3), dorsalin (drsln), inhibin  $\alpha$  (INH $\alpha$ ), the *MIS* gene (MIS), growth factor 9 (GDF-9), glial-derived neurotropic growth factor (GDNF), neurturin (NTN) and persephin (see Figure 16). In addition, the crossover point can be any residue between the first and seventh canonical framework cysteines molecules of neurturin and the particular other family member. Furthermore, additional crossover points can be used to incorporate any desired number of persephin portions or fragments with portions or fragments of any one or more other family members.

In constructing a particular chimeric molecule, the portions of persephin and portions of the other, non-persephin growth factor are amplified using PCR, mixed and used as template for a PCR reaction using the forward primer from one and the reverse primer from the other of the two component portions of the chimeric molecule. Thus, for example a forward and reverse primers are selected to amplify the portion of persephin from the beginning to the selected crossover point between the third and fourth canonical cysteine residues using a persephin plasmid as template. A forward primer with a 5' portion overlapping with the persephin sequence and a reverse primer are then used to amplify the portion of the other, non-persephin growth factor member of the TGF-

β superfamily from the corresponding crossover point through the 3' end using a plasmid template containing the coding sequence for the non-persephin TGF-β family member. The products of the two PCR reactions are gel 5 purified and mixed together and a PCR reaction performed. Using an aliquot of this reaction as template a PCR reaction is performed using the persephin forward primer and the reverse primer for the non-persephin growth factor. The product is then cloned into an expression 10 vector for production of the chimeric molecule.

Chimeric growth factors would be expected to be effective in promoting the growth and development of cells and for use in preventing the atrophy, degeneration or death of cells, particular in neurons. The chimeric 15 polypeptides may also act as receptor antagonists of one or both of the full length growth factors from which the chimeric polypeptide was constructed or as an antagonist of any other growth factor that acts at the same receptor or receptors.

20 The present invention also includes therapeutic or pharmaceutical compositions comprising persephin in an effective amount for treating patients with cellular degeneration or dysfunction and a method comprising administering a therapeutically effective amount of 25 persephin. These compositions and methods are useful for treating a number of degenerative diseases. Where the cellular degeneration involves neuronal degeneration, the diseases include, but are not limited to peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's 30 disease, Parkinson's disease, Huntington's disease, ischemic stroke, acute brain injury, acute spinal chord injury, nervous system tumors, multiple sclerosis, peripheral nerve trauma or injury, exposure to neurotoxins, metabolic diseases such as diabetes or renal 35 dysfunctions and damage caused by infectious agents. In particular, the ability of persephin to promote survival

in mesencephalic cells suggests an applicability of this growth factor in treating neuronal degenerative diseases of the CNS such as Parkinson's disease.

Where the cellular degeneration involves bone marrow cell degeneration, the diseases include, but are not limited to disorders of insufficient blood cells such as, for example, leukopenias including eosinopenia and/or basopenia, lymphopenia, monocytopenia, neutropenia, anemias, thrombocytopenia as well as an insufficiency of stem cells for any of the above. The cellular degeneration can also involve myocardial muscle cells in diseases such as cardiomyopathy and congestive heart failure. The above cells and tissues can also be treated for depressed function.

The compositions and methods herein can also be useful to prevent degeneration and/or promote survival in other non-neuronal tissues as well. One skilled in the art can readily determine using a variety of assays known in the art for identifying whether persephin would be useful in promoting survival or functioning in a particular cell type.

In certain circumstances, it may be desirable to modulate or decrease the amount of persephin expressed. Thus, in another aspect of the present invention, persephin anti-sense oligonucleotides can be made and a method utilized for diminishing the level of expression of persephin, respectively, by a cell comprising administering one or more persephin anti-sense oligonucleotides. By persephin anti-sense oligonucleotides reference is made to oligonucleotides that have a nucleotide sequence that interacts through base pairing with a specific complementary nucleic acid sequence involved in the expression of persephin such that the expression of persephin is reduced. Preferably, the specific nucleic acid sequence involved in the expression of persephin is a genomic DNA molecule or mRNA

molecule that contains sequences of the persephin gene. This genomic DNA molecule can comprise flanking regions of the persephin gene, untranslated regions of persephin mRNA, the pre- or pro- portions of the persephin gene or 5 the coding sequence for mature persephin protein. The term complementary to a nucleotide sequence in the context of persephin antisense oligonucleotides and methods therefor means sufficiently complementary to such a sequence as to allow hybridization to that sequence in 10 a cell, i.e., under physiological conditions. The persephin antisense oligonucleotides preferably comprise a sequence containing from about 8 to about 100 nucleotides and more preferably the persephin antisense oligonucleotides comprise from about 15 to about 30 15 nucleotides. The persephin antisense oligonucleotides can also contain a variety of modifications that confer resistance to nucleolytic degradation such as, for example, modified internucleoside linkages (Uhlmann and Peyman, *Chemical Reviews* 90:543-548, 1990; Schneider and 20 Banner, *Tetrahedron Lett* 31:335, 1990 which are incorporated by reference), modified nucleic acid bases and/or sugars and the like.

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable 25 route known in the art including for example intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of slow release formulation. For treating 30 tissues in the central nervous system, administration can be by injection or infusion into the cerebrospinal fluid (CSF). When it is intended that persephin be administered to cells in the central nervous system, administration can be with one or more agents capable of 35 promoting penetration of persephin across the blood-brain barrier.

Persephin can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, persephin can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor, and administered by intravenous injection. (See for example, Friden et al., *Science* 259:373-377, 1993 which is incorporated by reference). Furthermore, persephin can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other pharmaceutically advantageous properties. (See for example Davis et al. *Enzyme Eng* 4:169-73, 1978; Burnham, *Am J Hosp Pharm* 51:210-218, 1994 which are incorporated by reference).

The compositions are usually employed in the form of pharmaceutical preparations. Such preparations are made in a manner well known in the pharmaceutical art. One preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. Persephin can also be incorporated into a solid or semi-solid biologically compatible matrix which can be implanted into tissues requiring treatment.

The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the

formulation. Similarly, the carrier may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or penetration across the blood-brain barrier. Such 5 excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dosage or multi-dose form or for direct infusion into the cerebrospinal fluid by continuous or periodic infusion.

10 Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

It is also contemplated that certain formulations containing persephin are to be administered orally. Such 15 formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, 20 calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating 25 agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the active ingredients after administration to the patient by 30 employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and promote absorption such as, for example, surface active agents.

The specific dose is calculated according to the 35 approximate body weight or body surface area of the patient or the volume of body space to be occupied. The

dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art in light of the activity of persephin. The activity of neurturin in target cells data is disclosed herein and in copending application Serial Number 10 08/519,777 and the concentration of persephin required for activity at the cellular level is believed to be similar to that of neurturin. The activity of persephin on mesencephalic cells is reported in Example 17 below. Persephin activity on a particular target cell type can be determined by routine experimentation. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

25 In one embodiment of this invention, persephin may be therapeutically administered by implanting into patients vectors or cells capable of producing a biologically-active form of persephin or a precursor of persephin, i.e. a molecule that can be readily converted 30 to a biological-active form of persephin by the body. In one approach cells that secrete persephin may be encapsulated into semipermeable membranes for implantation into a patient. The cells can be cells that normally express persephin or a precursor of persephin or 35 the cells can be transformed to express persephin or a precursor thereof. It is preferred that the cell be of

human origin and that the persephin be human persephin when the patient is human. However, the formulations and methods herein can be used for veterinary as well as human applications and the term "patient" as used herein 5 is intended to include human and veterinary patients.

Cells can be grown *ex vivo* for use in transplantation or engraftment into patients (Muensch et al., *Leuk & Lymph* 16:1-11, 1994 which is incorporated by reference). In another embodiment of the present 10 invention, persephin can be used to promote the *ex vivo* expansion of a cells for transplantation or engraftment. Current methods have used bioreactor culture systems containing factors such as erythropoietin, colony 15 stimulating factors, stem cell factor, and interleukins to expand hematopoietic progenitor cells for erythrocytes, monocytes, neutrophils, and lymphocytes (Verfaillie, *Stem Cells* 12:466-476, 1994 which is incorporated by reference). These stem cells can be isolated from the marrow of human donors, from human 20 peripheral blood, or from umbilical cord blood cells. The expanded blood cells are used to treat patients who lack these cells as a result of specific disease conditions or as a result of high dose chemotherapy for treatment of malignancy (George, *Stem Cells* 12(*Suppl 25 1*):249-255, 1994 which is incorporated by reference). In the case of cell transplant after chemotherapy, autologous transplants can be performed by removing bone 30 marrow cells before chemotherapy, expanding the cells *ex vivo* using methods that also function to purge malignant cells, and transplanting the expanded cells back into the patient following chemotherapy (for review see Rummel and Van Zant, *J Hematotherapy* 3:213-218, 1994 which is incorporated by reference). Since persephin and the 35 related growth factor, neurturin, may be expressed in the developing animal in particular tissues where proliferation and differentiation of progenitor cells

occur, it is believed that persephin can function to regulate the proliferation of hematopoietic stem cells and the differentiation of mature hematopoietic cells. Thus, the addition of persephin to culture systems used 5 for *ex vivo* expansion of cells could stimulate the rate at which certain populations of cells multiply or differentiate, and improve the effectiveness of these expansion systems in generating cells needed for transplant.

10 It is also believed that persephin can be used for the *ex vivo* expansion of precursor cells in the nervous system. Transplant or engraftment of cells is currently being explored as a therapy for diseases in which certain populations of neurons are lost due to degeneration such 15 as, for example, in parkinson's disease (Bjorklund, *Curr Opin Neurobiol* 2:683-689, 1992 which is incorporated by reference). Neuronal precursor cells can be obtained from animal or human donors or from human fetal tissue and then expanded in culture using persephin. These 20 cells can then be engrafted into patients where they would function to replace some of the cells lost due to degeneration. Because neurotrophins have been shown to be capable of stimulating the survival and proliferation of neuronal precursors cells such as, for example, NT-3 25 stimulation of sympathetic neuroblast cells (Birren et al., *Develop* 119:597-610, 1993 which is incorporated by reference), persephin could also function in similar ways during the development of the nervous system and could be useful in the *ex vivo* expansion of neuronal cells.

30 In a number of circumstances it would be desirable to determine the levels of persephin in a patient. The identification of persephin along with the present report that persephin is expressed by certain tissues provides the basis for the conclusion that the presence of 35 persephin serves a normal physiologic function related to cell growth and survival. Indeed, other neurotrophic

factors are known to play a role in the function of neuronal and non-neuronal tissues. (For review see Scully and Otten, *Cell Biol Int* 19:459-469, 1995; Otten and Gadient, *Int J Devl Neurosciences* 13:147-151, 1995  
5 which are incorporated by reference). Endogenously produced persephin may also play a role in certain disease conditions, particularly where there is cellular degeneration such as in neurodegenerative conditions or diseases. Other neurotrophic factors are known to change  
10 during disease conditions. For example, in multiple sclerosis, levels of NGF protein in the cerebrospinal fluid are increased during acute phases of the disease (Bracci-Laudiero et al., *Neuroscience Lett* 147:9-12, 1992 which is incorporated by reference) and in systemic lupus  
15 erythematosus there is a correlation between inflammatory episodes and NGF levels in sera (Bracci-Laudiero et al. *NeuroReport* 4:563-565, 1993 which is incorporated by reference).

Given that persephin is expressed in certain  
20 tissues, it is thus likely that the level of persephin may be altered in a variety of conditions and that quantification of persephin levels would provide clinically useful information. Furthermore, in the treatment of degenerative conditions, compositions  
25 containing persephin can be administered and it would likely be desirable to achieve certain target levels of persephin in sera, in cerebrospinal fluid or in any desired tissue compartment. It would, therefore, be advantageous to be able to monitor the levels of  
30 persephin in a patient. Accordingly, the present invention also provides methods for detecting the presence of persephin in a sample from a patient.

The term "detection" as used herein in the context of detecting the presence of persephin in a patient is  
35 intended to include the determining of the amount of persephin or the ability to express an amount of

persephin in a patient, the distinguishing of persephin from other growth factors, the estimation of prognosis in terms of probable outcome of a degenerative disease and prospect for recovery, the monitoring of the persephin levels over a period of time as a measure of status of the condition, and the monitoring of persephin levels for determining a preferred therapeutic regimen for the patient.

To detect the presence of persephin in a patient, a sample is obtained from the patient. The sample can be a tissue biopsy sample or a sample of blood, plasma, serum, CSF or the like. Persephin is expressed in kidney and brain tissues as shown in example 18 and it is believed that persephin is expressed in other tissues not tested as well. Samples for detecting persephin can be taken from any tissue expressing persephin. When assessing peripheral levels of persephin, it is preferred that the sample be a sample of blood, plasma or serum or alternatively from a tissue biopsy sample. When assessing the levels of persephin in the central nervous system a preferred sample is a sample obtained from cerebrospinal fluid.

In some instances it is desirable to determine whether the persephin gene is intact in the patient or in a tissue or cell line within the patient. By an intact persephin gene it is meant that there are no alterations in the gene such as point mutations, deletions, insertions, chromosomal breakage, chromosomal rearrangements and the like wherein such alteration might alter production of persephin or alter its biological activity, stability or the like to lead to disease processes or susceptibility to cellular degenerative conditions. Conversely, by a non-intact persephin gene it is meant that such alterations are present. Thus, in one embodiment of the present invention a method is provided for detecting and characterizing any alterations

in the persephin gene. The method comprises providing an oligonucleotide that contains the persephin cDNA, genomic DNA or a fragment thereof or a derivative thereof. By a derivative of an oligonucleotide, it is meant that the 5 derived oligonucleotide is substantially the same as the sequence from which it is derived in that the derived sequence has sufficient sequence complementarity to the sequence from which it is derived to hybridize to the persephin gene. The derived nucleotide sequence is not 10 necessarily physically derived from the nucleotide sequence, but may be generated in any manner including for example, chemical synthesis or DNA replication or reverse transcription or transcription.

Typically, patient genomic DNA is isolated from a 15 cell sample from the patient and digested with one or more restriction endonucleases such as, for example, TaqI and AluI. Using the Southern blot protocol, which is well known in the art, this assay determines whether a patient or a particular tissue in a patient has an intact 20 persephin gene or a persephin gene abnormality.

Hybridization to the persephin gene would involve denaturing the chromosomal DNA to obtain a single-stranded DNA; contacting the single-stranded DNA with a gene probe associated with the persephin gene sequence; 25 and identifying the hybridized DNA-probe to detect chromosomal DNA containing at least a portion of the human persephin gene.

The term "probe" as used herein refers to a structure comprised of a polynucleotide which forms a 30 hybrid structure with a target sequence, due to complementarity of probe sequence with a sequence in the target region. The probes need not reflect the exact sequence of the target sequence, but must be sufficiently complementary to selectively hybridize with the strand 35 being amplified. By selective hybridization or specific hybridization it is meant that a polynucleotide

preferentially hybridizes to a target polynucleotide. Oligomers suitable for use as probes may contain a minimum of about 8-12 contiguous nucleotides which are complementary to the targeted sequence and preferably a 5 minimum of about 15 nucleotides although polynucleotide probes up to about 20 nucleotides and up to about 100 nucleotides or even greater are within the scope of this invention.

The persephin gene probes of the present invention 10 can be DNA or RNA oligonucleotides and can be made by any method known in the art such as, for example, excision, transcription or chemical synthesis. Probes may be labelled with any detectable label known in the art such as, for example, radioactive or fluorescent labels or 15 enzymatic marker. Labeling of the probe can be accomplished by any method known in the art such as by PCR, random priming, end labelling, nick translation or the like. One skilled in the art will also recognize that other methods not employing a labelled probe can be 20 used to determine the hybridization. Examples of methods that can be used for detecting hybridization include Southern blotting, fluorescence *in situ* hybridization, and single-strand conformation polymorphism with PCR amplification.

25 Hybridization is typically carried out at 25-45°C, more preferably at 32-40°C and more preferably at 37-38°C. The time required for hybridization is from about 0.25 to about 96 hours, more preferably from about one to about 72 hours, and most preferably from about 4 to about 30 24 hours.

Persephin gene abnormalities can also be detected by using the PCR method and primers that flank or lie within the persephin gene. The PCR method is well known in the art. Briefly, this method is performed using two 35 oligonucleotide primers which are capable of hybridizing to the nucleic acid sequences flanking a target sequence

that lies within a persephin gene and amplifying the target sequence. The terms "oligonucleotide primer" as used herein refers to a short strand of DNA or RNA typically ranging in length from about 8 to about 30 bases. The upstream and downstream primers are preferably a minimum of from about 15 nucleotides to about 20 nucleotides and up to about 30 nucleotides or even greater in length. The primers can hybridize to the flanking regions for replication of the nucleotide sequence. The polymerization is catalyzed by a DNA-polymerase in the presence of deoxynucleotide triphosphates or nucleotide analogs to produce double-stranded DNA molecules. The double strands are then separated by any denaturing method including physical, chemical or enzymatic. Commonly, the method of physical denaturation is used involving heating the nucleic acid, typically to temperatures from about 80°C to 105°C for times ranging from about 1 to about 10 minutes. The process is repeated for the desired number of cycles.

The primers are selected to be substantially complementary to the strand of DNA being amplified. Therefore, the primers need not reflect the exact sequence of the template, but must be sufficiently complementary to selectively hybridize or specifically hybridize with the strand being amplified. By selective hybridization or specific hybridization it is meant that a polynucleotide preferentially hybridizes to a target polynucleotide.

After PCR amplification, the DNA sequence comprising persephin or pre-pro persephin or a fragment thereof is then directly sequenced and analyzed by comparison of the sequence with the sequences disclosed herein to identify alterations which might change activity or expression levels or the like.

In another embodiment a method for detecting persephin is provided based upon an analysis of tissue

expressing the persephin gene. Certain tissues such as those identified below in example 18 have been found to express the persephin gene. The method comprises hybridizing a polynucleotide probe to mRNA from a sample 5 of tissues that normally express the persephin gene or from a cDNA produced from the mRNA of the sample. The sample is obtained from a patient suspected of having an abnormality in the persephin gene or from a particular patient tissue or cell type suspected of having an 10 abnormality in the persephin gene. The reference persephin polynucleotide probe can comprise SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NOS:203-206 or derivatives thereof or fragments thereof so long as such derivatives or fragments 15 specifically hybridize to persephin mRNA or from a cDNA produced from a persephin mRNA.

To detect the presence of mRNA encoding persephin protein, a sample is obtained from a patient. The sample can be from blood or from a tissue biopsy sample. The 20 sample may be treated to extract the nucleic acids contained therein. The resulting nucleic acid from the sample is subjected to gel electrophoresis or other size separation techniques.

The mRNA of the sample is contacted with a nucleic 25 acid serving as a probe to form hybrid duplexes. The use of a labeled probes as discussed above allows detection of the resulting duplex.

When using the cDNA encoding persephin protein or a derivative of the cDNA as a probe, high stringency 30 conditions can be used in order to prevent false positives, that is the hybridization and apparent detection of persephin nucleotide sequences when in fact an intact and functioning persephin gene is not present. When using sequences derived from the persephin cDNA, 35 less stringent conditions could be used, however, this would be a less preferred approach because of the

likelihood of false positives. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time and 5 concentration of formamide. These factors are outlined in, for example, Sambrook et al. (Sambrook, et al., 1989, *supra*).

In order to increase the sensitivity of the detection in a sample of mRNA encoding the persephin 10 protein, the technique of reverse transcription/polymerization chain reaction (RT/PCR) can be used to amplify cDNA transcribed from mRNA encoding the persephin protein. The method of RT/PCR is well known in the art (see example 9 and figure 6 below).

15 The RT/PCR method can be performed as follows. Total cellular RNA is isolated by, for example, the standard guanidium isothiocyanate method and the total RNA is reverse transcribed. The reverse transcription method involves synthesis of DNA on a template of RNA 20 using a reverse transcriptase enzyme and a 3' end primer. Typically, the primer contains an oligo(dT) sequence. The cDNA thus produced is then amplified using the PCR method and persephin specific primers. (Belyavsky et al, *Nucl Acid Res* 17:2919-2932, 1989; Krug and Berger, 25 *Methods in Enzymology*, Academic Press, N.Y., Vol.152, pp. 316-325, 1987 which are incorporated by reference).

The polymerase chain reaction method is performed as described above using two oligonucleotide primers that are substantially complementary to the two flanking 30 regions of the DNA segment to be amplified.

Following amplification, the PCR product is then electrophoresed and detected by ethidium bromide staining or by phosphoimaging.

The present invention further provides for methods 35 to detect the presence of the persephin protein in a sample obtained from a patient. Any method known in the

art for detecting proteins can be used. Such methods include, but are not limited to immunodiffusion, immunoelectrophoresis, immunochemical methods, binder-ligand assays, immunohistochemical techniques, 5 agglutination and complement assays. (for example see *Basic and Clinical Immunology*, Sites and Terr, eds., Appleton & Lange, Norwalk, Conn. pp 217-262, 1991 which is incorporated by reference). Preferred are binder-ligand immunoassay methods including reacting antibodies 10 with an epitope or epitopes of the persephin protein or derivative thereof and competitively displacing the labeled persephin protein or derivative thereof.

As used herein, a derivative of persephin protein is intended to include a polypeptide in which certain amino acids have been deleted or replaced with other amino acids or changed to modified or unusual amino acids wherein the persephin derivative is biologically equivalent to persephin and/or wherein the polypeptide derivative cross-reacts with antibodies raised against 20 the persephin protein. By cross-reaction it is meant that an antibody reacts with an antigen other than the one that induced its formation.

Numerous competitive and non-competitive protein binding immunoassays are well known in the art. 25 Antibodies employed in such assays may be unlabeled, for example as used in agglutination tests, or labeled for use in a wide variety of assay methods. Labels that can be used include radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates or co-factors, enzyme 30 inhibitors, particles, dyes and the like for use in radioimmunoassay (RIA), enzyme immunoassays, e.g., enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassays and the like.

Polyclonal or monoclonal antibodies to the persephin 35 protein or to an epitope thereof can be made for use in immunoassays by any of a number of methods known in the

art. By epitope reference is made to an antigenic determinant of a polypeptide. The term epitope can also include persephin-specific B cell epitopes or T helper cell epitopes. An epitope could comprise 3 amino acids 5 in a spacial conformation which is unique to the epitope. Generally an epitope consists of at least 5 such amino acids. Methods of determining the spatial conformation of amino acids are known in the art, and include, for example, x-ray crystallography and 2 dimensional nuclear 10 magnetic resonance.

One approach for preparing antibodies to a protein is the selection and preparation of an amino acid sequence of all or part of the protein, chemically synthesizing the sequence and injecting it into an 15 appropriate animal, usually a rabbit or a mouse (See Example 10).

Oligopeptides can be selected as candidates for the production of an antibody to the persephin protein based upon the oligopeptides lying in hydrophilic regions, 20 which are thus likely to be exposed in the mature protein.

Antibodies to persephin can also be raised against oligopeptides that include one or more of the conserved regions identified herein such that the antibody can 25 cross-react with other family members. Such antibodies can be used to identify and isolate the other family members.

Methods for preparation of the persephin protein or an epitope thereof include, but are not limited to 30 chemical synthesis, recombinant DNA techniques or isolation from biological samples. Chemical synthesis of a peptide can be performed, for example, by the classical Merrifeld method of solid phase peptide synthesis (Merrifeld, *J Am Chem Soc* 85:2149, 1963 which is 35 incorporated by reference) or the Fmoc strategy on a Rapid Automated Multiple Peptide Synthesis system (DuPont

Company, Wilmington, DE) (Caprino and Han, *J Org Chem* 37:3404, 1972 which is incorporated by reference).

5 Polyclonal antibodies can be prepared by immunizing rabbits or other animals by injecting antigen followed by subsequent boosts at appropriate intervals. The animals are bled and sera assayed against purified persephin protein usually by ELISA or by bioassay based upon the ability to block the action of persephin. When using avian species, e.g. chicken, turkey and the like, the 10 antibody can be isolated from the yolk of the egg.

Monoclonal antibodies can be prepared after the method of Milstein and Kohler by fusing splenocytes from immunized mice with continuously replicating tumor cells such as myeloma or lymphoma cells. (Milstein and Kohler *Nature* 15 256:495-497, 1975; Gelfre and Milstein, *Methods in Enzymology: Immunochemical Techniques* 73:1-46, Langone and Banatis eds., Academic Press, 1981 which are incorporated by reference). The hybridoma cells so formed are then cloned by limiting dilution methods and 20 supernates assayed for antibody production by ELISA, RIA or bioassay.

The unique ability of antibodies to recognize and specifically bind to target proteins provides an approach for treating an over expression of the protein. Thus, 25 another aspect of the present invention provides for a method for preventing or treating diseases involving over expression of the persephin protein by treatment of a patient with specific antibodies to the persephin protein.

30 Specific antibodies, either polyclonal or monoclonal, to the persephin protein can be produced by any suitable method known in the art as discussed above. For example, murine or human monoclonal antibodies can be produced by hybridoma technology or, alternatively, the 35 persephin protein, or an immunologically active fragment thereof, or an anti-idiotypic antibody, or fragment

thereof can be administered to an animal to elicit the production of antibodies capable of recognizing and binding to the persephin protein. Such antibodies can be from any class of antibodies including, but not limited 5 to IgG, IgA, IgM, IgD, and IgE or in the case of avian species, IgY and from any subclass of antibodies.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one 10 skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims 15 which follow the examples.

#### Example 1

This example illustrates the isolation and purification of neurturin from CHO cell conditioned 20 medium.

##### Preparation of CHO cell conditioned medium:

A derivative of DG44 Chinese hamster ovary cells, DG44CHO-pHSP-NGFI-B (CHO) cells, was used (Day et al, *J Biol Chem* 265:15253-15260, 1990 which is incorporated by 25 reference). The inventors herein have also obtained neurturin in partially purified form from other derivatives of DG44 Chinese hamster ovary cells. The CHO cells were maintained in 20 ml medium containing minimum essential medium (MEM) alpha (Gibco-BRL No. 12561, 30 Gaithersburg, MD) containing 10% fetal calf serum (Hyclone Laboratories, Logan, UT), 2 mM l-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 25nM methotrexate using 150 cm<sup>2</sup> flasks (Corning Inc., Corning NY). For passage and expansion, medium from a confluent 35 flask was aspirated; the cells were washed with 10 ml phosphate buffered saline (PBS) containing in g/l, 0.144

$\text{KH}_2\text{PO}_4$ , 0.795  $\text{Na}_2\text{HPO}_4$  and 9.00 NaCl; and the flask was then incubated for 2-3 minutes with 2 ml 0.25% trypsin in PBS. Cells were then knocked off the flask surface, 8 ml of medium were added and cells were triturated several times 5 with a pipette. The cells were split 1:5 or 1:10, incubated at 37°C under an atmosphere of 5%  $\text{CO}_2$  in air and grown to confluence for 3-4 days.

The cell culture was then expanded into 850  $\text{cm}^2$  roller bottles (Becton Dickinson, Bedford, MA). A 10 confluent 150  $\text{cm}^2$  flask was trypsinized and seeded into one roller bottle containing 240 ml of the above modified MEM medium without methotrexate. The pH was maintained either by blanketing the medium with 5%  $\text{CO}_2$  in air or by preparing the medium with 25 mM HEPES pH 7.4 (Sigma, St. 15 Louis, MO). The roller bottles were rotated at 0.8-1.0 revolutions per minute. Cells reached confluence in 4 days.

For collecting conditioned medium, serum-free CHO cell (SF-CHO) medium was used. SF-CHO was prepared using 20 1:1 DME/F12 base medium, which was prepared by mixing 1:1 (v/v) DMEM (Gibco-BRL product No. 11965, Gibco-BRL, Gaithersburg, MD) with Ham's F12 (Gibco-BRL product No. 11765). The final SF-CHO medium contained 15 mM HEPES pH 7.4 (Sigma, St. Louis, MO), 0.5 mg/ml bovine serum 25 albumin (BSA, Sigma, St. Louis MO), 25  $\mu\text{g}/\text{ml}$  heparin, (Sigma, St. Louis, MO), 1X insulin-transferrin-selenite supplement (bovine insulin, 5  $\mu\text{g}/\text{ml}$ ; human transferrin, 5  $\mu\text{g}/\text{ml}$ ; sodium selenite, 5 ng/ml; Sigma, St. Louis, MO), 2 mM l-glutamine, 100 U/ml penicillin, and 100  $\mu\text{g}/\text{ml}$  30 streptomycin. The medium from the confluent roller bottles was removed and the cells washed once with 30 ml SF-CHO medium to remove serum proteins. Cells were then incubated at 37°C for 16-24 hrs in 80 ml SF-CHO medium to further remove serum proteins. The 80 ml medium was 35 removed and discarded. A volume of 120 ml of SF-CHO medium was added to the flask and the cells incubated at

37°C. Every 48 hrs thereafter, 120 ml was collected and replaced with the same volume of SF-CHO medium.

Collected media was pooled and centrifuged at 4°C in polypropylene conical tubes to remove cellular debris and 5 the supernatant stored at -70°C. Media was collected 5 times over 10 days to yield a total of approximately 600 ml conditioned medium per roller bottle.

Fractions collected from the columns at each stage of purification were assayed for biological activity 10 using the neuronal survival assay and for protein content by the dye binding assay of Bradford (*Anal Biochem* 72:248 et seq., 1976 which is incorporated by reference). The total mg of protein in the starting volume, typically 50 liters, of conditioned medium was determined.

15 Superior Cervical Ganglion Survival Assay:

The neurotrophic activity of CHO conditioned medium starting material and at various stages of purification was assessed using the superior cervical ganglion survival assay system previously reported (Martin, et al 20 *J of Cell Biology* 106:829-844; Deckwerth and Johnson, *J Cell Bio* 123:1207-1222, 1993 which are incorporated by reference). Primary cultures of sympathetic neurons from superior cervical ganglion (SCG) were prepared by dissecting tissue from Day 20-21 rat embryo (E20-E21). 25 The SCG's were placed in Leibovitz's L15 with l-glutamine medium (Cat #11415-023 Gibco-BRL, Gaithersburg, MD), digested for 30 minutes with 1 mg/ml collagenase (Cat #4188 Worthington Biochemical, Freehold, NJ) in Leibovitz's L15 medium at 37°C, followed by a 30 minute 30 digestion in trypsin-lyophilized & irradiated (Type TRLVMF Cat #4454 Worthington Biochemical, Freehold, NJ) which was resuspended in modified Hanks' Balanced Salt Solution (Cat #H-8389 Sigma Chemical Co., St. Louis, MO). The digestion was stopped using AM50 which contains 35 Minimum Essential Medium with Earle's salts and without l-glutamine (Cat #11090-016 Gibco-BRL), 10% fetal calf

serum (Cat #1115 Hyclone Laboratories, Logan, UT), 2mM l-glutamine (Cat #G5763 Sigma Chemical Co., St. Louis, MO), 20 µM FuDr (F-0503 Sigma Chemical Co., St. Louis, MO), 20 µM Uridine (Cat #3003 Sigma Chemical Co., St. Louis, MO), 5 100 U/ml penicillin, 100 µg/ml Streptomycin, and 50 ng/ml 2.5 S NGF. The cells were dissociated into a suspension of single cells using a silanized and flame-polished Pasteur pipet. After filtration of the suspension through a nitex filter (size 3-20/14, Tetko Inc., 10 Elmsford, NY), the cells were placed in AM50 medium as above and preplated on a 100 mm Falcon or Primaria culture dish (Becton Dickinson Labware, Lincoln Park, NJ) to reduce the number of non-neuronal cells. After 2 hours, the medium containing the unattached neuronal 15 cells was removed from these dishes and triturated again through a silanized and flame-polished Pasteur pipet. The single cell suspension was plated on 24-well tissue culture plates (Costar, Wilmington, MA) that have been previously coated with a double layer of collagen, one 20 layer of collagen that had been ammoniated and a second layer of collagen that had been air dried. They were allowed to attach for 30 minutes to 2 hours. A specific number of viable cells, usually about 1200 to about 3000 total cells per well, or a specific percentage of the 25 ganglion, usually 25% of the cells obtained per ganglion were plated into each well. When cell counts were to be performed they were placed in the 24-well dishes as stated above or alternatively, on 2-well chamber slides (Nunc, Naperville, IL). Cultures were then incubated for 30 5-6 days at 37° in AM50 medium in a 5% CO<sub>2</sub>/95% air atmosphere. The death of the cultured neurons was induced by exchanging the medium with medium without NGF and with 0.05% goat anti-NGF (final titer in the wells is 1:10). This NGF-deprivation results in death of the 35 neurons over a period of 24-72 hours. Aliquots of partially purified or purified factor, or appropriate

controls, were added to the cultures at the time of NGF removal to determine the ability to prevent the neuronal death.

Evaluation of the ability of column fraction, gel 5 eluates, or purified factor to prevent neuronal death was by visual inspection of cultures under phase contrast microscopy. Viable neurons remained phase bright with intact neurites, whereas dead neurons were shrunken, phase dark, had irregular membranes and neurites were 10 fragmented (Figure 3). Where precise quantitation of neuronal survival was required, the cultures were fixed in 4% paraformaldehyde or 10% Formalin in PBS, and stained with crystal violet solution, (Hunton Formula Harleco E.M. Diagnostics Systems, Gibbstown, NJ). When 15 using 24 well dishes, 1  $\mu$ l crystal violet solution was added to each well containing 10% formalin and the cells were counted using a phase contrast microscope. If the 2-well chamber slides were used, the cultures were fixed, stained with crystal violet, destained with water, 20 dehydrated in increasing ethanol concentrations to toluene, and mounted in a toluene-based mounting solution. Neurons were scored as viable if they had a clear nucleolus and nuclei and were clearly stained with crystal violet.

25 The neuronal death at 72 hours is shown in Figure 3B. Also shown are (A) the positive control cells maintained with nerve growth factor and (C) the cells treated with anti-NGF and neurturin (approximately 3 ng/ml) showing survival of neurons.

30 Activity was quantitated by calculation of a "survival unit". The total survival units in a sample were defined as the minimal volume of an aliquot of the sample which produced maximal survival divided into the total volume of that sample. Specific activity was 35 calculated as the survival units divided by the mg total protein.

Survival units were determined in an assay using approximately 1200 viable neurons in a 0.5 ml culture assay and a culture period of 48 hours following addition of the fraction. Survival was assessed visually after 5 the 48 hours. Intrinsic activity as shown in Figure 4 was determined in an assay using approximately 2700 neurons and a culture period of 72 hours. Survival was assessed by fixing the neurons and counting the number of surviving neurons. Because the stability, as assessed by 10 half-life of activity, for neurturin decreases as the number of neurons increases, the intrinsic activity measurement would be expected to be lower than that predicted by Specific Activity determinations. The intrinsic activity measurement would also be expected to 15 be lower than that predicted by specific activity because the survival was measured after 72 hours instead of 48 hours.

To ensure the reproducibility of these activity unit assays, it was necessary to plate the primary neuronal 20 cultures at reproducible cell densities, as the stability of the activity decreases significantly with increasing neuronal density. The range of cell densities was from about 1200 to about 2700 cells per well. The presence of soluble heparin in the assay medium had no effect on the 25 short-term (~3 days) stability of the survival activity.

Purification of Neurturin:

Pooled conditioned medium was filtered through 0.2  $\mu$ l pore bottle-top filters (cellulose acetate membrane, Corning Inc., Corning, NY). Typically 50 liters of 30 conditioned medium was used and processed in 25 liter batches. Each 25 liter batch was introduced at a rate of 20 ml/min onto a 5 x 5 cm column containing 100 ml heparin-agarose (Sigma, St. Louis, MO) equilibrated with 25 mM HEPES, pH 7.4 buffer with 150 mM NaCl. The column 35 was then washed with approximately 1000 ml 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl at 20 ml/min and the

activity was then eluted with 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl. After switching to the 1.0M NaCL elution buffer, the first 50 ml of buffer was discarded and, thereafter, one 300 ml fraction was collected.

5 Pooled material eluted from the Heparin-agarose column was then diluted 1:1 (v/v) with 25 mM HEPES, pH 7.4 buffer containing 0.04% TWEEN 20 to a NaCl concentration of 0.5 M and introduced into a 1.5 cm x 9 cm column containing 16 ml SP SEPHAROSE® High Performance  
10 ion exchange resin (Pharmacia, Piscataway, NJ) equilibrated in 25 mM HEPES 7.4 containing 0.5 M NaCl and 0.02% TWEEN 20. The column was then washed with 160 ml 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl and 0.02% TWEEN 20 and the activity was eluted with 25 mM  
15 HEPES, pH 7.4 buffer containing 1.0 M NaCl and 0.02% TWEEN 20 at a flow rate of 2 ml/min. One 50 ml fraction was collected after the first 7 ml of eluate from the column.

Material eluted from the SP SEPHAROSE® column was  
20 fractionated using fast protein liquid chromatography (FPLC) on a Chelating Superose HR 10/2 column charged with Cu<sup>++</sup> (Pharmacia, Piscataway, NJ). The column had been prepared by washing with 10 ml water, charging with 3 ml of 2.5 mg/ml CuSO<sub>4</sub>·5H<sub>2</sub>O, washing with 10 ml water,  
25 and equilibrating with 10 ml of 25 mM HEPES pH 7.4 buffer containing 1.0 M NaCl and 0.02% TWEEN 20. The eluate was introduced into the column in 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl at a rate of 1.0 ml/min. The bound proteins were eluted with a linear gradient of increasing  
30 glycine concentration (0-300 mM) in 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl at a rate of 1.0 ml/min. The gradient was produced by a Pharmacia FPLC system using an LCC-500 controller and P-500 pumps to establish a 0-300 mM glycine gradient in 40 ml at 1.0 ml/min, thus  
35 increasing the gradient by 7.5 mM glycine per min. One ml fractions were collected and assayed for SCG survival

promotion. Peak activity was observed in fractions 17-20, i.e. 17-20 min or ml from the start of the gradient.

Absorbance measurements at 280 nM by an in-line UV monitor indicated that most proteins eluted prior to the 5 survival activity in fractions 17-20. Thus, significant purification was achieved at this step. A 25 kD band co-purified with the survival activity.

The combined eluted fractions from the Cu<sup>++</sup> superose column were diluted to 0.45 M NaCl using 25 mM HEPES pH 10 7.4 buffer containing 0.02% TWEEN 20 and introduced into a Mono S HR 5/5 cation exchange column (Pharmacia, Piscataway, NJ) for further FPLC purification. The column had been equilibrated with 25 mM HEPES pH 7.4 buffer containing 0.45 M NaCl containing 0.02% TWEEN 20. 15 Bound proteins were eluted with a linear gradient of increasing NaCl concentration (0.45-1.0 M). The gradient was produced as described above from 0.45 M - 1.0 M NaCl in 35 mls at 1.0 ml/min, thus increasing concentration at 0.0157 M per ml or min. Thirteen 1.0 ml fractions 20 (fractions 1-13) were collected followed by 44 0.5 ml fractions (fractions 14-53). Peak activity in SCG assay was in fractions 26-29. Each fraction was assayed in the SCG survival assay over a range of volumes of from 0.1 to 1.0 µl per 0.5 ml culture medium.

25 One percent (5 µl) of each fraction was loaded onto a non-reducing, 14% SDS polyacrylamide gel and electrophoresed for 750 V-hr at 25°C. Proteins were visualized by silver stain. The results are shown in Figure 2. Markers shown in lane M on the gel represent 30 20 ng of Bovine serum albumin, carbonic anhydrase, B-lactoglobulin, and lysozyme in the order of descending molecular weight.

A 25 kD band appeared in fractions 25-30, a 28 kD protein elutes earlier in the gradient and an 18 kD 35 elutes later in the gradient. Figure 2 illustrates the survival activity in each of the fractions. The survival

activity is noted to correspond with the presence and apparent intensity of the 25 kD protein in fractions 25-30.

To demonstrate that the 25 kD band was responsible for survival promoting activity, the 25 kD protein was eluted from the polyacrylamide gel after electrophoresis and assayed for survival activity in the SCG assay. After electrophoresis of 150  $\mu$ l of the SP SEPHAROSE® 1.0 M NaCl fraction in one lane of a non-reducing 14% SDS-polyacrylamide gel as above, the lane was cut into 12 slices and each slice was crushed and eluted by diffusion with rocking in buffer containing 25 mM HEPES, pH 7.4, 0.5 M NaCl, 0.02% Tween-20 for 18 hr at 25°C. BSA was added to the eluate to a final concentration of 200  $\mu$ g/ml and the eluate was filtered through a 0.45 micron filter to remove acrylamide gel fragments. The filtrate was then added to a SP SEPHAROSE® column to concentrate and purify the sample. Before eluting the sample, the column was washed once in 400  $\mu$ l 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl, 0.02% Tween-20 and 200  $\mu$ g BSA per ml and once in 400  $\mu$ l 25 mM HEPES, pH 7.4 buffer containing 0.02% Tween-20 and 200  $\mu$ g BSA per ml. The column was then washed again in 400  $\mu$ l of 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl, 0.02% Tween 20 and 200  $\mu$ g BSA per ml. The sample was eluted with 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl, 0.02% Tween-20 and 200  $\mu$ g BSA per ml. Samples were then analyzed for survival activity. Only the slice corresponding to the 25 kD band showed evidence of survival activity. The 25 kD protein purified from CHO cell conditioned media is believed to be a homodimer.

The yield from the purification above was typically 1-1.5  $\mu$ g from 50 liters of CHO cell conditioned medium. Overall recovery is estimated to be 10-30%, resulting in a purification of approximately 390,000 fold.

The progressive purification using the above steps is shown in table 2.

Table 2

5

	Protein <sup>a</sup> (mg)	Activity <sup>b</sup> (units)	Specific Activity <sup>d</sup> (units/mg)	Yield (%)	Purification (fold)
Conditioned Medium	5000	48000 <sup>c</sup>	9.6	-	-
Heparin Agarose	45	48000	1068	100	111
SP Sepharose	5.3	48000	9058	100	943
Cu++ Superose	0.31	30000	96700	62	10070
Mono S	0.004	15000	3750000	31	390000

15 a. mg protein was determined using the dye binding method of Bradford (*Anal Biochem* 72:248, 1976).

20 b. The total activity units or survival units in a sample were defined as the minimal volume of an aliquot of the sample which produced maximal survival divided into the total volume of that sample.

25 c. Activity for Conditioned Medium was derived from the assumption that 100% of the activity was recovered in the heparin agarose fraction because the activity of conditioned medium was too low to be directly assayed.

30 d. Specific Activity was the Activity units divided by the mg total protein.

30

#### Example 2

This example illustrates the characterization of neurturin and several members of the TGF- $\beta$  family of growth factors in the SCG assay and the lack of cross reactivity of anti-GDNF antibodies with neurturin.

The SCG assay of the purified protein indicated that the factor is maximally active at a concentration of approximately 3 ng/ml or approximately 100 pM and the EC<sub>50</sub> was approximately 1.5 ng/ml or approximately 50 pM in the

expected range for a diffusible peptide growth factor (Figure 4).

Several members of the TGF- $\beta$  family influence neuropeptide gene expression in sympathetic neurons, 5 while others promote survival of different neuronal populations. Neurturin, which is a distant member of this family of proteins, is capable of promoting virtually complete survival of sympathetic neurons for 3 days. In addition, further culturing of the SCG cells 10 revealed that neurturin could continue to maintain these neurons for at least 10 days after withdrawal of NGF.

We tested several other members of the TGF- $\beta$  family for their ability to promote survival in the SCG assay including TGF- $\beta$ 1, activin, BMP-2, BMP-4, BMP-6 and 15 GDNF. Of these factors, only GDNF had survival promoting activity, however, the activity of GDNF was much less potent than neurturin in this activity showing an EC<sub>50</sub> of 2-4 nM in the 3-day survival assay. The GDNF tested in this assay was rhGDNF produced in *E. Coli* obtained from 20 Prepro Tech, Inc., Rocky Hill, N.J. The duration of action of GDNF was also less than that of neurturin inasmuch as the ability of GDNF (50 ng/ml) to maintain survival longer than 3 days was substantially diminished. These experiments suggest the possibility that GDNF is a 25 weak agonist for the neurturin receptor. Furthermore, the inability of activin and BMP-2 to promote survival, in contrast to their strong induction of transmitter-related gene expression in these neurons (Fann and Paterson, *Int J Dev Neurosci* 13:317-330, 1995; Fann and 30 Patterson, *J Neurochem* 61:1349-1355, 1993) suggests that they signal through alternate receptors or signal transduction pathways.

To determine the cross-reactivity of anti-GDNF antibodies with partially purified neurturin, SCG 35 neurons, that had been dissected and plated as described in Example 1 were treated on Day 6 with 1 ng/ml, 3 ng/ml,

10 ng/ml, or 30 ng/ml GDNF (Prepro Tech, Inc, Rocky Hill, N.J.) in the presence of anti-NGF alone, or in the presence of anti-NGF and anti-GDNF (goat IgG antibody to *E. coli*-derived rhGDNF, R & D Systems, Minneapolis, 5 Minn.). A partially purified 1.0 M SP Sepharose fraction of neurturin was used in the assay at the approximate concentrations of 375 pg/ml, 750 pg/ml, 1.5 ng/ml and 3 ng/ml. This fraction was tested in the presence of anti-NGF alone, and in the presence of anti-NGF and 10 anti-GDNF. The anti-GDNF antibody blocked the survival promoting activity of GDNF at a concentration up to 30 ng/ml, but did not block the survival promoting activity of neurturin.

15

### Example 3

This example illustrates the effect of neurturin on sensory neurons in a nodose ganglion survival assay.

CHO cell conditioned media that had been partially purified on the SP Sepharose column was assayed for 20 neurotrophic activity on sensory neurons using nodose ganglia. The survival assay is a modification of that previously reported above for superior cervical ganglia. Primary dissociated cultures of nodose ganglia were prepared by dissecting tissue from E18 Sprague Dawley rat 25 pups. The nodose ganglia were placed in Leibovitz's L15 with 2 mM l-glutamine (Cat# 11415-023, GIBCO-BRL. Gaithersburg, MD) as the tissues was dissected, digested for 30 min with 1 mg/ml collagenase (Cat#4188, Worthington Biochemical, Freehold, New Jersey) in 30 Leibovitz's L15 medium at 37°C, followed by 30 min digestion in trypsin (lyophilized and irradiated, type TRLVMF, Cat #4454 Worthington Biochemical, Freehold, NJ), and resuspension to a final concentration of 0.25% in modified Hank's Balanced Salt Solution (Cat#H8389, Sigma 35 Chemical Co., St. Louis, Mo). The digestion was stopped using AM0-BDNF100, a medium containing Minimum Essential

Medium with Earle's salts and without l-glutamine (#11090-016 GIBCO-BRL), 10% fetal Calf Serum (Cat#11115, Hyclone Laboratories, Logan, UT), 2 mM l-glutamine (Cat#G5763 Sigma Chemical Co., St. Louis, Mo.), 20 µM 5 FuDr (F-0503, Sigma Chemical Co.), 20 µM Uridine (Cat #3003, Sigma Chemical Co., St. Louis, Mo.) 100 U/ml penicillin, 100 µg/ml Streptomycin, and 100 ng Brain Derived Neurotropic Factor (BDNF, Amgen, Thousand Oaks, CA). The cells were dissociated into a suspension of 10 single cells using a silanized and flame-polished Pasteur pipet in the AMO-BDNF100 medium, and preplated on a 100 mm Falcon or Primaria culture dish (Becton Dickinson Labware, Lincoln Park, NJ) to remove non-neuronal cells. After 2 hours, the medium containing the unattached 15 neuronal cells was removed from these dishes and triturated again through a silanized and flame-polished Pasteur pipet. The single cell suspension was plated on 24-well tissue culture plates (Costar, Wilmington, MA) that have been previously coated with a double layer of 20 collagen, one layer of which had been ammoniated and a second layer that had been air dried. Ganglia from ten E18 rat embryos were dissociated into 2.5 mls of media and 100 µl of this suspension was added to each well. The cells were allowed to attach for 30 min in a 37°C 25 incubator with 5% CO<sub>2</sub>/95% air. The wells were fed with AMO-BDNF100 media overnight.

The next day the cells were washed 3 times for 20 min each time with AMO medium containing no BDNF. The wells were fed with 0.5 ml of this media alone or this 30 media containing either 50 ng/ml NGF, 100 ng/ml BDNF (Amgen, Thousand Oaks, CA), 100 ng/ml GDNF (Prepro Tech, Inc., Rocky Hill, N.J) or 3 ng/ml Neurturin. The cells were incubated at 37°C in a 5% CO<sub>2</sub>/95% air incubator for 3 days, fixed with 10% formalin, stained with crystal 35 violet (1 µl/ml 10% formalin) and counted. Survival was ascertained as noted previously.

The neuronal Death at 72 hours is shown in Figure 10. Neuronal survival of nodose neurons cultured in BDNF has been previously reported (Thaler et al, *Develop Biol* 161:338-344, 1994 which is incorporated by reference). This was used as the standard for survival for these neurons and given the value of 100% survival. Nodose ganglia that had no trophic support (AMO) showed 20%-30% survival, as did neurons that were cultured in the presence of 50 ng/ml NGF. Neurons cultured in the presence of 3 ng/ml neurturin and absence of BDNF showed survival similar to those neurons cultured in the presence of BDNF (100 ng/ml). GDNF at a concentration of 100 ng/ml promoted greater survival of nodose neurons than did BDNF (100 ng/ml). Similar findings with GDNF were recently reported for sensory neurons from chicken (Ebendal, T. et al, *J Neurosci Res* 40:276-284 1995 which is incorporated by reference).

#### Example 4

This example illustrates the determination of partial amino acid sequences of neurturin isolated from CHO cell conditioned medium.

To obtain N-terminal amino acid sequence from a purified preparation of approximately 1 µg of neurturin, the Mono S fractions 26-29 containing the peak of activity were concentrated to 25 µl by centrifuge ultrafiltration in a microcon-3 concentrators (Amicon, Inc., Beverley, MA) and loaded onto a non-reducing 14% SDS polyacrylamide gel. After electrophoretic separation, proteins were electroblotted to a PVDF membrane (Bio-Rad, Hercules, CA) and stained with 0.1% Coomassie Blue. The 25 kD band was excised and inserted into the reaction cartridge of an automated sequencer (Model 476, Applied Biosystems (Foster City, CA)). Phenylthiohydantoin-amino acid (PTH-aa) recovery in the first 2-3 cycles of automated sequencing by Edman

degradation indicated a sequencing yield of 4 pmoles, which was approximately 10% of the estimated amount of protein loaded on the SDS gel.

Two N-terminal sequencing runs were performed from 5 two 50 liter purification preparations. In the first run, 1 µg of protein in 3 pooled fractions of 1.5 ml total volume were concentrated to 25 µl and electroblotted at 100V for 2 hrs at 25°C using an electroblot buffer of 10 mM CAPS pH 11.0 buffer (Sigma, 10 St. Louis, MO) containing 5% methanol. The amino acid sequence was obtained from 13 cycles of Edman degradation and the sequencing yield was 4 pmoles as above.

In the second run, 1.5 µg of protein in 4 pooled fractions of 2.0 ml total volume were concentrated to 25 15 µl and electroblotted at 36V for 12 hours at 4°C using an electroblot buffer of 25 mM Tris, 192 mM glycine, 0.04% SDS and 17% MeOH. Sequencing yield was 15 pmoles and the sequence after 16 cycles was SGARPXGLRELEVSVS (SEQ ID NO:3). The sequence obtained after 16 cycles 20 corresponded to the shorter sequence obtained in the first run. Definite assignments could not be made at 3 of the amino acid residues in the sequence (residues 1, 6 and 11 from the N-terminal). A search of protein databases did not detect any significantly homologous 25 sequences, suggesting that the purified factor was a novel protein.

This initial N-terminal amino acid sequence data did not enable the isolation of cDNA clones using degenerate oligonucleotides as PCR primers or probes for 30 screening libraries. To facilitate these approaches, additional protein was purified in order to obtain internal amino acid sequence from proteolytic fragments. To obtain internal amino acid sequence from neurturin, an additional 50 liters of CHO cell conditioned medium was 35 purified using only the first 3 chromatographic steps as outlined above, except that the gradient used to elute

the Cu++ Chelating Superose column was as follows: 0-60 mM glycine (4 ml), 60mM glycine (10ml), 60-300 mM glycine (32 ml). Fractions No. 20-23 containing neuriturin were concentrated to 25  $\mu$ l by ultrafiltration (Amicon microcon 5 3, Amicon, Beverley, MA) and loaded on a non-reducing SDS polyacrylamide gel. After electrophoresis, the gel was stained with Coomassie blue and the 25 kD neuriturin band was excised. Neurturin was digested in the gel slice with endoproteinase Lys-C, and the eluted proteolytic 10 fragments were purified by reverse phase HPLC. Only one peak was observed upon HPLC separation of the eluted peptides, which yielded amino acid sequence information for 23 cycles at the 1 pmole signal level using the automated sequencer, (internal fragment P2, SEQ ID NO:5).

15 Amino acid analysis performed on 10% of the above sample before subjecting it to digestion had indicated that 150 pmoles of protein were present in the gel slice, consisting of 7.6% lysine and 19.5% arginine. The single low level peak from the Lys-C digestion suggested that 20 the digestion and elution of peptides were inefficient. The same gel slice was redigested with trypsin and the eluted peptides separated by HPLC. Two peaks were observed on HPLC, resulting in the elucidation of two additional 10 residue amino acid sequences (4-5 pmole 25 signal level, internal fragment P1, SEQ ID NO:4 and internal fragment P3, SEQ ID NO:6) that were distinct from the N-terminal and previous internal amino acid sequences. The in situ digestion, elution and purification of peptides, and peptide sequencing was 30 performed by the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University according to standard protocols for this service.

## Example 5

The following example illustrates the isolation and sequence analysis of mouse and human neurturin cDNA clones.

- 5        Degenerate oligonucleotides corresponding to various stretches of confident amino acid sequence data were synthesized and used as primers in the polymerase chain reaction (PCR) to amplify cDNA sequences from reverse transcribed mRNA. A forward primer (M1676;
- 10 5'-CCNACNGCNTAYGARGA, SEQ ID NO:50) corresponding to peptide sequence P2 Xaa<sub>1</sub>-Xaa<sub>2</sub>-Val-Glu-Ala-Lys-Pro-Cys-Cys-Gly-Pro-Thr-Ala-Tyr-Glu-Asp-Xaa<sub>3</sub>-Val-Ser-Phe-Leu-Ser-Val where Xaa<sub>1</sub> and Xaa<sub>2</sub> were unknown, Xaa<sub>3</sub> was Gln or Glu (SEQ ID NO:5) in combination with a reverse primer (M1677;
- 15 5'-ARYTCYTGNARNGTRTGRTA (SEQ ID NO:52) corresponding to peptide sequence P3 (Tyr-His-Thr-Leu-Gln-Glu-Leu-Ser-Ala-Arg) (SEQ ID NO:6) were used to amplify a 69 nucleotide product from cDNA templates derived from E21 rat and adult mouse brain.
- 20 The PCR parameters were: 94°C for 30 sec; 55°C for 30 sec; 72°C for 1 min for 35 cycles. The product was subcloned into the Bluescript KS plasmid and sequenced. All nucleotide sequencing was performed using fluorescent dye terminator technology per manufacturer's instructions
- 25 on an Applied Biosystems automated sequencer Model #373 (Applied Biosystems, Foster City, CA). Plasmid DNA for sequencing was prepared using the Wizard Miniprep kit (Promega Corp., Madison, WI) according to the manufacturer's instructions. The sequence of the
- 30 amplified product correctly predicted amino acid sequence data internal to the PCR primers.

Primers corresponding to the amplified sequence were used in combination with the degenerate primers in the rapid amplification of cDNA ends (RACE) technique

35 (Frohman, M.A. *Methods in Enzymology* 218:340-356, 1993) using the Marathon RACE kit (CLONTECH, Palo Alto, CA) per

the manufacturer's instructions, except that first strand cDNA synthesis was carried out at 50°C using Superscript II reverse transcriptase (Gibco-BRL). Briefly, a double stranded adaptor oligonucleotide was ligated to the ends 5 of double stranded cDNA synthesized from postnatal day 1 rat brain mRNA. Using nested forward neurturin PCR primers (M1676; 5'-CCNACNGCNTAYGARGA, SEQ ID NO:50 and 1678; 5'-GACGAGGGTCCTCCTGGACGTACACA, SEQ ID NO:53) in combination with primers to the ligated adaptor supplied 10 in the kit (AP1, AP2), the 3' end of the neurturin cDNA was amplified by two successive PCR reactions (1st: M1676 and AP1, using 94°C for 30 sec, 55°C for 30 sec and 72°C for 2 min for 35 cycles; 2nd: M1678 and AP2 using 94°C for 30 sec and 68°C for 2 min for 35 cycles). A 5' 15 portion of the rat neurturin cDNA was obtained by two successive PCR reactions using the linker cDNA as template. The 1st reaction utilized primers M1677 (SEQ ID NO:52) and AP1; using 94°C for 30 sec; 55°C for 30 sec; and 72°C for 2 min for 35 cycles. The 2nd reaction 20 used M1679 5'-TAGCGGCTGTGTACGTCCAGGAAGGACACCTCGT (SEQ ID NO:54) and AP2 at 94°C for 30 sec and 68°C for 2 min for 35 cycles. These reactions resulted in a truncated form of the 5' end of the neurturin cDNA, apparently the result of premature termination of the cDNA during 25 reverse transcription. The 5' and 3' RACE products were subcloned into the plasmid Bluescript KS and sequenced. The sequence of these 3' and 5' RACE products resulted in a partial rat neurturin cDNA sequence of 220 nt. Primers (#467921 5'-CAGCGACGACGCGTGCGCAAAGAGCG, SEQ ID NO:55; and 30 M1679 (SEQ ID NO:54) corresponding to the partial rat cDNA sequence were used (PCR parameters 94°C for 30 sec and 68°C for 1 min for 35 cycles) to amplify a 101 nucleotide PCR product from mouse genomic DNA which was homologous to rat neurturin cDNA sequence.

35       These primers were then used to obtain murine neurturin genomic clones by amplifying gene fragments in

a mouse 129/Sv library in a P1 bacteriophage vector (library screening service of Genome Systems, Inc., St. Louis, MO). A 1.6 kb Nco I fragment from this P1 clone containing the neurturin gene was identified by 5 hybridization with primer (#465782; 5'-TAYGARGACGAGGTGTCCTCCTGGACGTACACAGCCGCTAYCAYAC, SEQ ID NO:56). This Nco I fragment was sequenced and found to contain a stretch of coding sequence corresponding to the N-terminal and internal amino acid sequences obtained 10 from sequencing the active protein isolated from CHO cell conditioned media. Beginning at the N-terminal amino acid sequence of the purified protein, this nucleotide sequence encodes a 100 amino acid protein with a predicted molecular mass of 11.5 kD. A search of protein 15 and nucleic acid databases identified neurturin as a novel protein that is approximately 40% identical to glial derived neurotrophic factor (GDNF). GDNF was purified and cloned as a factor which promotes the survival of midbrain dopaminergic neurons and is a 20 distantly related member of the TGF- $\beta$  superfamily, which now includes more than 25 different genes that possess a wide variety of proliferative and differentiative activities. Although GDNF is less than 20% identical to any other member of the TGF- $\beta$  family, it contains the 7 25 cysteine residues which are conserved across the entire family and believed to be the basis of a conserved cysteine knot structure observed in the crystal structure determination of TGF- $\beta$ 2. Neurturin also contains these 7 cysteine residues, but like GDNF is less than 20% 30 homologous to any other member of the TGF- $\beta$  family. Thus, neurturin and GDNF appear to represent a subfamily of growth factors which have significantly diverged from the rest of the TGF- $\beta$  superfamily.

To determine the sequence of the full length mouse 35 neurturin cDNA, 5' and 3' RACE PCR was performed as above for the rat, using nested primers predicted from

the mouse genomic sequence and cDNA from neonatal mouse brain. The 1st reaction for the 3' end used primers: M1777 5'-GCGGCCATCCGCATCTACGACCAGGG (SEQ ID NO:57) and AP1 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 35 cycles. The 2nd reaction used primer #467921 (SEQ ID NO:55) and AP2 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 20 cycles. The 5' end was obtained using for the 1st reaction primer M1759, 5'-CRTAGGCCGTGGCGRCARCACGGGT (SEQ ID NO:58) and AP1 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 35 cycles. The 2nd reaction used primer M1785, 5'-GCGCCGAAGGCCAGGTCGTAGATGCG (SEQ ID NO:59) and AP2 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 20 cycles. Both sets of PCR reactions included 5% DMSO.

The 5' and 3' mouse RACE products were subcloned into the plasmid Bluescript KS and sequenced. Using the sequence of RACE products, a 1.0 kb mouse neurturin cDNA sequence can be assembled. This cDNA sequence contains an open reading frame of 585 nucleotides that encodes a protein with a molecular mass of 24 kD. This full length mouse cDNA sequence is shown in Figure 7 (SEQ ID NO:12). Consistent with the processing events known to occur for TGF- $\beta$  family members, the 24 kD neurturin protein contains an amino terminal 19 amino acid signal sequence followed by a pro-domain which contains an RXXR proteolytic processing site immediately before the N-terminal amino acid sequence obtained when sequencing the protein purified from CHO cell conditioned media. Using these landmarks, the 11.5 kD mature neurturin molecule is predicted to be 11.5 kD and, by analogy to other members of the TGF- $\beta$  family, is predicted to form a disulfide linked homodimer of 23 kD, consistent with the 25 kD mass of the protein purified from CHO cell conditioned media as estimated by SDS-PAGE analysis.

For isolation of human genomic clones, primers (#467524; 5'-CGCTACTGCGCAGGCGCGTGCARGCGGC, SEQ ID NO:60

and #10005, 5'-CGCCGACAGCTCTTGCAGCGTRTGGTA, SEQ ID NO:61) predicted from the sequence of mouse neurturin were used to amplify (PCR parameters: Initial denaturation at 95°C for 1 min 30 sec followed by 94°C for 30 sec; 60°C for 15 sec; and 68°C for 60 sec for 35 cycles) a 192 nucleotide fragment from human genomic DNA. The sequence of the PCR product demonstrated that it was the human homolog of mouse neurturin. The primers were then used to screen a human genomic library constructed in the P1 vector 10 (library screening service, Genome Systems, Inc.) and two clones containing the human neurturin genomic locus were obtained.

The same strategy was used to determine the human sequence as discussed above for the mouse sequence. An 15 oligo (#30152, GACCTGGGCCTGGGCTACGCGTCCGACCGAG, SEQ ID NO:62) was used as a probe in a Southern blot analysis to identify restriction fragments of the P1 Clones which contained the human neurturin coding sequence. These restriction fragments (Eag I, Pvu II, Hind III, Kpn I) 20 were subcloned into the Bluescript KS plasmid and sequenced.

The results of subcloning and sequencing of human genomic fragments were as follows. The Eag I fragment was found to be approximately 6 kb in size with the 3' 25 Eag I site located 60 bp downstream from the stop codon. The Pvu II fragment was approximately 3.5 kb in size with the 3' Pvu II site located 250 bp downstream from the stop codon. The Hind III fragment was approximately 4.8 kb in size with the 3' Hind III site located 3kb 30 downstream from the stop codon. The Kpn I fragment was approximately 4.2 kb in size with the 3' Kpn I site located 3.1 kb downstream from the stop codon.

The second coding exon was sequenced using these subcloned fragments. In addition, sequence was obtained 35 from 250 bp flanking the 3' side of the second exon. The sequence was also obtained from 1000 bp flanking the 5'

side of the coding exon. From these flanking sequences, forward primer 30341 (5'-CTGGCGTCCCACCAAGGGTCTTCG-3', SEQ ID NO:71) and reverse primer 30331 (5'-GCCAGTGGTGCCGTGAGGCCGGG-3', SEQ ID NO:72) were designed 5 so that the entire coding sequence of the second exon could be amplified by PCR.

The first coding exon was not mapped relative to the restriction sites above but was contained in the Eag I fragment. The sequence of this exon was obtained from 10 the subcloned Eag I fragment using the mouse primer 466215 (5'-GGCCCAGGATGAGGCCTGGAAGG-3', SEQ ID NO:73), which contains the ATG initiation codon. Further sequence of the first coding exon was obtained with reverse primer 20215 (5'-CCACTCCACTGCCTGAWATTWACCCC-3', 15 SEQ ID NO:74), designed from the sequence obtained with primer 466215. Forward primer 20205 (5'-CCATGTGATTATCGACCATTGGC-3', SEQ ID NO:75) was designed from sequence obtained with primer 20215. Primers 20205 and 20215 flank the coding sequence of the first coding 20 exon and can be used to amplify this coding sequence using PCR.

The human cDNA and inferred amino acid sequence is shown in Figure 7 and the mouse cDNA and inferred amino acid sequence is shown in Figure 8.

25

#### Example 6

This example illustrates the preparation of expression vectors containing neuritin cDNA.

30 For expression of recombinant neuritin in mammalian cells the neuritin vector pCMV-NTN-3-1 was constructed. The 585 nucleotide open reading frame of the neuritin cDNA was amplified by PCR using a primer containing the first 27 nucleotides of the neuritin 35 coding sequence  
(5'-GCGACGCGTACCATGAGGCCTGGAAGGCAGCGGCCCTG, SEQ ID

NO:63) and a primer containing the last 5 codons and the stop codon (5'-GACGGATCCGCATCACACGCACGCCACTC) (SEQ ID NO:64) using reverse transcribed postnatal day 1 mouse brain mRNA as template using (PCR parameters: 94°C for 30 sec; 60°C for 15 sec; and 68°C for 2 min for 35 cycles and including 5% DMSO in the reaction). The PCR product was subcloned into the Eco RV site of BSKS and sequenced to verify that it contained no PCR generated mutations. The neuriturin coding sequence was then excised from this vector using Mlu I (5' end) and Bam H1 (3' end) and inserted downstream of the CMV IE promoter/enhancer in the mammalian expression vector pCB6 (Brewer, C.B. *Methods in Cell Biology* 43:233-245, 1994) to produce the pCMV-NTN-3-1 vector using these sites.

For expression of recombinant protein in E. Coli, the mature coding region of mouse neuriturin was amplified by PCR using a primer containing the first 7 codons of the mature coding sequence (5'-GACCATATGCCGGGGCTGGCCTTGTGG) (SEQ ID NO:65) and a primer containing the last 5 codons and the stop codon 5'-GACGGATCCGCATCACACGCACGCCACTC (SEQ ID NO:66) using a fragment containing the murine neuriturin gene as template using (PCR parameters: 94°C for 30 sec; 60°C for 15 sec and 68°C for 90 sec for 25 cycles with 5% DMSO added into the reaction). The amplified product was subcloned into the Eco RV site of BSKS, the nucleotide sequence was verified, and this fragment was then transferred to the expression vector pET-30a (Novagen, Madison, WI) using an Nde I site (5' end) and an Eco R1 site (3' end). The pET-neurturin (pET-NTN) vector codes for an initiator methionine in front of the first amino acid of the mature mouse neuriturin protein predicted from the N-terminal amino acid sequence of neuriturin purified from the CHO cell conditioned media.

## Example 7

This example illustrates the transient transfection of NIH3T3 cells with the neuriturin expression vector pCMV-NTN-3-1 and that the product of 5 the genomic sequence in Example 5 is biologically active.

To demonstrate that the cloned neuriturin cDNA was sufficient to direct the synthesis of biologically active neuriturin we transiently introduced the pCMV-NTN-3-1 plasmid into NIH3T3 cells using the lipofectamine method 10 of transfection. NIH3T3 cells were plated at a density of 400,000 cells per well (34.6 mm diameter) in 6 well plates (Corning, Corning, NY) 24 hours before transfection. DNA liposome complexes were prepared and added to the cells according to the manufacturer's 15 protocol using 1.5 µg CMV-neurturin plasmid DNA (isolated and purified using a Qiagen (Chatsworth, CA) tip-500 column according to manufacturer's protocol) and 10 µl lipofectamine reagent (Gibco BRL, Gaithersburg, MD) in 1:1 DME/F12 medium containing 5 µg/ml insulin, 5 µg/ml 20 transferrin, and 5 ng/ml sodium selenite (Sigma, St. Louis, MO). Five hours after the addition of DNA liposome complexes in 1 ml medium per well, 1 ml DME medium containing 20% calf serum was added to each well. Twenty-four hours after the addition of DNA-liposome 25 complexes, the 2 ml medium above was replaced with 1 ml DME medium containing 10% calf serum, 2 mM glutamine, 100 U/ml penicillin, 100 µ/ml streptomycin, and 25 µg/ml heparin. The cells were incubated for an additional 24 hours before the conditioned medium was harvested, 30 centrifuged to remove cellular debris, and frozen.

As a control, NIH3T3 cells were transfected as above using 1.5 µg CMV-neo expression plasmid (containing no cDNA insert) in place of the 1.5 µg CMV-neurturin plasmid. Conditioned medium from NIH3T3 cells 35 transfected with either control plasmid or CMV-neurturin plasmid was assayed by direct addition to the SCG culture

medium at the time of NGF deprivation. Addition of 0.25 ml conditioned medium from CMV-neurturin-transfected cells promoted 70% survival of sympathetic neurons, and >90% survival could be obtained with 0.45 ml of this 5 conditioned medium. No significant survival promoting activity was detected in the conditioned medium of control transfected NIH3T3 cells.

#### Example 8

10 This example illustrates the preparation of Chinese hamster ovary cells stably transformed with neurturin cDNA.

15 DG44 cells, a Chinese hamster ovary cell derivative that is deficient in dihydrofolate reductase (DHFR) (Urlaub et al Cell 3:405-412, 1983 which is incorporated by reference), were stably co-transfected with expression plasmid (pCMV-NTN-3-1) and a DHFR expression plasmid (HLD) (McArthur, and Stanners J. Biol. Chem. 266:6000-6005, 1991 which is incorporated by 20 reference).

On day 1 DG44 cells were plated at  $1 \times 10^6$  cells per 10 cm plate in Ham's F12 medium with 10% fetal calf serum (FCS). This density must not be exceeded or cells will overgrow before selection media is added on day 5.

25 On day 2 cells were transfected with a 9:1 ratio of pCMV-NTN to DHFR expression plasmid using the calcium phosphate method (10 ug DNA /10 cm plate) (Chen and Okayama, Mol Cell Biol 7:2745-2752, 1987 which is incorporated by reference).

30 On day 3 the transfected cells were washed with Ham's F12 medium and fed Ham's F12 with 10% FCS.

On day 5 the cells were washed with MEM alpha medium and fed selection medium, which is MEM alpha with 10% FCS and 400 ug/ml G418. The cells were maintained in 35 selection media, feeding every 4 days. Colonies began to appear approximately 14 days after transfection.

Colonies growing in selection media were then transferred to a 24 well plate and trypsinized the next day to disperse the cells. The cells were grown to confluence in either 24 well or 6 well plates in order to screen the 5 cells for expression of recombinant protein. Expression of neurturin was examined in 10 clonal lines and two high expressing lines were detected using the SCG survival assay. These clonal lines were expanded and expression in these selected cell lines was amplified by selection 10 in 50 nM methotrexate (MTX). For selection in MTX, cells were grown to 50% confluence in a 150 cm<sup>2</sup> flask in selection medium. The medium was changed to MEM alpha containing 50 nM MTX concentration (it was not necessary to use G418 during MTX amplification). After placement 15 in 50 nM MTX, the majority of cells died and colonies of resistant cells reappeared in 1-2 weeks. At this time, the cells were trypsinized to disperse colonies and are split when cells reach confluence. Cells eventually reached the same growth rate as before. The selected 20 cells were screened for expression of recombinant protein. A 2-3 fold increase in expression was observed after selection in 50 nM MTX. Frozen stocks were kept for cell lines obtained from the original selection and the 50 nM MTX selection. Further selection could be 25 continued in increasing MTX until desired levels of expression are obtained.

Using the above method, we isolated cells identified as DG44CHO5-3(G418)(pCMV-NTN-3-1) and DG44CHO5-3(50nMMTX)(pCMV-NTN-3-1). Cells from the 30 DG44CHO5-3(50nMMTX)(pCMV-NTN-3-1) strain expressed levels of approximately 100 µg of biologically active protein per liter of conditioned media determined by direct assay of conditioned medium in SCG assay according to the methods in example 1.

## Example 9

This example illustrates the expression of neuriturin in various tissues.

A survey of neuriturin and GDNF expression was 5 performed in rat embryonic tissues (E10, day 10 after conception), neonatal tissues (P1, Postnatal Day 1), and adult tissues (> 3 mos) using semi-quantitative RT/PCR (Estus et al., *J Cell Biol* 127:1717-1727, 1994 which is incorporated by reference). The RNA samples were 10 obtained from various tissues and PCR products were detected either by autoradiography after incorporation of  $\alpha$ -<sup>32</sup>P-dCTP in the PCR and electrophoresis on a polyacrylamide gel (Figure 6) or by ethidium bromide staining of DNA after electrophoresis on agarose gels 15 (Tables 3 and 4). The neuriturin fragment of 101 base pairs was obtained using the forward primer CAGCGACGACGCGTGCACAAAGAGCCG (SEQ ID NO:67) and reverse primer TAGCGGCTGTGTACGTCCAGGAAGGACACCTCGT (SEQ ID NO:68) and the GDNF fragment of 194 base pairs was obtained 20 using the forward primer AAAAATCGGGGGTGYGTCTTA (SEQ ID NO:69) and the reverse primer CATGCCTGGCCTACYTTGTCA (SEQ ID NO:70).

No neuriturin or GDNF mRNA was detected at the earliest embryonic age (embryonic day 10, E10) surveyed.

25 In neonates (postnatal day 1, P1) both transcripts were expressed in many tissues although neuriturin tended to show a greater expression in most tissues than did GDNF. (see table 3).

Table 3.

	NEURTURIN	GDNF
Liver	+++	-
5 Blood	+++	+
Thymus	+	-
Brain	++	+
Sciatic nerve	-	+
10 Kidney	++	++
Spleen	++	+
Cerebellum	++	+
Heart	++	+
Bone	+	+
15		

As shown in Table 3, differences in the tissue distributions of neurturin and GDNF were noted. In particular, no GDNF was detected in liver and thymus where neurturin expression was detected and no neurturin 20 was detected in sciatic nerve where GDNF was detected.

Neurturin and GDNF mRNA were detected in many tissues in the adult animal, but the tissue-specific pattern of expression for these two genes was very different. (table 4, Figure 5).

Table 4.

	NEURTURIN	GDNF
Liver	-	-
5 Blood	+	-
Thymus	+	++
Brain	+	-
Sciatic nerve	-	-
10 Kidney	++	+
Spleen	-	+
Cerebellum	-	-
Uterus	++	-
Bone marrow	++	-
15 Testis	++	++
Ovary	+	+
Placenta	+	-
Skeletal muscle	+	-
20 Spinal cord	+	-
Adrenal gland	++	++
Gut	+	++

25 As shown in table 4, neurturin was found to be expressed in brain and spinal cord as well as in blood and bone marrow where no GDNF was detected. The level of expression of neurturin in brain and blood was, however, less than that detected in neonatal tissue.

30 Neurturin was also highly expressed in freshly isolated rat peritoneal mast cells, whereas GDNF showed little or no expression.

#### Example 10

35 This example illustrates the preparation of antisera to neurturin by immunization of rabbits with a neurturin peptide.

The peptide sequence corresponding to amino acids 73-87 of the mature murine neurturin protein was synthesized and coupled to keyhole limpet hemocyanin (KLH) as described earlier (Harlow and Lane, *Antibodies: a laboratory manual*, 1988. Cold Spring Harbor Laboratory, New York, NY. p. 72-81 which is incorporated by reference). The KLH-coupled peptide was submitted to Caltag, Inc. and each of two rabbits were immunized. Immunization was by subcutaneous injection at 7-10 sites.

10 The first injection was with 150 µg KLH-coupled peptide which was resuspended in 0.5 ml saline and emulsified with 0.5 ml complete Freund's adjuvant. Boost injections were begun 4 weeks after the initial injection and were performed once every 7 days as above for a total of 5

15 injections except that 100 µg of KLH-coupled peptide and incomplete Freund's adjuvant were used. Serum samples were collected 1 week after the fifth boost.

A pooled volume of twenty ml of serum that had been collected from both rabbits one week after the 5th injection was purified. For purification, a peptide affinity column was prepared by coupling the above peptide to cyanogen bromide activated Sepharose 4B according to the manufacturers protocol (Pharmacia Biotech). The serum was diluted 10 fold in 10 mM Tris pH 25 7.5 buffer and mixed by gentle rocking for 16 hours at 4°C with 0.5 ml of peptide agarose matrix containing 5 mg of coupled peptide. The matrix was placed into a column, washed with 5 ml of 10 mM Tris pH 7.5, 150 mM NaCl, washed with 5 ml of 10 mM Tris pH 7.5 buffer containing 30 0.4 M NaCl and eluted with 5.5 ml of 100 mM glycine pH 2.5 buffer. One tenth volume of 1.0M Tris pH 8.0 buffer was added to the eluate immediately after elution to neutralize the pH. The glycine eluate was dialyzed overnight against 10 mM Tris pH 7.5, 150 mM NaCl.

35 The affinity-purified antibodies were used in a western blot to demonstrate specific recognition of

recombinant neuriturin protein. Ten ml of conditioned medium collected from DG44CHO5-3(G418)(pCMV-NTN-3-1) cells was purified over SP Sepharose as described in Example 1 and the proteins electrophoresed on a reducing SDS-PAGE gel in the tricine buffer system (Schagger and von Jagow *Analytical Biochemistry* 166:368-379, 1987). The proteins were electroblotted to a nitrocellulose membrane in 25 mM Tris, 192 mM glycine, 0.04% SDS, 17% methanol at 4°C for 16 hr. The membrane was incubated 10 with the affinity-purified anti-neurturin peptide antibodies and then with horseradish peroxidase-coupled sheep anti-rabbit IgG (Harlow and Lane, *supra*, p. 498-510). Bound antibodies were detected with enhanced chemiluminescence (ECL kit, Amersham, Buckinghamshire, 15 England). The anti-neurturin antibodies recognized a single, approximately 11.5 kD protein band in the conditioned medium of the DG44CHO5-3(G418)(pCMV-NTN-3-1) cells. Using these anti-neurturin antibodies, neuriturin protein could be detected in 10 ml of conditioned medium 20 from DG44CHO5-3(G418)(pCMV-NTN-3-1) cells but could not be detected in 10 ml of medium conditioned with DG44 cells that had not been transformed with the neuriturin expression vector.

25

#### Example 11

The following example illustrates the identification of additional members of the GDNF/neurturin/persephin gene subfamily.

The TGF- $\beta$  superfamily currently contains over 25 30 different gene members (for review see Kingsley, *Genes and Development* 8: 133-146, 1994 which is incorporated by reference). The individual family members display varying degrees of homology with each other and several subgroups within the superfamily can be defined by 35 phylogenetic analysis using the Clustal V program (Higgins et al, *Comput Appl Biosci* 8: 189-191, 1992 which

is incorporated by reference) and by bootstrap analysis of phylogenetic trees (Felsenstein, *Evolution* 39:783-791, 1985 which is incorporated by reference). Neurturin or persephin is approximately 40% identical to GDNF but less than 20% identical to any other member of the TGF- $\beta$  superfamily. Several sequence regions in neurturin can be identified (Figure 5) that are highly conserved within the GDNF/neurturin/persephin subfamily but not within the TGF- $\beta$  superfamily. These conserved regions are likely to characterize a subfamily containing previously unisolated genes, which can now be isolated using the conserved sequence regions identified by the discovery and sequencing of the neurturin and persephin genes. Regions of high sequence conservation between neurturin, persephin and GDNF allow the design of degenerate oligonucleotides which can be used either as probes or primers. Conserved-region amino acid sequences have been identified herein to include Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser, Thr or Ala and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:108); Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>4</sub>-Gly-Xaa<sub>5</sub>-Cys in which Xaa<sub>1</sub> is Thr, Glu or lys, Xaa<sub>2</sub> is Val, Leu or Ile, Xaa<sub>3</sub> is Leu or Ile; Xaa<sub>4</sub> is Ala or Ser, and Xaa<sub>5</sub> is Ala or Ser, (SEQ ID NO:113); and Cys-Cys-Xaa<sub>1</sub>-Pro-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Xaa<sub>5</sub>-Asp-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>-Phe-Leu-Asp-Xaa<sub>9</sub> in which Xaa<sub>1</sub> is Arg or Gln, Xaa<sub>2</sub> is Thr or Val or Ile, Xaa<sub>3</sub> is Ala or Ser, Xaa<sub>4</sub> is Tyr or Phe, Xaa<sub>5</sub> is Glu, Asp or Ala, Xaa<sub>6</sub> is Glu, Asp or no amino acid, Xaa<sub>7</sub> is val or leu, Xaa<sub>8</sub> is Ser or Thr, and Xaa<sub>9</sub> is Asp or Val (SEQ ID NO:114). Nucleotide sequences containing a coding sequence for the above conserved sequences or fragments of the above conserved sequences can be used as probes. Exemplary probe and primer sequences which can be designed from these regions are as follows.

Forward primers,

35 Primer A (M3119): 5'-GTNDGNGANYTGGGNYTGGGNTA (SEQ ID NO:115) 23 nt which codes for the amino acid

sequence, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Thr, Ser or Ala and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:125);

5 Primer B (M3123): 5'-GANBTNWCNTTYYTNGANG (SEQ ID NO:116) 19 nt which codes for the amino acid sequence, Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser, Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val  
10 (SEQ ID NO:126);

15 Primer C (M3126): 5'-GANBTNWCNTTYYTNGANGW (SEQ ID NO:117) 20 nt which codes for the amino acid sequence, Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser, Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val (SEQ ID NO:126);

20 Primer D (M3121): 5'-TTYMGNTAYTGYDSNGGNDNSNTG (SEQ ID NO:118) 23 nt which codes for the amino acid sequence, Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys where Xaa<sub>1</sub> is Ser or Ala and Xaa<sub>2</sub> is Ser or Ala (SEQ ID NO:127);

25 Primer E (M3122): 5'-GTNDGNGANYTGGGNYTNGG (SEQ ID NO:119) 20 nt which codes for the amino acid sequence, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly where Xaa<sub>1</sub> is Thr, Ser or Ala and Xaa<sub>2</sub> is Asp or Glu (SEQ ID NO:128); and

30 Primer F (M3176): 5'-GTNDGNGANYTGGGNYTGGGNTT (SEQ ID NO:120) 23 nt which codes for the amino acid sequence, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Phe where Xaa<sub>1</sub> is Thr, Ser or Ala and Xaa<sub>2</sub> is Glu or Asp  
35 (SEQ ID NO:129).

Reverse primers,

Primer G (M3125): 5'-WCNTCNARRAANGWNAVNTC (SEQ ID NO:121) 20 nt whose reverse complementary sequence codes for the amino acid sequence,

5 Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser, Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val (SEQ ID NO:126);

10 Primer H (M3124): 5'-WCNTCNARRAANGWNAVNT (SEQ ID NO:122) 19 nt whose reverse complementary sequence codes for the amino acid sequence, Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser, 15 Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val (SEQ ID NO:126);

20 Primer I (M3120): 5'-CANSNCCNSHRCARTANCKRAA (SEQ ID NO:123) 23 nt whose reverse complementary sequence codes for the amino acid sequence, Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys where Xaa<sub>1</sub> is Ser or Ala and Xaa<sub>2</sub> is Ser or Ala (SEQ ID NO:127); and

25 Primer J (M3118): 5'-CANSNCCNSHRCARTANCKRAANA (SEQ ID NO:124) 25 nt whose reverse complementary sequence codes for the amino acid sequence, Xaa<sub>1</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>2</sub>-Gly-Xaa<sub>3</sub>-Cys where Xaa<sub>1</sub> is Ile or Leu, Xaa<sub>2</sub> is Ser or Ala and Xaa<sub>3</sub> is Ser or Ala (SEQ ID NO:130).

30 In addition to the above, the following primers are based upon conserved regions in GDNF and neurturin (SEQ ID NOS:33-35).

35 Primer 1, GTNWSNGANYTNGGNYTNGGNTA (SEQ ID NO:42) which encodes the amino acid sequence, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser or Thr and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:33);

5 Primer 2, TTYMGNATGYDSNGGNDNTGYGANKCNGC (SEQ ID NO:43) which encodes amino acid sequence Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Ala where Xaa<sub>1</sub> is Ala or Ser, Xaa<sub>2</sub> is Ala or Ser, Xaa<sub>3</sub> is Glu or Asp and Xaa<sub>4</sub> is Ser or Ala (SEQ ID NO:36);

10 Primer 3 reverse GCNGMNTCRCANSNHNCNSHRTANCKRAA (SEQ ID NO:44) whose reverse complementary sequence encodes amino acid sequence Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Ala where Xaa<sub>1</sub> is Ala or Ser, Xaa<sub>2</sub> is Ala or Ser, Xaa<sub>3</sub> is Glu or Asp and Xaa<sub>4</sub> is Ser or Ala (SEQ ID NO:37);

15 Primer 4 reverse TCRTCNTCRWANGCNRYNGGNKCARCA (SEQ ID NO:45) whose reverse complementary sequence encodes amino acid sequence Cys-Cys-Arg-Pro-Xaa<sub>1</sub>-Ala-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Asp-Xaa<sub>4</sub> where Xaa<sub>1</sub> is Ile or Thr or Val, Xaa<sub>2</sub> Try or Phe, Xaa<sub>3</sub> is Glu or Asp and Xaa<sub>4</sub> is Glu or Asp (SEQ ID NO:38);

20 Primer 5 reverse TCNARRAANSWNAVNTCRTCNTRWANGC (SEQ ID NO:46) whose reverse complementary sequence encodes amino acid sequence Ala-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Asp-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Ser-Phe-Leu-Asp where Xaa<sub>1</sub> is Tyr or Phe, Xaa<sub>2</sub> Glu or Asp, Xaa<sub>3</sub> is Glu or Asp, and Xaa<sub>4</sub> is Val or Leu (SEQ ID NO:39);

25 Primer 6 GARRMNBTNHTNTTYMGNATYTG (SEQ ID NO:47) which encodes amino acid sequence Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys where Xaa<sub>1</sub> is Glu or Thr, Xaa<sub>2</sub> is Leu or Val and Xaa<sub>3</sub> is Ile or Leu (SEQ ID NO:40);

30 Primer 7 GARRMNBTNHTNTTYMGNATYTG (SEQ ID NO:48) which encodes amino acid sequence Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>4</sub>-Gly-Xaa<sub>5</sub>-

Cys-Xaa<sub>6</sub> where Xaa<sub>1</sub> is Glu or Thr, Xaa<sub>2</sub> is Leu or Val, Xaa<sub>3</sub> is Ile or Leu, Xaa<sub>4</sub> is Ser or Ala, Xaa<sub>5</sub> is Ser or Ala and Xaa<sub>6</sub> is Glu or Asp (SEQ ID NO:41).

5       The above sequences can be used as probes for screening libraries of genomic clones or as primers for amplifying gene fragments from genomic DNA or libraries of genomic clones or from reverse transcribed cDNA using RNA templates from a variety of tissues. Genomic DNA or  
10      libraries of genomic clones can be used as templates because the neurturin, persephin and GDNF coding sequences for the mature proteins are not interrupted by introns.

A degenerate oligonucleotide can be synthesized as  
15      a mixture of oligonucleotides containing all of the possible nucleotide sequences which code for the conserved amino acid sequence. To reduce the number of different oligonucleotides in a degenerate mix, an inosine or universal base (Loakes et al, *Nucleic Acids Res* 22:4039-43, 1994) can be incorporated in the synthesis at positions where all four nucleotides are possible. The inosine or universal base forms base pairs with each of the four normal DNA bases which are less stabilizing than AT and GC base pairs but which are also  
20      less destabilizing than mismatches between the normal bases (i.e. AG, AC, TG, TC).

To isolate family members a primer above can be end labeled with <sup>32</sup>P using T4 polynucleotide kinase and hybridized to libraries of human genomic clones according  
30      to standard procedures.

A preferred method for isolating family member genes would be to use various combinations of the degenerate primers above as primers in the polymerase chain reaction using genomic DNA as a template. The  
35      various combinations of primers can include sequential PCR reactions utilizing nested primers or the use of a

forward primer paired with an oligo dT primer. In addition, one of the degenerate primers can be used with a vector primer, a single primer can be used in an inverted PCR assay or PCR can be performed with one 5 degenerate primer and a random primer. As an example using the above set of primers, primer 2 (SEQ ID NO:43) can be used with primer 4 (SEQ ID NO:45) in PCR with 1 ug of human genomic DNA and cycling parameters of 94°C for 30 sec, 50°C for 30 sec, and 72°C for 60 sec. The above 10 PCR conditions are exemplary only and one skilled in the art will readily appreciate that a range of suitable conditions and primer combinations could be used or optimized such as different temperatures and varying salt concentrations in the buffer medium and the like. It is 15 preferred that DMSO be added to the PCR reaction to a final concentration of 5% inasmuch as this was found to be necessary for amplification of this region of the neurturin gene. The PCR reaction, when run on an agarose gel, should contain products in the size range of 100-150 20 base pairs since a one amino acid gap is introduced in the neurturin sequence and a five amino acid gap is introduced in the persephin sequence when either sequence is aligned with GDNF, and thus family member genes might also contain a slightly variable spacing between the 25 conserved sequences of primers 2 and 4. The PCR products in the range of 100-150 base pairs should contain multiple amplified gene products including GDNF, neurturin and persephin as well as previously unisolated family members. To identify sequences of these products, 30 they can be gel purified and ligated into the Bluescript plasmid (Stratagene), and then transformed into the XL1-blue E. Coli host strain (Stratagene). Bacterial colonies containing individual subclones can be picked for isolation and plated on nitrocellulose filters in two 35 replicas. Each of the replicate filters can be screened with an oligonucleotide probe for either unique GDNF or

unique neuriturin or unique persephin sequence in the amplified region. Subclones not hybridizing to either GDNF or neuriturin or persephin can be sequenced and if found to encode previously unisolated family members, the 5 sequence can be used to isolate full length cDNA clones and genomic clones as was done for neuriturin (Example 5). A similar method was used to isolate new gene members (GDF-3 and GDF-9) of the TGF- $\beta$  superfamily based on homology between previously identified genes (McPherron *J 10 Biol Chem* 268: 3444-3449, 1993 which is incorporated by reference).

The inventors herein believe that the most preferred way to isolate family member genes may be to apply the above PCR procedure as a screening method to 15 isolate individual family member genomic clones from a library. This is because there is only one exon for the coding region of both mature neuriturin and GDNF. If, for example, the above PCR reaction with primers 2 and 4 generates products of the appropriate size using human 20 genomic DNA as template, the same reaction can be performed using, as template, pools of genomic clones in the P1 vector according to methods well known in the art, for example that used for isolating neuriturin human genomic clones (Example 5). Pools containing the 25 neuriturin gene in this library have previously been identified and persephin and GDNF-containing pools can be readily identified by screening with GDNF and PSP specific primers. Thus non-neurturin, non-persephin, non-GDNF pools which generate a product of the correct 30 size using the degenerate primers will be readily recognized as previously unisolated family members. The PCR products generated from these pools can be sequenced directly using the automated sequencer and genomic clones can be isolated by further subdivision and screening of 35 the pooled clones as a standard service offered by Genome Systems, Inc.

## Example 12

The following example illustrates the isolation and identification of persephin utilizing the procedures and primers described in Example 11.

- 5       The degenerate PCR strategy devised by the inventors herein has now been successfully utilized to identify a third factor, persephin, that is approximately 35-50% identical to both GDNF and neurturin. The experimental approach was described above and is provided
- 10      in greater detail as follows. Primers corresponding to the amino acid sequence Val-Xaa1-Xaa2-Leu-Gly-Leu-Gly-Tyr where Xaa1 is Ser or Thr and Xaa2 is Glu or Asp (SEQ ID NO:33) [M1996; 5'-GTNWSNGANYTNGGNYTNGGNTA (SEQ ID NO:42)] and Phe-Arg-Tyr-Cys-Xaa1-Gly-Xaa2-Cys-Xaa3-Xaa4-Ala where
- 15      Xaa1 is Ala or Ser, Xaa2 is Ala or Ser, Xaa3 is Glu or Asp and Xaa4 is Ser or Ala (SEQ ID NO:37) [M1999; 5'-GCNGMNTCRCANSNHNCCNSHRCARTANCKRAA (SEQ ID NO:44)] were used to amplify a 77 nt fragment from rat genomic DNA using KlenTaq enzyme and buffer under the following
- 20      conditions: 94°C for 30 sec; 44°C for 30 sec; 72°C for 30 sec for 40 cycles. The resulting product was subcloned into the Bluescript KS plasmid and sequenced. All nucleotide sequencing was performed using fluorescent dye terminator technology per manufacturer's instructions
- 25      on an Applied Biosystems automated sequencer Model #373 (Applied Biosystems, Foster City, CA). Plasmid DNA for sequencing was prepared using the Wizard Miniprep kit (Promega Corp., Madison, WI) according to the manufacturer's instructions.
- 30      The sequence of one of the amplified products predicted amino acid sequence data internal to the PCR primers that was different from that of GDNF or neurturin but had more than 20% identity with GDNF and neurturin, whereas the sequences of others we obtained corresponded
- 35      to GDNF or neurturin, as would be expected. The novel

100

sequence was thought to identify a new member of this family which we named persephin.

The sequence of this fragment internal to the primers was 5'-TGCCTCAGAGGAGAAGATTATC (SEQ ID NO:90).

- 5 This encodes the last nucleotide of the Tyr codon, and then encodes the amino acids: Ala-Ser-Glu-Glu-Lys-Ile-Ile (SEQ ID NO:91). This sequence was then aligned with the rat sequences of GDNF and neuritin. This analysis confirmed that persephin was unique.
- 10 LGLGYETKEELIFRYC GDNF (rat) (SEQ ID NO:92)  
LGLGYTSDETVLFRYC NTN (rat) (SEQ ID NO:93)  
LGLGYASEEKIIFRYC PSP (rat) (SEQ ID NO:94)

To obtain additional persephin sequence, primers containing portions of the unique 22 nt of the amplified fragment above were used in the rapid amplification of cDNA ends (RACE) technique (Frohman, M.A. *Methods in Enzymology* 218:340-356, 1993) using the Marathon RACE kit (CLONTECH, Palo Alto, CA) per the manufacturer's instructions, except that first strand cDNA synthesis was carried out at 50°C using Superscript II reverse transcriptase (Gibco-BRL). Briefly, a double stranded adaptor oligonucleotide was ligated to the ends of double stranded cDNA synthesized from postnatal day 1 rat brain mRNA. Using nested forward persephin PCR primers, (10135; 5'-AGTCGGGGTTGGGTATGCCCTCA, SEQ ID NO:95 and M2026; 5'-TATGCCTCAGAGGAGAAGATTATCTT SEQ ID NO:96) in combination with primers to the ligated adaptor supplied in the kit (AP1, AP2), the 3' end of the persephin cDNA was amplified by two successive PCR reactions (1st: 10135 and AP1, using 94°C for 30 sec, 60°C for 15 sec and 68°C for 2 min for 35 cycles; 2nd: M2026 and AP2 using 94°C for 30 sec, 60 for 15 sec and 68°C for 2 min for 21 cycles). An approximately 350 nt fragment was obtained from this PCR reaction and this fragment was directly sequenced using primer M2026. The sequence of this 3' RACE product resulted in a partial rat persephin cDNA sequence of approximately 350 nt (SEQ ID NO:97). The

101

predicted amino acid sequence of this cDNA was compared to that of GDNF and neurturin, and found to be approximately 40% homologous to each of these proteins. Importantly, the characteristic spacing of the cysteine residues in members of the TGF- $\beta$  superfamily was present. Furthermore, in addition to the region of similarity encoded by the degenerate primers used to isolate persephin, another region of high homology shared between GDNF and neurturin, but absent in other members of the TGF- $\beta$  superfamily, was also present in persephin

GDNF ACCRPVAFDDDSLDD (aa 60-76) (SEQ ID NO:98)  
NTN PCCRPTAYEDEVSKD (aa 61-77) (SEQ ID NO:99)  
PSP PCCQPTSYAD-VTFLDD (aa 57-72) (SEQ ID NO:100)

(Amino acid numbering uses the first Cys residue as amino acid 1).

With the confirmation that persephin was indeed a new member of the GDNF/neurturin subfamily, we isolated murine genomic clones of persephin to obtain additional sequence information. Primers (forward, M2026; 5'-TATGCCTCAGAGGAGAAGATTATCTT, SEQ ID NO:96 and reverse, M3028; 5'-TCATCAAGGAAGGTACATCAGCATA, SEQ ID NO:101) corresponding to rat cDNA sequence were used in a PCR reaction (PCR parameters: 94°C for 30 sec, 55°C for 15 sec and 72°C for 30 sec for 35 cycles) to amplify a 155 nt fragment from mouse genomic DNA which was homologous to rat persephin cDNA sequence. These primers were then used to obtain murine persephin genomic clones from a mouse 129/Sv library in a P1 bacteriophage vector (library screening service of Genome Systems, Inc., St. Louis, MO).

Restriction fragments (3.4 kb Nco I and a 3.3 kb Bam H1) from this P1 clone containing the persephin gene were identified by hybridization with a 210 nt fragment obtained by PCR using mouse genomic DNA with primers (forward, M2026; SEQ ID NO:96 and reverse, M3159; 5'-CCACCACAGCCACAAGCTGCGGSTGAGAGCTG, SEQ ID NO:102) and PCR

parameters: 94°C for 30 sec, 55°C for 15 sec and 72°C for 30 sec for 35 cycles. The Nco I and Bam H1 fragments were sequenced and found to encode a stretch of amino acids corresponding to that present in the rat persephin 5 RACE product, as well as being homologous to the mature regions of both neuriturin and GDNF (Figure 11).

When the amino acid sequences of murine GDNF, neuriturin and persephin are aligned using the first cysteine as the starting point (which is done because 10 alterations in the cleavage sites between family members creates variability in the segments upstream of the first cysteine), persephin (91 amino acids) is somewhat smaller than either neuriturin (95 amino acids) or GDNF (94 amino acids). The overall identity within this region is about 15 50% with neuriturin and about 40% with GDNF (Figure 12).

Further nucleotide sequencing of the murine persephin Nco I fragment revealed the nucleotide sequence of the entire murine persephin gene (SEQ ID NO:131; Figure 17A). An open reading frame extends from the 20 sequence coding for an initiator methionine up to a stop codon at positions 244-246. However, somewhere in this sequence there is an apparent anomaly such that the sequence encoding the RXXR cleavage site (nucleotides at positions 257-268) and the sequence corresponding to the 25 mature persephin protein (positions 269-556) are not co-linear with this open reading frame. Instead, a second reading frame encodes the cleavage site and the mature persephin.

Additional sequencing of the rat persephin has also 30 been performed. Rat genomic fragments were amplified by PCR using KlenTaq and rat genomic DNA as a template. The forward primer #40266 (5'-AATCCCCAGGACAGGCAGGGAAT; SEQ ID NO:137) corresponding to a region upstream of the mouse persephin gene and a reverse primer M3156 (5'- 35 CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC, SEQ ID NO:138) corresponding to a region within the mature rat persephin

sequence were used with the following parameters (95°C for 15 sec, 55°C for 15 sec, 68°C for 45 sec x 30 cycles). The amplified product was kinased with T4 polynucleotide kinase, the ends were blunted with E. coli 5 DNA polymerase I (Klenow fragment), and cloned into BSKS plasmid.

Nucleotide sequencing was performed to establish the sequence of the entire rat persephin gene (SEQ ID NO:134; Figure 18A). An open reading frame was found to extend 10 from the sequence coding for an initiator methionine up to a stop codon at positions 244-246 as was seen with murine persephin. As was also seen with murine persephin, an anomaly was found to occur between the sequence encoding the initiator methionine and that 15 encoding the cleavage site for the mature rat persephin such that two cogent reading frames exist. Irrespective of this anomaly, mammalian cells were found to express persephin from either the murine or rat full length genomic sequence as illustrated below (see Example 14).

20 To pursue the genesis of this anomaly, we prepared mammalian expression vectors for both murine and rat persephin. To construct the murine plasmid, a P1 clone containing the murine persephin gene was used as a template in a PCR assay. Primers were designed such that 25 the resulting fragment would contain the persephin gene extending from the initiator Methionine to the stop codon. The PCR reaction utilized a forward primer M3175 [5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA] and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]. To 30 construct the analogous rat plasmid, rat genomic DNA was used as a template in a PCR assay. The PCR reaction utilized a forward primer M3175 [5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA] and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]. The 35 amplified products were cloned into BSKS and sequenced to verify that the correct clone had been obtained. The rat

and murine persephin fragments were excised using Sma I and Hind III and cloned into a Asp718 (blunted) and Hind III sites of the mammalian expression vector pCB6.

COS monkey cells were transfected with either the rat or murine persephin expression vectors or the non-recombinant vector (pCB6) itself. Forty eight hr later the cells were lysed, the samples were loaded onto a 15% SDS-polyacrylamide gel, and the proteins were separated by electrophoresis. The proteins were then transferred to nitrocellulose by electroblotting. This nitrocellulose membrane was incubated with anti-persephin antibodies (which we raised to mature persephin produced in bacteria from a pET plasmid) to detect the presence of persephin in the lysates. Lysates from cells transfected with either the rat or murine persephin expression vectors, but not the lysate from cells transfected with pCB6, contain high amounts of persephin. The size of the persephin detected was 10-15 kD, consistent with the size predicted for the processed (i.e. mature form of persephin). Conditioned media harvested from these cells also contained mature persephin. These results demonstrate that both the murine and rat persephin genes are capable of directing the synthesis of a properly processed persephin molecule.

To pursue the mechanism by which this occurred, we isolated RNA from cells transfected with either rat or murine persephin expression vector. RT/PCR analysis was performed using primers corresponding to the initiator Met and the stop codon. We detected two fragments: one corresponding to the predicted size of the persephin gene and the other somewhat smaller, suggesting that RNA splicing had occurred. We confirmed this with a number of other primer pairs. Both the large and small persephin fragments were cloned and sequenced. As expected, the larger fragment corresponded to the persephin gene. The small fragment corresponded to a

105

spliced version of persephin. A small 88 nt intron within the pro-domain (situated 154 nt downstream of the start codon) had been spliced out. After this splicing event, the "frameshift" was no longer present (i.e. the 5 initiator Met and the mature region are in-frame) in either rat or mouse persephin (see Figures 17B and 18B).

#### Example 13

This example illustrates the preparation of a 10 bacterial expression vector for murine persephin and its introduction into an *E. Coli* for expression of recombinant mature persephin.

The persephin polynucleotide encoding the mature murine persephin protein which begins 5 amino acids 15 upstream of the first framework Cys residue (SEQ ID NO:80) was cloned into the pET expression vector pET-30a at the Nde I and Bgl II sites. This persephin polynucleotide was generated by PCR using the murine persephin P1 genomic clone as a template. A forward 20 primer M3157 (5'-GGACTATCATATGGCCCACCACCACCAACCACGACGACGACAAGGC CTTGGCTGGTTCATGCCGA, SEQ ID NO:139) encoding an Nde I site, 8 histidine residues, and an enterokinase site, and a reverse primer M3156 (5'-CGGTACCCAGATCTCAGCCACCACAGCCACAAGC, SEQ ID NO:138), which corresponds to the sequence encoding the last 6 25 amino acid residues of the mature persephin sequence, the stop codon and a Bgl II site, were used. The PCR reaction conditions were 95°C for 15 sec, 55°C for 15 30 sec, 68°C for 60 sec x 25 cycles. This PCR product was subcloned into the EcoRV site of BSKS plasmid and sequenced to verify that it contained no mutations. The persephin sequence was then excised from this vector 35 using Nde I and Bgl II and cloned into the Nde I (5') and Bgl II (3') sites of the bacterial expression vector pET30a (Novagen, Madison, WI). This expression vector

would, therefore, produce the mature form of the persephin protein possessing an amino terminal tag consisting of 8 histidine residues followed directly by an enterokinase site.

5       The plasmid was introduced into E.coli strain BL21 (DE3). To produce persephin, bacteria harboring this plasmid were grown for 16 hr, harvested, and lysed using 6M guanidine-HCl, 0.1 M NaH<sub>2</sub>PO<sub>4</sub>, 0.01 M Tris at pH 8.0, and recombinant persephin protein was purified from these 10 lysates via chromatography over a Ni-NTA resin (Qiagen). The protein was eluted using 3 column volumes of Buffer E containing 8 M urea, 0.1 M NaH<sub>2</sub>PO<sub>4</sub>, 0.01 M Tris, at pH 4.5. The persephin was then renatured by dialysis in renaturation buffer consisting of 0.1 M NaH<sub>2</sub>PO<sub>4</sub>, 0.01 M 15 Tris at pH 8.3, 0.15 M NaCl, 3 mM cysteine, 0.02% Tween-20, 10% glycerol and containing decreasing concentrations of urea beginning with 4 M for 16 hr, followed by 2 M for 16 hr, 1M for 72 hr, and 0.5 M for 16 hr. The persephin concentration was then determined using a Dot Metric 20 assay (Geno Technology, St. Louis, MO) and stored at 4°C.

This bacterially produced recombinant persephin was used as an immunogen in rabbits to produce antibodies to mature persephin. All of the immunogen injections and blood drawing were performed at Cal Tag Inc. (Healdsburg, 25 CA). The anti-persephin antiserum was demonstrated to specifically recognize persephin, but not neurturin or GDNF, using protein blot analysis. This persephin-specific antiserum was then used to detect persephin in lysates prepared from transfected COS cells.

30

#### Example 14

This example illustrates the preparation of mammalian expression vectors containing the murine or rat persephin genes and their incorporation into mammalian 35 cell lines for the production of mature persephin. To construct the murine plasmid, a P1 clone containing the

murine persephin gene was used as a template in a PCR assay. Primers were designed such that the resulting polynucleotide would contain the persephin gene extending from the initiator Methionine codon to the stop codon 3' 5 to the mature persephin coding sequence (SEQ ID NO:131). The PCR reaction utilized a forward primer M3175 (5'- TGCTGTCACCAGCATGGCTGCAGGAAGACTTCGGA, SEQ ID NO:140) and reverse primer M3156 (5'- CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC, SEQ ID NO:138). To 10 construct the analogous rat plasmid, rat genomic DNA was used as a template in a PCR assay. The PCR reaction utilized a forward primer M3175 (5'- TGCTGTCACCAGCATGGCTGCAGGAAGACTTCGGA, SEQ ID NO:140) and reverse primer M3156 (5'- CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC, SEQ ID NO:138). Both PCR reactions were carried out using Klenetaq and the following parameters: 95°C for 15 sec, 55°C for 15 sec, 68°C for 45 sec x 25 cycles. The amplified products were kinased with T4 polynucleotide kinase, the ends were 20 blunted with E. coli DNA polymerase I (Klenow fragment), and cloned into BSKS plasmid. Nucleotide sequencing was performed to verify that the correct clone was obtained. The rat and murine persephin polynucleotides were excised using Sma I and Hind III and each cloned into a Asp718 25 (blunted) and Hind III sites of the mammalian expression vector pCB6.

COS monkey cells were transfected with either the rat or murine persephin expression vectors (16 µg per 5 x 10<sup>5</sup> cells) or the non-recombinant vector (pCB6) itself 30 using the calcium phosphate precipitation method (Chen and Okayama, *Mol Cell Biol* 7:2745-2752, 1987 which is incorporated by reference). Forty eight hr later the cells were lysed in IP buffer containing 50 mM Tris at pH 7.5, 300 mM NaCl, 1% Triton X-100, 1% deoxycholate, 10 mM 35 EDTA, 0.1% SDS, 5 µg/ml leupeptin, 7 µg/ml pepstatin, and 250 µM PMSF. The samples were loaded onto a 15% SDS-

polyacrylamide gel and the proteins were separated by electrophoresis. The proteins were then transferred to nitrocellulose by electroblotting. This nitrocellulose membrane was incubated with anti-persephin antibodies to 5 detect the presence of persephin in the lysates.

As is shown in Figure 19, lysates from cells transfected with either the rat or murine persephin expression vectors, but not the lysate from cells transfected with pCB6, contain high amounts of persephin. 10 The size of the persephin detected was approximately 14 kD which is consistent with the size predicted for the processed, i.e. mature form of persephin. This demonstrates that both the murine and rat persephin genes are capable of directing the synthesis of a properly 15 processed persephin molecule.

#### Example 15

The following example illustrates the isolation and identification of human persephin.

20 In order to identify the human homologue of persephin or additional members of the GDNF family, degenerate PCR primers were designed based on the human Neurturin and GDNF sequences and used to amplify human genomic DNA. The following primers were used (SEQ ID 25 NOS:225-228):

DhNeurturin1 (DN1)	GTSASYGASYTGGGYCTGGGCTAY	REF:B-46Z
DhNeurturin2 (DN2)	TTYMGSTACTGCRSMGGCKCYTGC	REF:B-46X
DhNeurturin3r (DN3)	RWAGGCSRTSGGKCKGCARCAKGS	REF:B-46V
30 DhNeurturin4r (DN4)	MKCRTCYARRAASGACASSTC	REF:B-46W

Human genomic DNA (Clontech 6550-1 0.1 $\mu$ g/ $\mu$ l) was amplified with all 4 possible primer combinations (DN1-DN3r, DN1-DN4r, DN2-DN3r, DN2-DN4r). Reaction mixtures 35 contained 5  $\mu$ l of 10x KlenTaq buffer, 0.5  $\mu$ l dNTP (20mM); 1  $\mu$ l human genomic DNA, 0.6  $\mu$ l KlenTaq (Clontech) and 1.5

μl of each primers (0.1 OD/μl) in a total volume of 50 μl. The DNA was amplified by touchdown PCR on Perkin Elmer Gene AMP 9600 in the following conditions: initial denaturation at 98°C for 2', then 5 cycles [98°C 30", 5 72°C 1.5'], 5 cycles [98°C 30", 70°C 1.5'] and 25 cycles [98°C 30', 68°C 1.5'] followed by a last extension step at 68°C for 5'.

PCR products of approximately 130 to 200 bp were identified after electrophoresis on agarose gel, purified 10 and cloned into pCR 2.1 vector using In Vitrogen TA cloning kit (Cat # K2000-01). Clones containing a 130-200bp insert (after EcoR1 digestion) were sequenced and one of them (clone A3) obtained with the primer pair DN1-DN3r had a sequence homologous to mouse persephin and 15 corresponded to human persephin.

The partial sequence of the human persephin genomic DNA in clone A3 is shown below (SEQ ID NO:229):

CGGCTTGTGACCGAGCTGGGCCTGGGCTACGCCTCAGAGGAGAAGGTATCTCCGC  
TACTGCGCCGGCAGCTGCCCGTGGTGCCCCGACCCAGCATGCCCTGGCGCTGGCC  
20 CGGCTGCAGGGCCAGGGCCAGGCCACGGCGGGCCCTGCTGCCGCCATGGCC

In order to identify a source from which to isolate a full length cDNA clone of human persephin, cDNA libraries were screened by PCR using exact match primers designed based on the genomic DNA sequence described 25 above. Two sets of human persephin specific primers were prepared (SEQ ID NOS:230-233),

	hPSP-5'.1	GAGGAGAAGGTATCTTCCG	REF:B-95K
	hPSP-3'.1	GCCGTGGCCTGGCCCTGGC	REF:B-95L
and			
30	hPSP-5'.3	AGAGGAGAAGGTATCTTCCGCTA	REF:C-62Y
	hPSP-3'.4	CTCGGCCCTGGCCCTGCAGC	REF:C-62X

and used to amplify single stranded DNA from pRK5 cDNA libraries (1μl of 200 ng/μl) or the Stratagene's 35 Quickscreen panel (3μl of each library) using the same conditions as described above. PCR products of the

expected size (108 bp for hPSP-5'1 with hPSP-3'.1 and 101 bp for hPSP-5'.3 with hPSP-3'.4) were detected in fetal lung, fetal liver, fetal kidney, small intestine, retina, cerebellum and HT+13 Lymphoblast.

5 To isolate cDNA clones encoding human persephin, pRK5 libraries from human tissues were enriched for persephin cDNA clones by extension of single stranded DNA from plasmid libraries grown in a dut<sup>-</sup>/ung<sup>-</sup>-host using either of the following primers (SEQ ID NOS:233-234):

10 hPSP-3'.2 TGCAGCCGGGCCAGCGCCAG REF:D-68T  
hPSP-3'.4 CTCGGCCCTGGCCCTGCAGC REF:C-62X

in a reaction containing 10µl of 10x PCR Buffer (Perkin 15 Elmer), 1µl dNTP (20mM), 1µl library DNA (200 ng), 0.5µl primer, 86.5µl H<sub>2</sub>O and 1µl of AmpliTaq (Perkin Elmer) added after a hot start. The reaction was denatured for 1 min at 95°C, annealed for 1 min at 50, 60 or 68°C then extended for 20 min at 72°C. DNA was extracted with 20 phenol/chloroform, ethanol precipitated, then transformed by electroporation into DH10B host bacteria.

Approximately 40,000 colonies from each transformation were lifted on nylon membranes and screened with a DNA probe derived from the sequence of 25 clone A3 (described above). The fragment was labeled by the random oligonucleotide method using [32P]-dCTP. Filters were hybridized overnight at 42°C in 50% formamide, 5xSSC, 10xDenhardt's, 0.05M sodium phosphate (pH 6.5), 0.1% sodium pyrophosphate, 50 µg/ml of 30 sonicated salmon sperm DNA. Filters were then rinsed in 2xSSC and washed in 0.1xSSC, 0.1% SDS then exposed overnight to Kodak X Ray films. Pure positive clones were obtained after secondary screening and the isolated clones were then sequenced. Human persephin clones were 35 isolated from fetal lung, fetal kidney and fetal liver libraries. All such persephin clones isolated belong to

two categories: unspliced (10 clones) or chimeric (6 clones). Unspliced clones were ~900bp long and contain a region encoding a fragment corresponding to human persephin. However there is no initiation methionine and 5 signal peptide present in that reading frame (Frame +2). A potential upstream initiation codon (ATG) is present in another reading frame (+1) and is followed by a hydrophobic sequence corresponding to a potential signal peptide. This suggests that such cDNAs are incompletely 10 spliced and that an intron remains between the exons encoding the signal peptide and the persephin protein. Consensus splice donor and acceptor sequences can actually be identified at position 340 and 425, respectively. Splicing of an intron located between 15 these positions would lead to a cDNA where the persephin coding sequence is "in frame" with the initiation methionine. Interestingly, aberrant chimeric clones were identified resulting from the joining of a cDNA encoding the predicted exon 2 of persephin exactly at the splice 20 acceptor site present at position 425. The corresponding transcript was probably generated by aberrant splicing but confirms the presence of a splice acceptor site at position 425.

As an alternative approach to isolate a human 25 persephin cDNA clone, 3 million clones of a human cerebellum cDNA library in lambda ZAP (Stratagene cat #935201) were screened with a DNA probe corresponding to clone A3 labeled by the random oligonucleotide method using [32P]-dCTP. The library was screened under high 30 stringency hybridization conditions. The filters were prehybridized for 2h then hybridized overnight at 42°C in 50% formamide, 5xSSC, 10xDenhardt's, 0.05M sodium phosphate (pH 6.5), 0.1% sodium pyrophosphate, 50 µg/ml of sonicated salmon sperm DNA. Filters were then rinsed 35 in 2xSSC and washed once in 0.1xSSC, 0.1% SDS at 60°C. Filters were exposed overnight to Kodak X Ray films.

Four positive clones (Cere 1.1, 1.2, 6.1, 6.2) were picked and plaque purified. The plasmid contained within the lambda ZAP phage arms was rescued as described per manufacturer's instructions using Ex Assist helper phage.

5 Sequencing of the four clones indicated that these clones were siblings and contained 2 silent mutations when compared to the human persephin clones isolated from the pRK5 library described above. These silent mutations occur at positions 30 (T→C) and 360 (T→C) of the sequence

10 shown in Figure 24. Direct sequencing of the human persephin gene revealed that these silent mutations are actual allelic variations in the gene.

In order to determine if the correct protein could be expressed from the unspliced cDNA identified above, 15 constructs were generated where the sequence encoding a Flag tag was inserted just before the stop codon present at position 685 (frame + 1) or at position 746 (frame +2) starting from an ATG codon present at position 46 or 193. All four possible constructs were generated by PCR using 20 the following primers (SEQ ID NOS:235-238):

hPSP1stMet.F	5' CGC GGA TCC ATG CCT GGA TTC GAG GGT GCA G 3'	REF:B-127R
hPSP2ndMet.F	5' CGC GGA TCC ATG GCC GTA GGG AAG TTC CTG C 3'	REF:B-127S
25 hPSP.FLAG.R	5' CTC CCA AGC TTT TAC TTG TCA TCG TCG TCC TTG TAG TCG CCA CCA CAG CCG CAG GCA GCC 3'	REF:A-120C
hPSP.sig.FLAG.R	5' CTC CCA AGC TTT TAC TTG TCA TCG TCG TCC TTG TAG TCT CGA GGA AGG CCA CGT CGG TG 3'	REF:A-120B
30		

In all four PCR reactions, the Cere 1.2 clone was used as template and amplified with Pfu polymerase on a 35 Stratagene Robocycler gradient cycler 96. PCR conditions were 95°C for 2', 30 cycles of [95°C 30", 1' at 52, 56,

60 or 63°C, 72°C for 2 min] followed by a last extension of 5 min at 72°C.

Forward primers have a Bam HI site and the reverse primers have Hind III restriction site. The PCR products 5 digested with Bam HI and Hind III and were subcloned into these sites in pRK5. DNA from each of the construct was transfected overnight into 293 cells using CaPO4 method. Serum containing media was conditioned for 24h then harvested. Cells were also harvested and divided in two; 10 1/4 of each plate for RT-PCR and the remaining 3/4 of each plate for immunoprecipitation.

Analysis of expressed proteins was performed by immunoprecipitation. The cell pellet was lysed in 1 ml of lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM 15 EDTA, 1% NP40, Aprotinin, Leupeptin, PMSF, 1 mM NaF and 1 mM Sodium Vanadate) for 20 min at 4°C. The extract was spun for 10 min at 10K rpm and then the supernatant was transferred to a new tube and precleared with 20 µl Protein A Sepharose for 1h. From here, 1 ml of the 20 conditioned media was processed in parallel. The protein A sepharose was spun down and 1 µl of anti-Flag antibody (3.6 µg) was added to each tube. After overnight incubation at 4°C, 30 µl of Protein G sepharose were added and the tubes incubated at 4°C for 1 hour. The 25 protein G beads were then spun down for 1 min, washed 3 times with lysis buffer, resuspended in 20 µl of Laemli buffer in the presence of β-mercapto-ethanol. Samples were denatured for 5 min at 100°C then loaded on a 16% polyacrylamide gel. Proteins were then transferred to 30 nitrocellulose and analyzed by Western blot using the same anti-Flag antibody overnight at 1µg/ml in blocking buffer (PBS + 0.5% tween + 5% nonfat dry milk +3% Goat serum). Following this an anti-mouse HRP.ECL was used for the detection and the membrane was exposed for 90 sec 35 to X-Ray film.

A specific band of 16 kDa was detected in the cell pellet of cells transfected with the construct starting at ATG 193 of frame +1 and with the flag inserted in frame +2 and a specific band of approximately 10 kDa 5 could be detected in the corresponding supernatant. No Flag tagged protein could be detected in any other transfection or in mock transfected cells.

The correctly spliced mRNA was identified by RT-PCR as follows. Total RNA was extracted from the transfected 10 cells (1/4 of each pellet) using RNAzol B (Tel-Test Inc.) and treated for 40 min at 37°C with DNase. RNA was then purified on an RNAeasy column (Promega) and collected in a final volume of 50µl. First strand cDNA was synthesized on 4 µl RNA using superscript RT (GIBCO-BRL) for 1h at 15 37°C then 5' at 95° to inactivate.

Two µl of each RT reaction were then used as template for amplification by PCR in the presence of the following 2 primers (SEQ ID NOS:236 and 239):

20

hPSP2ndMet.F 5' CGCGGATCCATGGCCGTAGGGAAAGTTCCCTGC 3'

REF:B-127S

hPSP.stop.R TCAGGCCACCACAGCCGCAGGCAGCC

REF:D-103N

25 on a Stratagene Robocycler gradient cycler 96. PCR conditions were 98°C for 1.5', 28 cycles of [98°C for 30", anneal 1' between 60°C and 76°C, 72°C for 1.5'] followed by a last extension of 5 min at 72°C.

Analysis of the PCR product on agarose gel indicates 30 that PCR using the pRK5.hPSP-FLAG.2 plasmid as template gave the expected product of about 570 bp while the RT PCR product, using RNA from cells transfected with this construct as template, was smaller than 500 bp. PCR product from the latter reaction was subcloned into the 35 pCR 2.1 vector using In Vitrogen TA cloning kit (cat #K2000-01) and sequenced. Sequence analysis revealed

that the predicted 84 bp intron has been spliced out of the transcript.

In summary, the human persephin cDNA has a 471 bp open reading frame encoding a 156 amino acid long protein (predicted Mr 16.6kDa). Cleavage of the 23 amino acid long predicted signal peptide will lead to a 133 amino acid pro-persephin molecule (Mr 14.2 kDa); proteolytic cleavage of the pro-persephin at a RXXR consensus sequence should yield a 96 amino acid mature protein with a molecular weight of 10.3 kDa. This predicted size corresponds to the size of the Flag-tagged protein immunoprecipitated from the conditioned media of transfected 293 cells. Furthermore, amino terminal sequencing of Flag-tagged persephin purified from conditioned media of 293 transfected cells confirmed that the first residue of the mature form is Ala 61. Alignment between human persephin and human Neurturin indicates 38% similarity between the two molecules (50% for the mature region) and that human persephin is 30% similar to human GDNF (40% in the mature region).

#### Example 16

This example illustrates the preparation of chimeric or hybrid polypeptide molecules that contain portions derived from persephin (PSP) and portions derived from neurturin (NTN).

As closely related members of the TGF $\beta$  family, each of persephin and neurturin is predicted to have a very similar overall structure, yet while neurturin promotes the survival of sympathetic neurons, the closely related persephin does not. Two chimeras were produced by essentially replacing portions of persephin with neurturin, with the crossover point located between the two adjacent, highly conserved third and fourth cysteine residues. The first chimera, named PSP/NTN (SEQ ID NO:141, Figure 20), contains the first 63 residues of

mature murine persephin combined with residues 68 through 100 of mature murine neurturin (using E. coli preferred codons). To construct this molecule, two PCR reactions were performed: 1) using the forward primer M2012 (5'-  
5 TAATACGACTCACTATAAGGGAA, SEQ ID NO:142) and reverse primer M2188 (5'-  
TCGTCTTCGTAAGCAGTCGGACGGCAGCAGGGTCGGCCATGGGCTCGAC, SEQ ID NO:143) and the pET30a-murine persephin plasmid as template (see Example 13); and 2) using the forward 10 primer M2190 (5'-TGCTGCCGTCCGACTGCTTACGAAGACGA, SEQ ID NO:144) and reverse primer M2186 (5'-  
GTTATGCTAGTTATTGCTAGCGGT, SEQ ID NO:145) and the pET30a-murine (E.coli preferred codons) neurturin plasmid as template (see Example 6). Both PCR reactions were  
15 carried out using the following parameters: 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec x 25 cycles. The products of these two PCR reactions were gel purified, mixed together, and a PCR reaction was performed under the following conditions: 94°C for 30 sec, 60°C for 20 min, 68°C for 5 min. After 8 cycles, an aliquot of this reaction was used as template in a third PCR reaction using the forward primer M2012 and reverse primer M2186 under the following conditions: 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec x 25 cycles. The resulting  
20 product was kinased with T4 polynucleotide kinase, the ends were blunted with E. coli DNA polymerase I (Klenow fragment), and cloned into BSKS plasmid. Nucleotide sequencing was performed to verify that the correct clone was obtained. The PSP/NTN fragment was excised using Nde  
25 I and Bam H1 and cloned into the corresponding sites of the bacterial expression vector pET30a.  
30

The second chimera, named NTN/PSP (SEQ ID NO:146, Figure 20), encodes the converse molecule. It contains the first 67 residues of mature murine neurturin (using 35 E.coli preferred codons) combined with residues 64 to 96 of mature murine persephin. To construct this molecule,

we performed two PCR reactions: 1) using the forward primer M2012 and reverse primer M2183 (5'-CACATCAGCATAGCTGGTGGGCTGGCAGCACGGGTGAGCACGAGCACGTT, SEQ ID NO:147) and the pET30a-murine (E.coli preferred 5 codons) neuriturin plasmid as template; and 2) using the forward primer M2187 (5'-TGCTGCCAGCCCACCAGCTATGCTG, SEQ ID NO:148) and reverse primer M2186 (5'-GTTATGCTAGTTATTGCTCAGCGGT, SEQ ID NO:145) and the pET30a-murine persephin plasmid as template. Both PCR reactions 10 were carried out using the following parameters: 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec x 25 cycles. The products of these two PCR reactions were used to construct the final NTN/PSP pET30a plasmid as detailed above for PSP/NTN except that Bgl II was used instead of 15 Bam H1. These chimeric proteins were produced in E.coli and purified by Ni-NTA chromatography as described above (Example 13).

The purified proteins were assayed for their ability to promote survival in the SCG sympathetic neuron assay. 20 The NTN/PSP protein did not promote survival, whereas the PSP/NTN protein promoted the survival of sympathetic neurons similar to that observed for neuriturin itself. These results indicate that neuriturin residues lying downstream of the 2 adjacent, highly conserved cysteine 25 residues are critical for activity in promoting survival in SCG sympathetic neurons. In contrast, the corresponding residues of persephin are not sufficient for promoting survival in sympathetic neurons.

30

#### Example 17

This example illustrates the neuronal survival promoting activity of persephin in mesencephalic cells.

The profile of survival promoting activity of persephin is different from that of neuriturin and GDNF. 35 In contrast to the survival promoting activity produced by neuriturin and GDNF in sympathetic and sensory neurons,

persephin showed no survival promoting activity in these tissues. We further evaluated the neuronal survival promoting activity of persephin in mesencephalic cells.

Timed-pregnant Sprague-Dawley rats were purchased 5 from Harlan Sprague-Dawley. The mesencephalon was taken from rats measuring 1.2 to 1.4 cm in length and time dated to be embryonic day 14. The cranium was removed and the entire mesencephalon was placed in cold L15. The pooled mesencephalic tissue was resuspended in a serum-free medium consisting of DME/Hams F12 (#11330-032, Life Technologies) 1 mg/ml BSA, Fraction V (A-6793, Sigma Chemical Co.,), 5 µM Insulin (I-5500, Sigma), 10 nM progesterone (P0130, Sigma), 100 µM putrescine, (p7505, Sigma), 30 nM Selenium (S07150, Pflatz & Bauer), 10 ng/ml 10 rat transferrin (012-000-050, Jackson Chompure), 100 U/ml penicillin, and 100 U/ml of streptomycin. The 15 pooled mesencephalic tissues were triturated approximately 80 times using a bent-tip pipette and the cells were plated in a 24-well dish (CoStar) at a density 20 of 15,000 cells in a 100-µl drop. The dishes were coated with 125 ng/ml poly-d-lysine (p-7280, Sigma) and 25 ng/ml laminin (#40232, Collaborative Biomedical Products). These dissociated cells were allowed to attach for 2 hours at 37°C in 5% CO<sub>2</sub> and then fed with another 500 µl 25 of the above serum-free medium with or without approximately 100 ng/ml of recombinant Persephin. These cells were photographed after 3 days of culture.

Inspection of the cells over the course of 3 days in culture, showed a gradual decrease in cell number. In 30 the absence of any growth factor, almost all of the cells were dead (Figure 21A). In the presence of persephin, a large increase in mesencephalic neuronal cell survival was evident (Figure 21B).

This study was repeated to obtain comparative 35 effects on mesencephalic cell for persephin and the related growth factors, neurturin and GDNF.

Mesencephalic tissue was removed from E14 par pps, pooled and dissociated in dispase for 30 min. Cells were then triturated and plated in supplemented N2 media and plated at a density of 20,000 cells per well in an 8-well chamber slide. The cells in a given well were either untreated or treated with a growth factor at 50 ng/ml for four days. Cells were washed once with PBS, fixed with 4% paraformaldehyde for 30 minutes and stained with tyrosine hydroxylase (TOH) antibody (Chemicon, ABC- Vectastain kit) and counted. TOH staining served as a marker for dopaminergic cells inasmuch as TOH is a synthetic enzyme for dopamine. Figure 22 shows the mean cell counts for untreated and treated cells. Persephin (PSP), neurturin (NTN) and GDNF promoted survival of mesencephalic neuronal cells to a comparable extent.

#### Example 18

This example illustrates the expression of persephin in various tissues.

A survey of persephin expression was performed in adult mouse tissues using semi-quantitative RT/PCR (see Example 9). Poly A RNA was isolated from brain, cerebellum, kidney, lung, heart, ovary, sciatic nerve, dorsal root ganglia, blood and spleen. This was then reverse transcribed to produce cDNA (see Kotzbauer et al. *Nature* 384:467-470, 1996 which is incorporated by reference). The PCR primers used were as follows: forward primer: 5'-CCTCGGAGGAGAAGGGTCATCTTC (SEQ ID NO:149) and reverse primer: 5'TCATCAAGGAAGGTACATCAGCATA (SEQ ID NO:101). PCR was done for 26 cycles with an annealing temperature of 60°C. To control for the presence of genomic DNA, RNA samples which were not reverse transcribed were used for PCR (for example, the tissue control shown in figure 22 is labeled "Kidney no RT"). All the samples were found to be without genomic DNA contamination.

120

As shown in Figure 23, a band of the correct size (160 bp) was seen in the kidney sample. At higher cycle numbers a persephin band was also seen in brain. Thus, the distribution of expression of persephin in various 5 mouse tissues differs from that of neurturin in rat (Example 8).

Deposit of Strain. The following strain is on deposit under the terms of the Budapest Treaty, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, 10 MD. The accession number indicated was assigned after successful viability testing, and the requisite fees were paid. Access to said cultures will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 15 and 35 USC 122. All restriction on availability of said cultures to the public will be irrevocably removed upon the granting of a patent based upon the application. Moreover, the designated deposits will be maintained for a period of thirty (30) years from the date of deposit, 20 or for five (5) years after the last request for the deposit, or for the enforceable life of the U.S. patent, whichever is longer. Should a culture become nonviable or be inadvertently destroyed, or, in the case of plasmid-containing strains, lose its plasmid, it will be 25 replaced with a viable culture. The deposited materials mentioned herein are intended for convenience only, and are not required to practice the present invention in view of the description herein, and in addition, these materials are incorporated herein by reference.

30

	Strain	Deposit Date	ATCC No.
35	DG44CHO-pHSP-NGFI-B	August 25, 1995	CRL 11977

121

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.

As various changes could be made in the above 5 methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: JOHNSON, EUGENE M  
MILBRANDT, JEFFREY D  
KOTZBAUER, PAUL T  
LAMPE, PATRICIA A  
KLEIN, ROBERT  
DESAUVAGE, FRED
- (ii) TITLE OF INVENTION: PERSEPHIN AND RELATED GROWTH FACTOR
- (iii) NUMBER OF SEQUENCES: 242
- (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: HOWELL & HAVERKAMP, L.C.  
(B) STREET: 7733 FORSYTH BOULEVARD, SUITE 1400  
(C) CITY: ST. LOUIS  
(D) STATE: MO  
(E) COUNTRY: USA  
(F) ZIP: 63105
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: HOLLAND, DONALD R.  
(B) REGISTRATION NUMBER: 35,197  
(C) REFERENCE/DOCKET NUMBER: 971486
- (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: 314-727-5188  
(B) TELEFAX: 314-727-6092

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 102 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala	Arg	Leu	Gly	Ala	Arg	Pro	Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg
1					5				10					15	
Val	Ser	Glu	Leu	Gly	Leu	Gly	Tyr	Ala	Ser	Asp	Glu	Thr	Val	Leu	Phe
		20					25						30		
Arg	Tyr	Cys	Ala	Gly	Ala	Cys	Glu	Ala	Ala	Ala	Arg	Val	Tyr	Asp	Leu
		35					40				45				
Gly	Leu	Arg	Arg	Leu	Arg	Gln	Arg	Arg	Leu	Arg	Arg	Glu	Arg	Val	
		50				55				60					

123

Arg	Ala	Gln	Pro	Cys	Cys	Arg	Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser
65						70				75					80
Phe	Leu	Asp	Ala	His	Ser	Arg	Tyr	His	Thr	Val	His	Glu	Leu	Ser	Ala
					85				90					95	
Arg	Glu	Cys	Ala	Cys	Val										
					100										

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 100 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Pro	Gly	Ala	Arg	Pro	Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg	Val	Ser
1						5			10				15		
Glu	Leu	Gly	Leu	Gly	Tyr	Thr	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr
					20				25				30		
Cys	Ala	Gly	Ala	Cys	Glu	Ala	Ala	Ile	Arg	Ile	Tyr	Asp	Leu	Gly	Leu
					35			40			45				
Arg	Arg	Leu	Arg	Gln	Arg	Arg	Arg	Val	Arg	Arg	Glu	Arg	Ala	Arg	Ala
					50			55			60				
His	Pro	Cys	Cys	Arg	Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser	Phe	Leu
					65			70			75			80	
Asp	Val	His	Ser	Arg	Tyr	His	Thr	Leu	Gln	Glu	Leu	Ser	Ala	Arg	Glu
					85				90				95		
Cys	Ala	Cys	Val												
			100												

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 6
  - (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ser	Gly	Ala	Arg	Pro	Xaa	Gly	Leu	Arg	Glu	Leu	Glu	Val	Ser	Val	Ser
1							5			10			15		

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 10 amino acids

124

- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "SERINE OR CYSTEINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Xaa Cys Ala Gly Ala Xaa Glu Ala Ala Val  
1 5 10

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 17
- (D) OTHER INFORMATION: /note= "GLUTAMINE OR GLUTAMIC ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Xaa Xaa Val Glu Ala Lys Pro Cys Cys Gly Pro Thr Ala Tyr Glu Asp  
1 5 10 15

Xaa Val Ser Phe Leu Ser Val  
20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

125

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Tyr His Thr Leu Gln Glu Leu Ser Ala Arg  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 197 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser  
1 5 10 15

Val Leu Ser Ile Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg  
20 25 30

Leu Gly Pro Ala Leu Val Pro Leu His Arg Leu Pro Arg Thr Leu Asp  
35 40 45

Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala  
50 55 60

Pro Asp Ala Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro  
65 70 75 80

Pro Gly Pro Arg Arg Ala Gly Pro Arg Arg Arg Ala Arg Ala  
85 90 95

Arg Leu Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val  
100 105 110

Ser Glu Leu Gly Leu Gly Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg  
115 120 125

Tyr Cys Ala Gly Ala Cys Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly  
130 135 140

Leu Arg Arg Leu Arg Gln Arg Arg Leu Arg Arg Glu Arg Val Arg  
145 150 155 160

Ala Gln Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe  
165 170 175

Leu Asp Ala His Ser Arg Tyr His Thr Val His Glu Leu Ser Ala Arg  
180 185 190

Glu Cys Ala Cys Val  
195

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 195 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

126

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Arg	Arg	Trp	Lys	Ala	Ala	Ala	Leu	Val	Ser	Leu	Ile	Cys	Ser	Ser
1				5					10				15		
Leu	Leu	Ser	Val	Trp	Met	Cys	Gln	Glu	Gly	Leu	Leu	Leu	Gly	His	Arg
			20				25						30		
Leu	Gly	Pro	Ala	Leu	Ala	Pro	Leu	Arg	Arg	Pro	Pro	Arg	Thr	Leu	Asp
	35					40						45			
Ala	Arg	Ile	Ala	Arg	Leu	Ala	Gln	Tyr	Arg	Ala	Leu	Leu	Gln	Gly	Ala
	50				55							60			
Pro	Asp	Ala	Val	Glu	Leu	Arg	Glu	Leu	Ser	Pro	Trp	Ala	Ala	Arg	Ile
	65				70				75			80			
Pro	Gly	Pro	Arg	Arg	Ala	Gly	Pro	Arg	Arg	Arg	Arg	Ala	Arg	Pro	
	85					90						95			
Gly	Ala	Arg	Pro	Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg	Val	Ser	Glu
	100					105						110			
Leu	Gly	Leu	Gly	Tyr	Thr	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr	Cys
	115					120						125			
Ala	Gly	Ala	Cys	Glu	Ala	Ala	Ile	Arg	Ile	Tyr	Asp	Leu	Gly	Leu	Arg
	130					135						140			
Arg	Leu	Arg	Gln	Arg	Arg	Arg	Val	Arg	Arg	Glu	Arg	Ala	Arg	Ala	His
	145					150				155			160		
Pro	Cys	Cys	Arg	Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser	Phe	Leu	Asp
	165					170						175			
Val	His	Ser	Arg	Tyr	His	Thr	Leu	Gln	Glu	Leu	Ser	Ala	Arg	Glu	Cys
	180					185						190			
Ala	Cys	Val													
	195														

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 306 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCGCGGTTGG	GGGCGCGGCC	TTGCGGGCTG	CGCGAGCTGG	AGGTGCGCGT	GAGCGAGCTG	60
GGCCTGGGCT	ACGCGTCCGA	CGAGACGGTG	CTGTTCCGCT	ACTGCGCAGG	CGCCTGCGAG	120
GCTGCCGC	GCGTCTACGA	CCTCGGGCTG	CGACGACTGC	GCCAGCGGCC	GCGCCTGCGG	180
CGGGAGCGGG	TGCGCGCGCA	GCCCTGCTGC	CGCCCCGACGG	CCTACGAGGA	CGAGGTGTCC	240
TTCCTGGACG	CGCACAGCCG	CTACCACACG	GTGCACGAGC	TGTCGGCGCC	CGAGTGCGCC	300
TGCGTG						306

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 300 base pairs

127

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGGGGGCTC	GGCCTTGTGG	GCTGCGCGAG	CTCGAGGTGC	GCGTGAGCGA	GCTGGGCCTG	60
GGCTACACGT	CGGATGAGAC	CGTGCTGTTC	CGCTACTGCG	CAGGCGCGTG	CGAGGCGGCC	120
ATCCGCATCT	ACGACCTGGG	CCTTCGGCGC	CTGCGCCAGC	GGAGGCGCGT	GCGCAGAGAG	180
CGGGCGCGGG	CGCACCCGTG	TTGTCGCCCG	ACGGCCTATG	AGGACGAGGT	GTCCTTCCTG	240
GACGTGCACA	GCCGCTACCA	CACGCTGCAA	GAGCTGTCGG	CGCGGGAGTG	CGCGTGCCTG	300

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 591 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGCAGCGCT	GGAAGGCGGC	GGCCTTGGCC	TCAGTGCTCT	GCAGCTCCGT	GCTGTCCATC	60
TGGATGTGTC	GAGAGGGCCT	GCTTCTCAGC	CACCGCCTCG	GACCTGCGCT	GGTCCCCCTG	120
CACCGCCTGC	CTCGAACCCCT	GGACGCCCGG	ATTGCCCGCC	TGGCCCAGTA	CCGTGCACTC	180
CTGCAGGGGG	CCCCGGATGC	GATGGAGCTG	CGCGAGCTGA	CGCCCTGGGC	TGGCGGCC	240
CCAGGTCCGC	GCCGTCGGGC	GGGGCCCCGG	CGGCGGCGCG	CGCGTGCCTG	GTTGGGGCG	300
CGGCCTTGC	GGCTGCGCGA	GCTGGAGGTG	CGCGTGAGCG	AGCTGGGCCT	GGGCTACGCG	360
TCCGACGAGA	CGGTGCTGTT	CCGCTACTGC	GCAGGCCCT	GCGAGGCTGC	CGCGCGCGTC	420
TACGACCTCG	GGCTGCGACG	ACTGCGCCAG	CGGCAGCGCC	TGCGGCAGGA	GCAGGTGCGC	480
GCGCAGCCCT	GCTGCCGCC	GACGGCCTAC	GAGGACGAGG	TGTCCCTCCT	GGACGCGCAC	540
AGCCGCTACC	ACACGGTGCA	CGAGCTGTCG	GCGCGCGAGT	GCGCCTGCGT	G	591

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 585 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATGAGGCGCT	GGAAGGCAGC	GGCCCTGGTG	TCGCTCATCT	GCAGCTCCCT	GCTATCTGTC	60
------------	------------	------------	------------	------------	------------	----

128

TGGATGTGCC	AGGAGGGTCT	GCTCTTGGGC	CACCGCCTGG	GACCCGCGCT	TGCCCCGCTA	120
CGACGCCCTC	CACGCACCCCT	GGACGCCCGC	ATCGCCCGCC	TGGCCCAGTA	TCGCGCTCTG	180
CTCCAGGGCG	CCCCCGACGC	GGTGGAGCTT	CGAGAACTTT	CTCCCTGGGC	TGCCCCGCATC	240
CCGGGACCGC	GCCGTCGAGC	GGGTCCCCGG	CGTCGGCGGG	CGCGGCCGGGG	GGCTCGGCCT	300
TGTGGGCTGC	GCGAGCTCGA	GGTGCGCGTG	AGCGAGCTGG	GCCTGGGCTA	CACGTGGAT	360
GAGACCGTGC	TGTTCCGCTA	CTGCGCAGGC	GCGTGCAGGG	CGGCCATCCG	CATCTACGAC	420
CTGGGCCTTC	GGCGCCTGCG	CCAGCGGAGG	CGCGTGCAGCA	GAGAGCGGGC	GCGGGCGCAC	480
CCGTGTTGTC	GCCCCGACGGC	CTATGAGGAC	GAGGTGTCCCT	TCCTGGACGT	GCACAGCCGC	540
TACCACACGC	TGCAAGAGCT	GTCGGCGCGG	GAGTGCGCGT	GCGTG		585

## (2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 348 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GGAGGGAGAG	CGCGCGGTGG	TTTCGTCCGT	GTGCCCCGCG	CCCGGCGCTC	CTCGCGTGGC	60
CCCGCGTCCT	GAGCGCGCTC	CAGCCTCCCA	CGCGCGCCAC	CCCAGGGTTC	ACTGAGCCCG	120
GCGAGCCCGG	GGAAGACAGA	GAAAGAGAGG	CCAGGGGGGG	AACCCCATGG	CCCGGCCCCGT	180
GTCCCGCACC	CTGTGCGGTG	GCCTCCTCCG	GCACGGGGTC	CCCAGGGTCGC	CTCCGGTCCC	240
CGCGATCCGG	ATGGCGCACG	CAGTGGCTGG	GGCCGGGCCG	GGCTCGGGTG	GTCGGAGGAG	300
TCACCACTGA	CCGGGTCAATC	TGGAGCCCGT	GGCAGGCCGA	GGCCCAGG		348

## (2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 87 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGCTACCTCA	CGCCCCCGA	CCTGCGAAAG	GGCCCTCCCT	GCCGACCCCTC	GCTGAGAACT	60
GAATTACACAT	AAAGTGTGGG	AACTCCC				87

## (2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser  
1 5 10 15  
Val Leu Ser

## (2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met Arg Arg Trp Lys Ala Ala Ala Leu Val Ser Leu Ile Cys Ser Ser  
1 5 10 15  
Leu Leu Ser

## (2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 57 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ATGCAGCGCT GGAAGGCGGC GGCCCTGGCC TCAGTGCTCT GCAGCTCCGT GCTGTCC

57

## (2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 57 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATGAGGCGCT GGAAGGCAGC GGCCCTGGTG TCGCTCATCT GCAGCTCCCT GCTATCT

57

## (2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 76 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

130

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ile	Trp	Met	Cys	Arg	Glu	Gly	Leu	Leu	Leu	Ser	His	Arg	Leu	Gly	Pro
1					5				10						15
Ala	Leu	Val	Pro	Leu	His	Arg	Leu	Pro	Arg	Thr	Leu	Asp	Ala	Arg	Ile
								25					30		
Ala	Arg	Leu	Ala	Gln	Tyr	Arg	Ala	Leu	Leu	Gln	Gly	Ala	Pro	Asp	Ala
								40				45			
Met	Glu	Leu	Arg	Glu	Leu	Thr	Pro	Trp	Ala	Gly	Arg	Pro	Pro	Gly	Pro
							55				60				
Arg	Arg	Arg	Ala	Gly	Pro	Arg	Arg	Arg	Arg	Ala	Arg				
							70				75				

## (2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 228 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ATCTGGATGT GTCGAGAGGG CCTGCTTCTC AGCCACCGCC TCGGACCTGC GCTGGTCCCC	60
CTGCACCGCC TGCCTCGAAC CCTGGACGCC CGGATTGCC GCCTGGCCCA GTACCGTGCA	120
CTCCTGCAGG GGGCCCCGGA TGCGATGGAG CTGCGCGAGC TGACGCCCTG GGCTGGCGGG	180
CCCCCAGGTC CGCGCCGTCG GGCGGGGCC CGGCAGCGGC GCGCGCGT	228

## (2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 228 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GTCTGGATGT GCCAGGGAGGG TCTGCTCTTG GGCCACCGCC TGGGACCCGC GCTTGGCCCG	60
CTACGACGCC CTCCACGCAC CCTGGACGCC CGCATCGCCC GCCTGGCCCA GTATCGCGCT	120
CTGCTCCAGG GCGCCCCCGA CGCGGTGGAG CTTCGAGAAC TTTCTCCCTG GGCTGCCCGC	180
ATCCCAGGAC CGCGCCGTCG AGCGGGTCCC CGGCAGCGGC GGGCGCGG	228

## (2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 76 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

131

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Val	Trp	Met	Cys	Gln	Glu	Gly	Leu	Leu	Leu	Gly	His	Arg	Leu	Gly	Pro
1					5				10						15
Ala	Leu	Ala	Pro	Leu	Arg	Arg	Pro	Pro	Arg	Thr	Leu	Asp	Ala	Arg	Ile
	20						25						30		
Ala	Arg	Leu	Ala	Gln	Tyr	Arg	Ala	Leu	Leu	Gln	Gly	Ala	Pro	Asp	Ala
	35					40					45				
Val	Glu	Leu	Arg	Glu	Leu	Ser	Pro	Trp	Ala	Ala	Arg	Ile	Pro	Gly	Pro
	50				55						60				
Arg	Arg	Arg	Ala	Gly	Pro	Arg	Arg	Arg	Arg	Ala	Arg				
	65				70						75				

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 95 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Met	Gln	Arg	Trp	Lys	Ala	Ala	Ala	Leu	Ala	Ser	Val	Leu	Cys	Ser	Ser
1					5				10						15
Val	Leu	Ser	Ile	Trp	Met	Cys	Arg	Glu	Gly	Leu	Leu	Leu	Ser	His	Arg
	20						25						30		
Leu	Gly	Pro	Ala	Leu	Val	Pro	Leu	His	Arg	Leu	Pro	Arg	Thr	Leu	Asp
	35					40					45				
Ala	Arg	Ile	Ala	Arg	Leu	Ala	Gln	Tyr	Arg	Ala	Leu	Leu	Gln	Ala	
	50					55					60				
Pro	Asp	Ala	Met	Glu	Leu	Arg	Glu	Leu	Thr	Pro	Trp	Ala	Gly	Arg	Pro
	65			70				75					80		
Pro	Gly	Pro	Arg	Arg	Ala	Gly	Pro	Arg	Arg	Arg	Ala	Arg			
	85					90						95			

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 95 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Met	Arg	Arg	Trp	Lys	Ala	Ala	Ala	Leu	Val	Ser	Leu	Ile	Cys	Ser	Ser
1					5				10						15

132

Leu Leu Ser Val Trp Met Cys Gln Glu Gly Leu Leu Leu Gly His Arg  
                   20                         25                         30

Leu Gly Pro Ala Leu Ala Pro Leu Arg Arg Pro Pro Arg Thr Leu Asp  
                   35                         40                         45

Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala  
                   50                         55                         60

Pro Asp Ala Val Glu Leu Arg Glu Leu Ser Pro Trp Ala Ala Arg Ile  
                   65                         70                         75                 80

Pro Gly Pro Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg  
                   85                         90                         95

## (2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 285 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

ATGCAGCGCT GGAAGGCGGC GGCCTTGGCC TCAGTGCTCT GCAGCTCCGT GCTGTCCATC	60
TGGATGTGTC GAGAGGGCCT GCTTCTCAGC CACCGCCTCG GACCTGCGCT GGTCCCCCTG	120
CACCGCCTGC CTCGAACCT GGACGCCCGG ATTGCCGCC TGGCCCAGTA CCGTGCACTC	180
CTGCAGGGGG CCCCGGATGC GATGGAGCTG CGCGAGCTGA CGCCCTGGGC TGGGCGGCC	240
CCAGGTCCGC GCCGTCGGGC GGGGCCCCGG CGGCGGCGCG CGCGT	285

## (2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 285 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ATGAGGCAGC GGAAGGCAGC GGCCCTGGTG TCGCTCATCT GCAGCTCCCT GCTATCTGTC	60
TGGATGTGCC AGGAGGGTCT GCTCTTGGGC CACCGCCTGG GACCCGCGCT TGCCCCGCTA	120
CGACGCCCTC CACGCACCCCT GGACGCCCGC ATCGGCCGCC TGGCCCAGTA TCGCGCTCTG	180
CTCCAGGGCG CCCCCGACGC GGTGGAGCTT CGAGAACTTT CTCCCTGGGC TGCCCGCATC	240
CCGGGACCGC GCCGTCGAGC GGGTCCCCGG CGTCGGCGGG CGCGG	285

## (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 169 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

ATGCAGCGCT GGAAGGCGGC GGCCTTGGCC TCAGTGCTCT GCAGCTCCGT GCTGTCCATC	60
TGGATGTGTC GAGAGGGCCT GCTTCTCAGC CACCGCCTCG GACCTGCGCT GGTCCCCCTG	120
CACCGCCTGC CTCGAACCCT GGACGCCCGG ATTGCCCGCC TGGCCCAGT	169

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 425 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ACCGTGCACT CCTGCAGGGG GCCCCGGATG CGATGGAGCT GCGCGAGCTG ACGCCCTGGG	60
CTGGGCGGCC CCCAGGTCCG CGCCGTCGGG CGGGGCCCCG GCGGCGGCGC CGCGTGC	120
GGTTGGGGGC CGGGCCTTGC GGGCTGCGCG AGCTGGAGGT GCGCGTGAGC GAGCTGGGCC	180
TGGGCTACCC GTCCGACGAG ACGGTGCTGT TCCGCTACTG CGCAGGCGCC TGCGAGGCTG	240
CCCGCGCGGT CTACGACCTC GGGCTGCGAC GACTGCCA GCGGCGGCGC CTGCGGCCGG	300
AGCGGGTCCG CGCGCAGCCC TGCTGCCGCC CGACGGCCTA CGAGGACGAG GTGTCTTCC	360
TGGACGCGCA CAGCCGCTAC CACACGGTGC ACGAGCTGTC GGCGCGCGAG TGCGCCTGCG	420
TGTGA	425

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 169 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

ATGAGGCAGT GGAAGGCAGC GGCCTGGTG TCGCTCATCT GCAGCTCCCT GCTATCTGTC	60
TGGATGTGCC AGGAGGGTCT GCTCTTGGGC CACCGCCTGG GACCCGCGCT TGCCCCGCTA	120
CGACGCCCTC CACGCACCCCT GGACGCCCGC ATCGCCCGCC TGGCCCAGT	169

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 419 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

ATCGCGCTCT	GCTCCAGGGC	GCCCCCGACG	CGGTGGAGCT	TCGAGAACCTT	TCTCCCTGGG	60
CTGCCCGCAT	CCCGGGACCG	CGCCGTCGAG	CGGGTCCCCG	GCGTCGGCGG	GCGCGGCCGG	120
GGGCTCGGCC	TTGTGGGCTG	CGCGAGCTCG	AGGTGCGCGT	GAGCGAGCTG	GGCCTGGGCT	180
ACACGTCGGA	TGAGACCCTG	CTGTTCCGCT	ACTGCGCAGG	CGCGTGCAG	GCGGCCATCC	240
GCATCTACGA	CCTGGGCCTT	CGCGCCTGC	GCCAGCGGAG	GCGCGTGCAG	AGAGAGCGGG	300
CGCGGGCGCA	CCCGTGTGT	CGCCCGACGG	CCTATGAGGA	CGAGGTGTCC	TTCCTGGACG	360
TGCACAGCCG	CTACCACACG	CTGCAAGAGC	TGTCGGCGCG	GGAGTGCGCG	TGCGTGTGA	419

## (2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 94 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg	Val	Ser	Glu	Leu	Gly		
1					5					10				15	
Tyr	Ala	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr	Cys	Ala	Gly	Ala	Cys
					20			25						30	
Glu	Ala	Ala	Ala	Arg	Val	Tyr	Asp	Leu	Gly	Leu	Arg	Arg	Leu	Arg	Gln
					35			40						45	
Arg	Arg	Arg	Leu	Arg	Arg	Glu	Arg	Val	Arg	Ala	Gln	Pro	Cys	Cys	Arg
			50		55						60				
Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser	Phe	Leu	Asp	Ala	His	Ser	Arg
	65				70				75					80	
Tyr	His	Thr	Val	His	Glu	Leu	Ser	Ala	Arg	Glu	Cys	Ala	Cys		
			85							90					

## (2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 94 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg	Val	Ser	Glu	Leu	Gly		
1						5				10				15	
Tyr	Thr	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr	Cys	Ala	Gly	Ala	Cys
					20			25						30	

135

Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln  
                   35                  40                  45

Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala His Pro Cys Cys Arg  
                   50                  55                  60

Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Val His Ser Arg  
                   65                  70                  75                  80

Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu Cys Ala Cys  
                   85                  90

## (2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "SERINE OR THREONINE"

(ix) FEATURE:
 

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Val Xaa Xaa Leu Gly Leu Gly Tyr  
       1                  5

## (2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "THREONINE OR GLUTAMIC ACID"

(ix) FEATURE:
 

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(ix) FEATURE:
 

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "LEUCINE OR ISOLEUCINE"

(ix) FEATURE:
 

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 9
- (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

136

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 11  
(D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 13  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
ACID"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 14  
(D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Glu Xaa Xaa Xaa Phe Arg Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Ala  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 5  
(D) OTHER INFORMATION: /note= "THREONINE OR VALINE OR  
ISOLEUCINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 7  
(D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 8  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
ACID"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 10  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
ACID"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 11  
(D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Cys Cys Arg Pro Xaa Ala Xaa Xaa Asp Xaa Xaa Ser Phe Leu Asp  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 11 amino acids

137

- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 5  
(D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 7  
(D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 9  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
ACID"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 10  
(D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Phe Arg Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Ala  
1 5 10

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 11 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 5  
(D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 7  
(D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 9  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
ACID"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 10  
(D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Phe Arg Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Ala  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:38:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "ISOLEUCINE OR THREONINE OR VALINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 8
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Cys	Cys	Arg	Pro	Xaa	Ala	Xaa	Xaa	Asp	Xaa
1				5				10	

## (2) INFORMATION FOR SEQ ID NO:39:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6

(D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Ala Xaa Xaa Asp Xaa Xaa Ser Phe Leu Asp  
1 5 10

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 2  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR THREONINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 3  
(D) OTHER INFORMATION: /note= "LEUCINE OR VALINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 4  
(D) OTHER INFORMATION: /note= "ISOLEUCINE OR LEUCINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Glu Xaa Xaa Xaa Phe Arg Tyr Cys  
1 5

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 2  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR THREONINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 3  
(D) OTHER INFORMATION: /note= "LEUCINE OR VALINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 4  
(D) OTHER INFORMATION: /note= "ISOLEUCINE OR LEUCINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 9  
(D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

140

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 11  
 (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 13  
 (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
 ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Glu Xaa Xaa Xaa Phe Arg Tyr Cys Xaa Gly Xaa Cys Xaa  
 1                   5                   10

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GTNWSNGANY TNGGNYTNGG NTA

23

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 32 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

TTYMGNTAYT GYDSNGGNDS NTGYGANKCN GC

32

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 32 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCNGMNTCRC ANSHNCCNSH RCARTANCKR AA

32

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 29 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single

141

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

TCRTCNTCRW ANGCNRYNGG NCKRCARCA

29

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TCNARRAANS WNAVNTCRTC NTCRWANGC

29

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GARRMNBTNH TNTTYMGNTA YTG

23

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GARRMNBTNH TNTTYMGNTA YTGYDSNGGN DSNTGHGA

38

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

142

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Ser	Gly	Ala	Arg	Pro	Xaa	Gly	Leu	Arg	Glu	Leu	Glu	Val	Ser	Val	Ser
1					5				10				15		

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

CCNACNGCNT AYGARGA

17

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Ala	Arg	Ala	His	Pro	Cys	Cys	Arg	Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val
1					5				10				15		

Ser	Phe	Leu	Asp
		20	

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

ARYTCYTGNA RRGTRTGRTA

20

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

143

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GACGAGGTGT CCTTCCTGGGA CGTACACACA

28

## (2) INFORMATION FOR SEQ ID NO:54:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 34 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

TAGCGGCTGT GTACGTCCAG GAAGGACACC TCGT

34

## (2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

CAGCGACGAC GCGTGCACAA AGAGCG

26

## (2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 47 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

TAYGARGACG AGGTGTCCTT CCTGGACGTA CACAGCCGCT AYCAYAC

47

## (2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GCGGCCATCC GCATCTACGA CCTGGGG

26

## (2) INFORMATION FOR SEQ ID NO:58:

## (i) SEQUENCE CHARACTERISTICS:

144

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

CRTAGGCCGT CGGGCGRCAR CACGGGT

27

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

GCGCCGAAGG CCCAGGTCGT AGATGCG

27

(2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

CGCTACTGCG CAGGCGCGTG CGARGCGGC

29

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

CGCCGACAGC TCTTGCAGCG TRTGGTA

27

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GAGCTGGGCC TGGGCTACGC GTCCGACGAG

30

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

GCGACGCGTA CCATGAGGCG CTGGAAGGCA GCGGCCCTG

39

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GACGGATCCG CATCACACGC ACGCGCACTC

30

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

GACCATATGC CGGGGGCTCG GCCTTGTGG

29

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GACGGATCCG CATCACACGC ACGCGCACTC

30

(2) INFORMATION FOR SEQ ID NO:67:

146

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

CAGCGACGAC GCGTGCGCAA AGAGCG

26

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 34 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

TAGCGGGCTGT GTACGTCCAG GAAGGACACC TCGT

34

(2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

AAAAATCGGG GGTGYGTCTT A

21

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

CATGCCTGGC CTACYTTGTC A

21

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

147

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:  
CTGGCGTCCC AMCAAGGGTC TTCG 24
- (2) INFORMATION FOR SEQ ID NO:72:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:  
GCCAGTGGTG CCGTCGAGGC GGG 23
- (2) INFORMATION FOR SEQ ID NO:73:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:  
GGCCCAGGAT GAGGCGCTGG AAGG 24
- (2) INFORMATION FOR SEQ ID NO:74:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:  
CCACTCCACT GCCTGAWATT CWACCCC 27
- (2) INFORMATION FOR SEQ ID NO:75:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:  
CCATGTGATT ATCGACCATT CGGC 24
- (2) INFORMATION FOR SEQ ID NO:76:

148

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 134 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Ser	Pro	Asp	Lys	Gln	Met	Ala	Val	Leu	Pro	Arg	Arg	Glu	Arg	Asn	Arg
1					5				10					15	
Gln	Ala	Ala	Ala	Ala	Asn	Pro	Glu	Asn	Ser	Arg	Gly	Lys	Gly	Arg	Arg
					20			25					30		
Gly	Gln	Arg	Gly	Lys	Asn	Arg	Gly	Cys	Val	Leu	Thr	Ala	Ile	His	Leu
					35			40			45				
Asn	Val	Thr	Asp	Leu	Gly	Leu	Gly	Tyr	Glu	Thr	Lys	Glu	Glu	Leu	Ile
					50			55			60				
Phe	Arg	Tyr	Cys	Ser	Gly	Ser	Cys	Asp	Ala	Ala	Glu	Thr	Thr	Tyr	Asp
65						70					75				80
Lys	Ile	Leu	Lys	Asn	Leu	Ser	Arg	Asn	Arg	Arg	Lys	Leu	Val	Ser	Asp
					85				90				95		
Val	Gly	Gln	Ala	Cys	Cys	Arg	Pro	Ile	Ala	Phe	Asp	Asp	Asp	Leu	Ser
					100			105					110		
Phe	Leu	Asp	Asp	Asn	Leu	Val	Tyr	His	Ile	Leu	Arg	Lys	His	Ser	Ala
					115			120					125		
Lys	Arg	Cys	Gly	Cys	Ile										
					130										

- (2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 134 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Ser	Pro	Asp	Lys	Gln	Ala	Ala	Ala	Leu	Pro	Arg	Arg	Glu	Arg	Asn	Arg
1					5				10					15	
Gln	Ala	Ala	Ala	Ala	Ser	Pro	Glu	Asn	Ser	Arg	Gly	Lys	Gly	Arg	Arg
					20			25					30		
Gly	Gln	Arg	Gly	Lys	Asn	Arg	Gly	Cys	Val	Leu	Thr	Ala	Ile	His	Leu
					35			40			45				
Asn	Val	Thr	Asp	Leu	Gly	Leu	Gly	Tyr	Glu	Thr	Lys	Glu	Glu	Leu	Ile
					50			55			60				
Phe	Arg	Tyr	Cys	Ser	Gly	Ser	Cys	Glu	Ser	Ala	Glu	Thr	Met	Tyr	Asp
65						70			75					80	
Lys	Ile	Leu	Lys	Asn	Leu	Ser	Arg	Ser	Arg	Arg	Lys	Leu	Thr	Ser	Asp
					85			90			95				

149

Val	Gly	Gln	Ala	Cys	Cys	Arg	Pro	Val	Ala	Phe	Asp	Asp	Asp	Leu	Ser
100								105						110	

Phe	Leu	Asp	Asp	Asn	Leu	Val	Tyr	His	Ile	Leu	Arg	Lys	His	Ser	Ala
115							120					125			

Lys	Arg	Cys	Gly	Cys	Ile										
130															

## (2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 134 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Ser	Pro	Asp	Lys	Gln	Ala	Ala	Ala	Leu	Pro	Arg	Arg	Glu	Arg	Asn	Arg
1					5				10					15	

Gln	Ala	Ala	Ala	Ala	Ser	Pro	Glu	Asn	Ser	Arg	Gly	Lys	Gly	Arg	Arg
					20			25				30			

Gly	Gln	Arg	Gly	Lys	Asn	Arg	Gly	Cys	Val	Leu	Thr	Ala	Ile	His	Leu
					35			40			45				

Asn	Val	Thr	Asp	Leu	Gly	Leu	Gly	Tyr	Glu	Thr	Lys	Glu	Glu	Leu	Ile
					50			55			60				

Phe	Arg	Tyr	Cys	Ser	Gly	Ser	Cys	Glu	Ala	Ala	Glu	Thr	Met	Tyr	Asp
					65			70			75		80		

Lys	Ile	Leu	Lys	Asn	Leu	Ser	Arg	Ser	Arg	Arg	Leu	Thr	Ser	Asp	Lys
					85			90			95				

Val	Gly	Gln	Ala	Cys	Cys	Arg	Pro	Val	Ala	Phe	Asp	Asp	Asp	Leu	Ser
							100		105				110		

Phe	Leu	Asp	Asp	Ser	Leu	Val	Tyr	His	Ile	Leu	Arg	Lys	His	Ser	Ala
					115			120			125				

Lys	Arg	Cys	Gly	Cys	Ile										
130															

## (2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 89 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Cys	Arg	Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala	Glu	Leu	Gly	Leu	Gly
1						5			10				15		

Tyr	Ala	Ser	Glu	Glu	Lys	Val	Ile	Phe	Arg	Tyr	Cys	Ala	Gly	Ser	Cys
					20			25			30				

150

Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
 35 40 45

Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
 50 55 60

Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln Gln Leu Pro  
 65 70 75 80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
 85

## (2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 96 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Ala Leu Ala Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala  
 1 5 10 15

Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
 20 25 30

Cys Ala Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val  
 35 40 45

Leu Ala Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys  
 50 55 60

Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp Gln His His  
 65 70 75 80

Trp Gln Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
 85 90 95

## (2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 134 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Val Arg Ile Pro Gly Gly Leu Pro Thr Pro Gln Phe Leu Leu Ser Lys  
 1 5 10 15

Pro Ser Leu Cys Leu Thr Ile Leu Leu Tyr Leu Ala Leu Gly Asn Asn  
 20 25 30

His Val Arg Leu Pro Arg Ala Leu Ala Gly Ser Cys Arg Leu Trp Ser  
 35 40 45

151

Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu  
 50 55 60

Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys Pro Gln Glu Ala Arg  
 65 70 75 80

Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg Gly Arg Gly Ala  
 85 90 95

His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe  
 100 105 110

Leu Asp Asp Gln His His Trp Gln Gln Leu Pro Gln Leu Ser Ala Ala  
 115 120 125

Ala Cys Gly Cys Gly Gly  
 130

## (2) INFORMATION FOR SEQ ID NO:82:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 89 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15

Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30

Pro Gln Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
 35 40 45

Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
 50 55 60

Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro  
 65 70 75 80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
 85

## (2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 91 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15

Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30

152

Pro	Gln	Glu	Val	Arg	Thr	Gln	His	Ser	Leu	Val	Leu	Ala	Arg	Leu	Arg
35															45
Gly	Gln	Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys	Gln	Pro	Thr	Ser	Tyr
50															60
Ala	Asp	Val	Thr	Phe	Leu	Asp	Asp	His	His	His	Trp	Gln	Gln	Leu	Pro
65															80
Gln	Leu	Ser	Ala	Ala	Ala	Cys	Gly	Cys	Gly	Gly					
						85			90						

## (2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 267 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

TGCCGACTGT GGAGCCTGAC CCTACCAGTG GCTGAGCTGG GCCTGGGCTA TGCCTCGGAG	60
GAGAAGGTCA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGCCCG TACCCAGCAC	120
AGTCTGGTAC TGGCCCGGCT TCGAGGGCGG GGTCGAGCCC ATGGCCGACC CTGCTGCCAG	180
CCCACCAGCT ATGCTGATGT GACCTTCCTT GATGATCAGC ACCATTGGCA GCAGCTGCCT	240
CAGCTCTCAG CTGCAGCTTG TGGCTGT	267

## (2) INFORMATION FOR SEQ ID NO:85:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 267 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

TGCCGGCTGT GGAGCCTGAC CCTACCAGTG GCTGAGCTTG GCCTGGGCTA TGCCTCAGAG	60
GAGAAGATTA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGTCCG TACCCAGCAC	120
AGTCTGGTGC TGGCCCGTCT TCGAGGGCAG GGTCGAGCTC ATGGCAGACC TTGCTGCCAG	180
CCCACCAGCT ATGCTGATGT GACCTTCCTT GATGACCACC ACCATTGGCA GCAGCTGCCT	240
CAGCTCTCAG CGCGCAGCTTG TGGCTGT	267

## (2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 273 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

```

TGCCGGCTGT GGAGCCTGAC CCTACCAGTG GCTGAGCTTG GCCTGGGCTA TGCCCTCAGAG 60
GAGAAGAGATTA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGTCCG TACCCAGCAC 120
AGTCTGGTGC TGGCCCGTCT TCGAGGGCAG GGTCGAGCTC ATGGCAGACC TTGCTGCCAG 180
CCCACCAGCT ATGCTGATGT GACCTTCCTT GATGACCACC ACCATTGGCA GCAGCTGCCT 240
CAGCTCTCAG CCCGAGCTTG TGGCTGTGGT GGC 273

```

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:

  - (A) LENGTH: 94 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Cys	Val	Leu	Thr	Ala	Ile	His	Leu	Asn	Val	Thr	Asp	Leu	Gly	Leu	Gly
					5					10				15	
Tyr	Glu	Thr	Lys	Glu	Glu	Leu	Ile	Phe	Arg	Tyr	Cys	Ser	Gly	Ser	Cys
							20			25				30	
Glu	Ser	Ala	Glu	Thr	Met	Tyr	Asp	Lys	Ile	Leu	Lys	Asn	Leu	Ser	Arg
					35			40				45			
Ser	Arg	Arg	Leu	Thr	Ser	Asp	Lys	Val	Gly	Gln	Ala	Cys	Cys	Arg	Pro
					50			55			60				
Val	Ala	Phe	Asp	Asp	Asp	Leu	Ser	Phe	Leu	Asp	Asp	Asn	Leu	Val	Tyr
					65			70			75				80
His	Ile	Leu	Arg	Lys	His	Ser	Ala	Lys	Arg	Cys	Gly	Cys	Ile		
					85				90						

(2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:

  - (A) LENGTH: 95 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg	Val	Ser	Glu	Leu	Gly	Leu	Gly
1				5					10					15	
Tyr	Thr	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr	Cys	Ala	Gly	Ala	Cys
			20					25					30		
Glu	Ala	Ala	Ile	Arg	Ile	Tyr	Asp	Leu	Gly	Leu	Arg	Arg	Leu	Arg	Gln
			35				40				45				

154

Arg	Arg	Arg	Val	Arg	Arg	Glu	Arg	Ala	Arg	Ala	His	Pro	Cys	Cys	Arg
50						55					60				
Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser	Phe	Leu	Asp	Val	His	Ser	Arg
65				70					75				80		
Tyr	His	Thr	Leu	Gln	Glu	Leu	Ser	Ala	Arg	Glu	Cys	Ala	Cys	Val	
				85					90				95		

## (2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 91 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Cys	Arg	Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala	Glu	Leu	Gly		
1				5					10				15		
Tyr	Ala	Ser	Glu	Glu	Lys	Val	Ile	Phe	Arg	Tyr	Cys	Ala	Gly	Ser	Cys
			20				25						30		
Pro	Gln	Glu	Ala	Arg	Thr	Gln	His	Ser	Leu	Val	Leu	Ala	Arg	Leu	Arg
	35						40						45		
Gly	Arg	Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys	Gln	Pro	Thr	Ser	Tyr
	50				55						60				
Ala	Asp	Val	Thr	Phe	Leu	Asp	Asp	Gln	His	His	Trp	Gln	Gln	Leu	Pro
	65				70				75					80	
Gln	Leu	Ser	Ala	Ala	Cys	Gly	Cys	Gly							
	85							90							

## (2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

TGCCTCAGAG GAGAAGATTA TC

22

## (2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

155

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Ala	Ser	Glu	Glu	Lys	Ile	Ile
1				5		

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Leu	Gly	Leu	Gly	Tyr	Glu	Thr	Lys	Glu	Glu	Leu	Ile	Phe	Arg	Tyr	Cys
1				5						10				15	

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Leu	Gly	Leu	Gly	Tyr	Thr	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr	Cys
1				5					10				15		

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Leu	Gly	Leu	Gly	Tyr	Ala	Ser	Glu	Glu	Lys	Ile	Ile	Phe	Arg	Tyr	Cys
1				5					10				15		

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

AGTCGGGGTT GGGGTATGCC TCA 23

(2) INFORMATION FOR SEQ ID NO:96:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

TATGCCTCAG AGGAGAAAGAT TATCTT 26

(2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 336 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

CCTCAGAGGA GAAGATTATC TTCCGATACT GTGCTGGCAG CTGTCCCCAA GAGGTCCGTA	60
CCCAGCACAG TCTGGTGCTG GCCCGTCTTC GAGGGCAGGG TCGAGCTCAT GGCAGACCTT	120
GCTGCCAGCC CACCAGCTAT GCTGATGTGA CCTTCCTTGA TGACCACCAC CATTGGCAGC	180
AGCTGCCTCA GCTCTCAGCC GCAGCTTGTG GCTGTGGTGG CTGAAGGCAGG CCAGCCTGGT	240
CTCTCAGAAT CACAAGCAAG AGGCAGCCTT TGAAAGGCTC AGGTGACGTT ATTAGAAACT	300
TGCATAGGAG AAGATTAAGA AGAGAAAGGG GACCTG	336

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 17 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Ala	Cys	Cys	Arg	Pro	Val	Ala	Phe	Asp	Asp	Asp	Leu	Ser	Phe	Leu	Asp
1					5					10				15	

Asp

157

## (2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Lys Asp  
1 5 10 15  
Val

## (2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Pro Cys Cys Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp  
1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

TCATCAAGGA AGGTCACATC AGCATA

26

## (2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

158

CCACCACAGC CACAAGCTGC GGSTGAGAGC TG

32

## (2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 5 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Ala	Leu	Ala	Gly	Ser
1				5

## (2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 43 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

Val	Arg	Ile	Pro	Gly	Gly	Leu	Pro	Thr	Pro	Gln	Phe	Leu	Leu	Ser	Lys
1										10				15	

Pro	Ser	Leu	Cys	Leu	Thr	Ile	Leu	Leu	Tyr	Leu	Ala	Leu	Gly	Asn	Asn
													20	25	30

His	Val	Arg	Leu	Pro	Arg	Ala	Leu	Ala	Gly	Ser
										35

40

## (2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 544 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

GAGGGACCTG GACGCCCAT CAGGGTAAGA ATTCCCTGGGG GCCTCCCGAC TCCCCAATTC	60
CTTCTCTCAA AGCCCTCACT TTGCCTTACA ATCCTACTCT ACCTTGCACT AGGTAACAAC	120
CATGTCCGTC TTCCAAGAGC CTTGGCTGGT TCATGCCGAC TGTGGAGCCT GACCCTACCA	180
GTGGCTGAGC TGGGCTGGG CTATGCCCTCG GAGGAGAAGG TCATCTTCCG ATACTGTGCT	240
GGCAGCTGTC CCCAAGAGGC CGGTACCCAG CACAGTCTGG TACTGGCCCG GCTTCGAGGG	300
CGGGGTGAG CCCATGGCCG ACCCTGCTGC CAGCCCACCA GCTATGCTGA TGTGACCTTC	360

159

CTTGATGATC AGCACCAATTG GCAGCAGCTG CCTCAGCTCT CAGCTGCAGC TTGTGGCTGT	420
GGTGGCTGAA GGAGGCCAGT CTGGTGTCTC AGAACACAA GCATGAGACA GGCTGGCCTT	480
TGAAAGGCTC AGGTGACATT ACTAGAAATT TGCATAGGTA AAGATAAGAA GGGAAAGGAC	540
CAGG	544

## (2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 336 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

CCTCAGAGGA GAAGAATTATC TTCCGATACT GTGCTGGCAG CTGTCCCCAA GAGGTCCGTA	60
CCCAGCACAG TCTGGTGCTG GCCCGTCTTC GAGGGCAGGG TCGAGCTCAT GGCAGACCTT	120
GCTGCCAGCC CACCAGCTAT GCTGATGTGA CCTTCCCTGA TGACCACCAC CATTGGCAGC	180
AGCTGCCTCA GCTCTCAGCC GCAGCTTGTG GCTGTGGTGG CTGAAGGCAG CCAGCCTGGT	240
CTCTCAGAAT CACAAGCAAG AGGCAGCCTT TGAAAGGCTC AGGTGACGTT ATTAGAAACT	300
TGCATAGGAG AAGATTAAGA AGAGAAAGGG GACCTG	336

## (2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 391 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

TGCCGGCTGT GGAGCCTGAC CCTACCAGTG GCTGAGCTTG GCCTGGGCTA TGCCTCAGAG	60
GAGAAGATTA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGTCCG TACCCAGCAC	120
AGTCTGGTGC TGGCCCGTCT TCGAGGGCAG GGTCGAGCTC ATGGCAGACC TTGCTGCCAG	180
CCCACCAAGCT ATGCTGATGT GACCTTCCTT GATGACCACC ACCATTGGCA GCAGCTGCCT	240
CAGCTCTCAG CCGCAGCTTG TGGCTGTGGT GGCTGAAGGC GGCCAGCCTG GTCTCTCAGA	300
ATCACACAAGCA AGAGGCAGCC TTTGAAAGGC TCAGGTGACG TTATTAGAAA CTTGCATAGG	360
AGAAGATTA GAAGAGAAAG GGGACCTGAT T	391

## (2) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 8 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

160

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "SERINE, THREONINE, OR ALANINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Val Xaa Xaa Leu Gly Leu Gly Tyr  
1 5

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Phe Arg Tyr Cys Xaa Gly Xaa Cys  
1 5

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "ASPARTIC ACID, GLUTAMIC ACID OR NO AMINO ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(ix) FEATURE:

161

(A) NAME/KEY: Modified-site  
(B) LOCATION: 4  
(D) OTHER INFORMATION: /note= "SERINE OR THREONINE"

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 8  
(D) OTHER INFORMATION: /note= "valine or aspartic acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Asp Xaa Xaa Xaa Phe Leu Asp Xaa  
1 5

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 142 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Glu Gly Pro Gly Arg Pro Ile Arg Val Arg Ile Pro Gly Gly Leu Pro  
1 5 10 15

Thr Pro Gln Phe Leu Leu Ser Lys Pro Ser Leu Cys Leu Thr Ile Leu  
20 25 30

Leu Tyr Leu Ala Leu Gly Asn Asn His Val Arg Leu Pro Arg Ala Leu  
35 40 45

Ala Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu  
50 55 60

Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala  
65 70 75 80

Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala  
85 90 95

Arg Leu Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro  
100 105 110

Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln  
115 120 125

Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
130 135 140

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

162

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Ala Leu Pro Gly Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO:113:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "THREONINE, GLUTAMIC ACID OR LYSINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "VALINE, LEUCINE OR ISOLEUCINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "LEUCINE OR ISOLEUCINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 9
- (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 11
- (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

Glu Xaa Xaa Xaa Phe Arg Tyr Cys Xaa Gly Xaa Cys  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:114:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "ARGININE OR GLUTAMINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "THREONINE, VALINE OR ISOLEUCINE"

163

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 6
  - (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 7
  - (D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 8
  - (D) OTHER INFORMATION: /note= "GLUTAMIC ACID, ASPARTIC ACID OR ALANINE"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 10
  - (D) OTHER INFORMATION: /note= "GLUTAMIC ACID, ASPARTIC ACID OR NO AMINO ACID"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 11
  - (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 12
  - (D) OTHER INFORMATION: /note= "SERINE OR THREONINE"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 16
  - (D) OTHER INFORMATION: /note= "ASPARTIC ACID OR VALINE"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Cys	Cys	Xaa	Pro	Xaa	Xaa	Xaa	Xaa	Asp	Xaa	Xaa	Xaa	Phe	Leu	Asp	Xaa
1															15

## (2) INFORMATION FOR SEQ ID NO:115:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

GTNDGNGANY TGGGNYTGGG NTA

23

## (2) INFORMATION FOR SEQ ID NO:116:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

GANBTNWCNT TYYTNGANG

19

(2) INFORMATION FOR SEQ ID NO:117:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

GANBTNWCNT TYYTNGANGW

20

(2) INFORMATION FOR SEQ ID NO:118:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

TTYMGNTAYT GYDSNGGNDS NTG

23

(2) INFORMATION FOR SEQ ID NO:119:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

GTNDGNGANY TGGGNYTNGG

20

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

165

GTNDGNGANY TGGGNYTGGG NTT

23

## (2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

WCNTCNARRA ANGWNNAVNTC

20

## (2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

WCNTCNARRA ANGWNNAVNT

19

## (2) INFORMATION FOR SEQ ID NO:123:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

CANSHNCCNS HRCARTANCK RAA

23

## (2) INFORMATION FOR SEQ ID NO:124:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

CANSHNCCNS HRCARTANCK RAANA

25

## (2) INFORMATION FOR SEQ ID NO:125:

166

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 2  
(D) OTHER INFORMATION: /note= "THREONINE, SERINE OR ALANINE"

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 3  
(D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Val Xaa Xaa Leu Gly Leu Gly Tyr  
1 5

(2) INFORMATION FOR SEQ ID NO:126:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 1  
(D) OTHER INFORMATION: /note= "ASPARTIC ACID OR GLUTAMIC ACID"

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 2  
(D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 3  
(D) OTHER INFORMATION: /note= "THREONINE OR SERINE"

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 6  
(D) OTHER INFORMATION: /note= "ASPARTIC ACID OR GLUTAMIC ACID"

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 7  
(D) OTHER INFORMATION: /note= "ASPARTIC ACID OR VALINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Xaa Xaa Xaa Phe Leu Xaa Xaa  
1 5

## (2) INFORMATION FOR SEQ ID NO:127:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 5
  - (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 7
  - (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Phe Arg Tyr Cys Xaa Gly Xaa Cys  
1 5

## (2) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 2
  - (D) OTHER INFORMATION: /note= "THREONINE, SERINE OR ALANINE"
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 3
  - (D) OTHER INFORMATION: /note= "ASPARTIC ACID OR GLUTAMIC ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

Val Xaa Xaa Leu Gly Leu Gly  
1 5

## (2) INFORMATION FOR SEQ ID NO:129:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 2
  - (D) OTHER INFORMATION: /note= "THREONINE, SERINE OR

**ALANINE"**

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 3  
 (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Val Xaa Xaa Leu Gly Leu Gly Phe  
 1 5

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 9 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 1  
 (D) OTHER INFORMATION: /note= "ISOLEUCINE OR LEUCINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 6  
 (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 8  
 (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Xaa Phe Arg Tyr Cys Xaa Gly Xaa Cys  
 1 5

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 559 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

ATGGCTGCAG GAAGACTTCG GATCCTGTGT CTGCTGCTCC TGTCCCTTGCA CCCGAGCCTC	60
GGCTGGGTCC TTGATCTTCA AGAGGCTTCT GTGGCAGATA AGCTCTCATT TGGGAAGATG	120
GCAGAGACTA GAGGGACCTG GACGCCCAT CAGGGTAAGA ATTCCCTGGGG GCCTCCCGAC	180
TCCCCAATTC CTTCTCTCAA AGCCCTCACT TTGCCTTACA ATCCTACTCT ACCTTGCACT	240
AGGTAACAAC CATGTCCGTC TTCCAAGAGC CTTGGCTGGT TCATGCCGAC TGTGGAGCCT	300

169

GACCCTACCA GTGGCTGAGC TGGGCCTGGG CTATGCCTCG GAGGAGAAGG TCATCTTCCG	360
ATACTGTGCT GGCAGCTGTC CCCAAGAGGC CCGTACCCAG CACAGTCTGG TACTGGCCCC	420
GCTTCGAGGG CGGGGTCGAG CCCATGGCCG ACCCTGCTGC CAGCCCCACCA GCTATGCTGA	480
TGTGACCTTC CTTGATGATC AGCACCATTG GCAGCAGCTG CCTCAGCTCT CAGCTGCAGC	540
TTGTGGCTGT GGTGGCTGA	559

## (2) INFORMATION FOR SEQ ID NO:132:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 81 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Met Ala Ala Gly Arg Leu Arg Ile Leu Cys Leu Leu Leu Ser Leu	
1 5 10 15	
His Pro Ser Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Ser Val Ala	
20 25 30	
Asp Lys Leu Ser Phe Gly Lys Met Ala Glu Thr Arg Gly Thr Trp Thr	
35 40 45	
Pro His Gln Gly Lys Asn Ser Trp Gly Pro Pro Asp Ser Pro Ile Pro	
50 55 60	
Ser Leu Lys Ala Leu Thr Leu Pro Tyr Asn Pro Thr Leu Pro Cys Thr	
65 70 75 80	

Arg

## (2) INFORMATION FOR SEQ ID NO:133:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 185 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Trp Leu Gln Glu Asp Phe Gly Ser Cys Val Cys Cys Ser Cys Pro Cys	
1 5 10 15	
Thr Arg Ala Ser Ala Gly Ser Leu Ile Phe Lys Arg Leu Leu Trp Gln	
20 25 30	
Ile Ser Ser His Leu Gly Arg Trp Gln Arg Leu Glu Gly Pro Gly Arg	
35 40 45	
Pro Ile Arg Val Arg Ile Pro Gly Gly Leu Pro Thr Pro Gln Phe Leu	
50 55 60	

170

Leu	Ser	Lys	Pro	Ser	Leu	Cys	Leu	Thr	Ile	Leu	Leu	Tyr	Leu	Ala	Leu
65					70					75				80	
Gly	Asn	Asn	His	Val	Arg	Leu	Pro	Arg	Ala	Leu	Ala	Gly	Ser	Cys	Arg
				85					90				95		
Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala	Glu	Leu	Gly	Leu	Gly	Tyr	Ala
				100					105				110		
Ser	Glu	Glu	Lys	Val	Ile	Phe	Arg	Tyr	Cys	Ala	Gly	Ser	Cys	Pro	Gln
				115			120					125			
Glu	Ala	Arg	Thr	Gln	His	Ser	Leu	Val	Leu	Ala	Arg	Leu	Arg	Gly	Arg
				130			135				140				
Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys	Gln	Pro	Thr	Ser	Tyr	Ala	Asp
				145			150			155				160	
Val	Thr	Phe	Leu	Asp	Asp	Gln	His	His	Trp	Gln	Gln	Leu	Pro	Gln	Leu
				165					170				175		
Ser	Ala	Ala	Ala	Cys	Gly	Cys	Gly	Gly							
				180											

## (2) INFORMATION FOR SEQ ID NO:134:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 559 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

ATGGCTGCAG	GAAGACTTCG	GATCTTGT	CTGCTGCTCC	TGTCCTTGCA	CCTGGGCC	TTT	60
GGCTGGT	CC	TTGATCTTCA	AGAGGCTC	CGGGCAGATG	AGCTCTCATC	TGGGAAAATG	120
GCAGAGACTG	GAAGGACCTG	GAAGCCCCAT	CAGGGTAAGA	ATTCTTGGGG	GCCTCCTAAC		180
TCTACAGTTC	TTCCCTCTCAA	AGCCCTCACT	TTGCCTCAC	ATCCTATTCT	ACCTTGCACT		240
AGGTAACAAAC	AATGTCCGCC	TTCCAAGAGC	CTTACCTGGT	TTGTGCCGGC	TGTGGAGCCT		300
GACCCTACCA	GTGGCTGAGC	TTGGCCTGGG	CTATGCCTCA	GAGGAGAAGA	TTATCTCCG		360
ATACTGTGCT	GGCAGCTGTC	CCCAAGAGGT	CCGTACCCAG	CACAGTCTGG	TGCTGGCCCG		420
TCTTCGAGGG	CAGGGTCGAG	CTCATGGCAG	ACCTTGCTGC	CAGCCCACCA	GCTATGCTGA		480
TGTGACCTTC	CTTGATGACC	ACCACCATTG	GCAGCAGCTG	CCTCAGCTCT	CAGCCGCAGC		540
TTGTGGCTGT	GGTGGCTGA						559

## (2) INFORMATION FOR SEQ ID NO:135:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 81 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

```

Met Ala Ala Gly Arg Leu Arg Ile Leu Phe Leu Leu Leu Ser Leu
1           5           10          15

His Leu Gly Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Pro Ala Ala
20          25          30

Asp Glu Leu Ser Ser Gly Lys Met Ala Glu Thr Gly Arg Thr Trp Lys
35          40          45

Pro His Gln Gly Lys Asn Ser Trp Gly Pro Pro Asn Ser Thr Val Leu
50          55          60

Pro Leu Lys Ala Leu Thr Leu Pro His Asn Pro Ile Leu Pro Cys Thr
65          70          75          80

Arg

```

## (2) INFORMATION FOR SEQ ID NO:136:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 185 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

```

Trp Leu Gln Glu Asp Phe Gly Ser Cys Phe Cys Cys Ser Cys Pro Cys
1           5           10          15

Thr Trp Ala Leu Ala Gly Ser Leu Ile Phe Lys Arg Leu Leu Arg Gln
20          25          30

Met Ser Ser His Leu Gly Lys Trp Gln Arg Leu Glu Gly Pro Gly Ser
35          40          45

Pro Ile Arg Val Arg Ile Leu Gly Gly Leu Leu Thr Leu Gln Phe Phe
50          55          60

Leu Ser Lys Pro Ser Leu Cys Leu Thr Ile Leu Phe Tyr Leu Ala Leu
65          70          75          80

Gly Asn Asn Asn Val Arg Leu Pro Arg Ala Leu Pro Gly Leu Cys Arg
85          90          95

Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly Tyr Ala
100         105         110

Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys Pro Gln
115         120         125

Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg Gly Gln
130         135         140

Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr Ala Asp
145         150         155         160

Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro Gln Leu
165         170         175

Ser Ala Ala Ala Cys Gly Cys Gly Gly
180         185

```

172

## (2) INFORMATION FOR SEQ ID NO:137:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

AATCCCCAGG ACAGGCAGGG AAT

23

## (2) INFORMATION FOR SEQ ID NO:138:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

CGGTACCCAG ATCTTCAGCC ACCACAGCCA CAAGC

35

## (2) INFORMATION FOR SEQ ID NO:139:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 76 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

GGACTATCAT ATGGCCCACC ACCACCACCA CCACCACAC GACGACGACG ACAAGGCCTT

60

GGCTGGTTCA TGCCGA

76

## (2) INFORMATION FOR SEQ ID NO:140:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

CGGTACCCAG ATCTTCAGCC ACCACAGCCA CAAGC

35

## (2) INFORMATION FOR SEQ ID NO:141:

173

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 96 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Ala	Leu	Ala	Gly	Ser	Cys	Arg	Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala
1										10					15
Glu	Leu	Gly	Leu	Gly	Tyr	Ala	Ser	Glu	Glu	Lys	Val	Ile	Phe	Arg	Tyr
					20				25					30	
Cys	Ala	Gly	Ser	Cys	Pro	Gln	Glu	Ala	Arg	Thr	Gln	His	Ser	Leu	Val
						35			40			45			
Leu	Ala	Arg	Leu	Arg	Gly	Arg	Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys
					50			55			60				
Arg	Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser	Phe	Leu	Asp	Val	His	Ser
					65			70			75			80	
Arg	Tyr	His	Thr	Leu	Gln	Glu	Leu	Ser	Ala	Arg	Glu	Cys	Ala	Cys	Val
					85				90			95			

(2) INFORMATION FOR SEQ ID NO:142:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

TAATACGACT CACTATAGGG GAA

23

(2) INFORMATION FOR SEQ ID NO:143:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 49 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

TCGTCTTCGT AAGCAGTCGG ACGGCAGCAG GGTCGGCCAT GGGCTCGAC

49

(2) INFORMATION FOR SEQ ID NO:144:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 29 base pairs  
 (B) TYPE: nucleic acid

174

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

TGCTGCCGTC CGACTGCTTA CGAAGACGA

29

(2) INFORMATION FOR SEQ ID NO:145:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

GTTATGCTAG TTATTGCTCA GCGGT

25

(2) INFORMATION FOR SEQ ID NO:146:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 100 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Pro	Gly	Ala	Arg	Pro	Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg	Val	Ser
1															15

Glu	Leu	Gly	Leu	Gly	Tyr	Thr	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr
															30
20															

Cys	Ala	Gly	Ala	Cys	Glu	Ala	Ala	Ile	Arg	Ile	Tyr	Asp	Leu	Gly	Leu
															45
35															

Arg	Arg	Leu	Arg	Gln	Arg	Arg	Val	Arg	Arg	Glu	Arg	Ala	Arg	Ala
50														

His	Pro	Cys	Cys	Gln	Pro	Thr	Ser	Tyr	Ala	Asp	Val	Thr	Phe	Leu	Asp
															80
65															

Asp	Gln	His	His	Trp	Gln	Gln	Leu	Pro	Gln	Leu	Ser	Ala	Ala	Cys
85														

Gly	Cys	Gly	Gly
			100

(2) INFORMATION FOR SEQ ID NO:147:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 50 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

175

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

CACATCAGCA TAGCTGGTGG GCTGGCAGCA CGGGTGAGCA CGAGCACGTT

50

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

TGCTGCCAGC CCACCAAGCTA TGCTG

25

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

CCTCGGAGGA GAAGGTCATC TTC

23

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 98 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

Cys Cys Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gly Trp  
1 5 10 15Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly  
20 25 30Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys Val Leu  
35 40 45Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro Cys Cys  
50 55 60

176

Val	Pro	Gln	Ala	Leu	Glu	Pro	Leu	Pro	Ile	Val	Tyr	Tyr	Val	Gly	Arg
65					70					75				80	
Lys	Pro	Lys	Val	Glu	Gln	Leu	Ser	Asn	Met	Ile	Val	Arg	Ser	Cys	Lys
					85					90				95	
Cys Ser															

## (2) INFORMATION FOR SEQ ID NO:151:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 98 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

Cys	Cys	Leu	Arg	Pro	Leu	Tyr	Ile	Asp	Phe	Lys	Arg	Asp	Leu	Gly	Trp
1					5				10				15		
Lys	Trp	Ile	His	Glu	Pro	Lys	Gly	Tyr	Asn	Ala	Asn	Phe	Cys	Ala	Gly
					20				25				30		
Ala	Cys	Pro	Tyr	Leu	Trp	Ser	Ser	Asp	Thr	Gln	His	Ser	Arg	Val	Leu
					35				40				45		
Ser	Leu	Tyr	Asn	Thr	Ile	Asn	Pro	Glu	Ala	Ser	Ala	Ser	Pro	Cys	Cys
					50				55				60		
Val	Ser	Gln	Asp	Leu	Glu	Pro	Leu	Thr	Ile	Leu	Tyr	Tyr	Ile	Gly	Lys
					65				70				75		80
Thr	Pro	Lys	Ile	Glu	Gln	Leu	Ser	Asn	Met	Ile	Val	Lys	Ser	Cys	Lys
					85				90				95		
Cys Ser															

## (2) INFORMATION FOR SEQ ID NO:152:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 98 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

Cys	Cys	Val	Arg	Pro	Leu	Tyr	Ile	Asp	Phe	Arg	Gln	Asp	Leu	Gly	Trp
1					5				10				15		
Lys	Trp	Val	His	Glu	Pro	Lys	Gly	Tyr	Tyr	Ala	Asn	Phe	Cys	Ser	Gly
					20				25				30		
Pro	Cys	Pro	Tyr	Leu	Arg	Ser	Ala	Asp	Thr	Thr	His	Ser	Thr	Val	Leu
					35				40				45		
Gly	Leu	Tyr	Asn	Thr	Leu	Asn	Pro	Glu	Ala	Ser	Ala	Ser	Pro	Cys	Cys
					50				55				60		

177

Val	Pro	Gln	Asp	Leu	Glu	Pro	Leu	Thr	Ile	Leu	Tyr	Tyr	Val	Gly	Arg
65					70					75				80	
Thr	Pro	Lys	Val	Glu	Gln	Leu	Ser	Asn	Met	Val	Val	Lys	Ser	Cys	Lys
					85				90				95		
Cys Ser															

## (2) INFORMATION FOR SEQ ID NO:153:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 106 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

Cys	Cys	Lys	Lys	Gln	Phe	Phe	Val	Ser	Phe	Lys	Asp	Ile	Gly	Trp	Asn
1					5				10				15		
Asp	Trp	Ile	Ile	Ala	Pro	Ser	Gly	Tyr	His	Ala	Asn	Tyr	Cys	Glu	Gly
		20						25				30			
Glu	Cys	Pro	Ser	His	Ile	Ala	Gly	Thr	Ser	Gly	Ser	Ser	Leu	Ser	Phe
		35				40			45						
His	Ser	Thr	Val	Ile	Asn	His	Tyr	Arg	Met	Arg	Gly	His	Ser	Pro	Phe
		50				55			60						
Ala	Asn	Leu	Lys	Ser	Cys	Cys	Val	Pro	Thr	Lys	Leu	Arg	Pro	Met	Ser
		65			70			75			80				
Met	Leu	Tyr	Tyr	Asp	Asp	Gly	Gln	Asn	Ile	Ile	Lys	Lys	Asp	Ile	Gln
			85					90			95				
Asn	Met	Ile	Val	Glu	Glu	Cys	Gly	Cys	Ser						
			100						105						

## (2) INFORMATION FOR SEQ ID NO:154:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 105 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

Cys	Cys	Arg	Gln	Gln	Phe	Phe	Ile	Asp	Phe	Arg	Leu	Ile	Gly	Trp	Asn
1					5			10				15			
Asp	Trp	Ile	Ile	Ala	Pro	Thr	Gly	Tyr	Tyr	Gly	Asn	Tyr	Cys	Glu	Gly
		20						25			30				
Ser	Cys	Pro	Ala	Tyr	Leu	Ala	Gly	Val	Pro	Gly	Ser	Ala	Ser	Ser	Phe
		35				40			45						
His	Thr	Ala	Val	Val	Asn	Gln	Tyr	Arg	Met	Arg	Gly	Leu	Asn	Pro	Gly
		50				55			60						

178

Thr	Val	Asn	Ser	Cys	Cys	Ile	Pro	Thr	Lys	Leu	Ser	Thr	Met	Ser	Met
65				70					75					80	
Leu	Tyr	Phe	Asp	Asp	Glu	Tyr	Asn	Ile	Val	Lys	Arg	Asp	Val	Pro	Asn
			85					90					95		
Met	Ile	Val	Glu	Glu	Cys	Gly	Cys	Ala							
		100					105								

(2) INFORMATION FOR SEQ ID NO:155:

- (i) SEQUENCE CHARACTERISTICS:

  - (A) LENGTH: 101 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

```

Cys Arg Arg Val Lys Phe Gln Val Asp Phe Asn Leu Ile Gly Trp Gly
1 5 10 15

Ser Trp Ile Ile Tyr Pro Lys Gln Tyr Asn Ala Tyr Arg Cys Glu Gly
20 25 30

Glu Cys Pro Asn Pro Val Gly Glu Glu Phe His Pro Thr Asn His Ala
35 40 45

Tyr Ile Gln Ser Leu Leu Lys Arg Tyr Gln Pro His Arg Val Pro Ser
50 55 60

Thr Cys Cys Ala Pro Val Lys Thr Lys Pro Leu Ser Met Leu Tyr Val
65 70 75 80

Asp Asn Gly Arg Val Leu Leu Glu His His Lys Asp Met Ile Val Glu
85 90 95

Glu Cys Gly Cys Leu
100

```

(2) INFORMATION FOR SEQ ID NO:156:

- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 101 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

Cys	Lys	Arg	His	Pro	Leu	Tyr	Val	Asp	Phe	Ser	Asp	Val	Gly	Trp	Asn
					5				10					15	
Asp	Trp	Ile	Val	Ala	Pro	Pro	Gly	Tyr	His	Ala	Phe	Tyr	Cys	His	Gly
					20			25					30		
Glu	Cys	Pro	Phe	Pro	Leu	Ala	Asp	His	Leu	Asn	Ser	Thr	Asn	His	Ala
					35			40				45			
Ile	Val	Gln	Thr	Leu	Val	Asn	Ser	Val	Asn	Ser	Lys	Ile	Pro	Lys	Ala
					50			55			60				

179

Cys	Cys	Val	Pro	Thr	Glu	Leu	Ser	Ala	Ile	Ser	Met	Leu	Tyr	Leu	Asp
65					70					75				80	
Glu	Asn	Glu	Lys	Val	Val	Leu	Lys	Asn	Tyr	Gln	Asp	Met	Val	Val	Glu
						85			90					95	
Gly	Cys	Gly	Cys	Arg											
				100											

## (2) INFORMATION FOR SEQ ID NO:157:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 101 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

Cys	Arg	Arg	His	Ser	Leu	Tyr	Val	Asp	Phe	Ser	Asp	Val	Gly	Trp	Asn
1					5					10				15	
Asp	Trp	Ile	Val	Ala	Pro	Pro	Gly	Tyr	Gln	Ala	Phe	Tyr	Cys	His	Gly
		20					25					30			
Asp	Cys	Pro	Phe	Pro	Leu	Ala	Asp	His	Leu	Asn	Ser	Thr	Asn	His	Ala
		35				40					45				
Ile	Val	Gln	Thr	Leu	Val	Asn	Ser	Val	Asn	Ser	Ser	Ile	Pro	Lys	Ala
		50			55					60					
Cys	Cys	Val	Pro	Thr	Glu	Leu	Ser	Ala	Ile	Ser	Met	Leu	Tyr	Leu	Asp
65					70					75				80	
Glu	Tyr	Asp	Lys	Val	Val	Leu	Lys	Asn	Tyr	Gln	Glu	Met	Val	Val	Glu
		85				90			95						
Gly	Cys	Gly	Cys	Arg											
				100											

## (2) INFORMATION FOR SEQ ID NO:158:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 102 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

Cys	Arg	Arg	His	Ser	Leu	Tyr	Val	Asp	Phe	Ser	Asp	Val	Gly	Trp	Asp
1					5					10				15	
Asp	Trp	Ile	Val	Ala	Pro	Leu	Gly	Tyr	Asp	Ala	Tyr	Tyr	Cys	His	Gly
		20				25		30							
Lys	Cys	Pro	Phe	Pro	Leu	Ala	Asp	His	Phe	Asn	Ser	Thr	Asn	His	Ala
		35				40				45					
Val	Val	Gln	Thr	Leu	Val	Asn	Asn	Met	Asn	Pro	Gly	Lys	Val	Pro	Lys
		50			55				60						

180

Ala	Cys	Cys	Val	Pro	Thr	Gln	Leu	Asp	Ser	Val	Ala	Met	Leu	Tyr	Leu	
65																80
Asn	Asp	Gln	Ser	Thr	Val	Val	Leu	Lys	Asn	Tyr	Gln	Glu	Met	Thr	Val	
																95
Val	Gly	Cys	Gly	Cys	Arg											
																100

## (2) INFORMATION FOR SEQ ID NO:159:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 102 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

Cys	Lys	Lys	His	Glu	Leu	Tyr	Val	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	
1																15
Asp	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala	Ala	Phe	Tyr	Cys	Asp	Gly	
																30
Glu	Cys	Ser	Phe	Pro	Leu	Asn	Ala	His	Met	Asn	Ala	Thr	Asn	His	Ala	
																45
Ile	Val	Gln	Thr	Leu	Val	His	Leu	Met	Phe	Pro	Asp	His	Val	Pro	Lys	
																60
Pro	Cys	Cys	Ala	Pro	Thr	Lys	Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe	
																80
Asp	Asp	Ser	Ser	Asn	Val	Ile	Leu	Lys	Lys	Tyr	Arg	Asn	Met	Val	Val	
																95
Arg	Ser	Cys	Gly	Cys	His											
																100

## (2) INFORMATION FOR SEQ ID NO:160:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 102 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

Cys	Arg	Lys	His	Glu	Leu	Tyr	Val	Ser	Phe	Gln	Asp	Leu	Gly	Trp	Gln	
1																15
Asp	Trp	Ile	Ile	Ala	Pro	Lys	Gly	Tyr	Ala	Ala	Asn	Tyr	Cys	Asp	Gly	
																30
Glu	Cys	Ser	Phe	Pro	Leu	Asn	Ala	His	Met	Asn	Ala	Thr	Asn	His	Ala	
																45
Ile	Val	Gln	Thr	Leu	Val	His	Leu	Met	Asn	Pro	Glu	Tyr	Val	Pro	Lys	
																60

181

```

Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe
65                               70                               75                               80

Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
          85                               90                               95

Arg Ala Cys Gly Cys His
          100

```

(2) INFORMATION FOR SEQ ID NO:161:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 102 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

```

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln
1 5 10 15

Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly
20 25 30

Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala Thr Asn His Ala
35 40 45

Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Glu Thr Val Pro Lys
50 55 60

Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser Val Leu Tyr Phe
65 70 75 80

Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
85 90 95

Arg Ala Cys Gly Cys His
100

```

(2) INFORMATION FOR SEQ ID NO:162:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 102 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

```

Cys Arg Arg His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Leu
1 5 10 15

Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly
20 25 30

Glu Cys Ser Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala
35 40 45

Ile Leu Gln Ser Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys
50 55 60

```

182

Ala	Cys	Cys	Ala	Pro	Thr	Lys	Leu	Ser	Ala	Thr	Ser	Val	Leu	Tyr	Tyr
65						70				75				80	
Asp	Ser	Ser	Asn	Asn	Val	Ile	Leu	Arg	Lys	His	Arg	Asn	Met	Val	Val
					85				90					95	
Lys	Ala	Cys	Gly	Cys	His										
					100										

## (2) INFORMATION FOR SEQ ID NO:163:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 102 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

Cys	Gln	Met	Gln	Thr	Leu	Tyr	Ile	Asp	Phe	Lys	Asp	Leu	Gly	Trp	His
1					5					10				15	
Asp	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Gly	Ala	Phe	Tyr	Cys	Ser	Gly
					20				25				30		
Glu	Cys	Asn	Phe	Pro	Leu	Asn	Ala	His	Met	Asn	Ala	Thr	Asn	His	Ala
					35				40				45		
Ile	Val	Gln	Thr	Leu	Val	His	Leu	Leu	Glu	Pro	Lys	Lys	Val	Pro	Lys
					50				55			60			
Pro	Cys	Cys	Ala	Pro	Thr	Arg	Leu	Gly	Ala	Leu	Pro	Val	Leu	Tyr	His
65						70				75				80	
Leu	Asn	Asp	Glu	Asn	Val	Asn	Leu	Lys	Lys	Tyr	Arg	Asn	Met	Ile	Val
					85				90				95		
Lys	Ser	Cys	Gly	Cys	His										
					100										

## (2) INFORMATION FOR SEQ ID NO:164:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 103 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

Cys	Ala	Arg	Arg	Tyr	Leu	Lys	Val	Asp	Phe	Ala	Asp	Ile	Gly	Trp	Ser
1					5					10				15	
Glu	Trp	Ile	Ile	Ser	Pro	Lys	Ser	Phe	Asp	Ala	Tyr	Tyr	Cys	Ser	Gly
					20				25				30		
Ala	Cys	Gln	Phe	Pro	Met	Pro	Lys	Ser	Leu	Lys	Pro	Ser	Asn	His	Ala
					35				40				45		
Thr	Ile	Gln	Ser	Ile	Val	Arg	Ala	Val	Gly	Val	Val	Pro	Gly	Ile	Pro
					50				55				60		

183

Glu	Pro	Cys	Cys	Val	Pro	Glu	Lys	Met	Ser	Ser	Leu	Ser	Ile	Leu	Phe
65						70					75				80
Phe	Asp	Glu	Asn	Lys	Asn	Val	Val	Leu	Lys	Val	Tyr	Pro	Asn	Met	Thr
						85				90					95
Val	Glu	Ser	Cys	Ala	Cys	Arg									
						100									

## (2) INFORMATION FOR SEQ ID NO:165:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 102 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

Cys	Lys	Lys	Arg	His	Leu	Tyr	Val	Glu	Phe	Lys	Asp	Val	Gly	Trp	Gln
1					5				10					15	
Asn	Trp	Val	Ile	Ala	Pro	Gln	Gly	Tyr	Met	Ala	Asn	Tyr	Cys	Tyr	Gly
					20				25					30	
Glu	Cys	Pro	Tyr	Pro	Leu	Thr	Glu	Ile	Leu	Asn	Gly	Ser	Asn	His	Ala
					35				40					45	
Ile	Leu	Gln	Thr	Leu	Val	His	Ser	Ile	Glu	Pro	Glu	Asp	Ile	Pro	Leu
					50				55					60	
Pro	Cys	Cys	Val	Pro	Thr	Lys	Met	Ser	Pro	Ile	Ser	Met	Leu	Phe	Tyr
					65				70					80	
Asp	Asn	Asn	Asp	Asn	Val	Val	Leu	Arg	His	Tyr	Glu	Asn	Met	Ala	Val
					85				90					95	
Asp	Glu	Cys	Gly	Cys	Arg										
					100										

## (2) INFORMATION FOR SEQ ID NO:166:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 106 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

Cys	Arg	Ala	Arg	Arg	Leu	Tyr	Val	Ser	Phe	Arg	Glu	Val	Gly	Trp	His
1					5				10					15	
Arg	Trp	Val	Ile	Ala	Pro	Arg	Gly	Phe	Leu	Ala	Asn	Tyr	Cys	Gln	Gly
					20				25					30	
Gln	Cys	Ala	Leu	Pro	Val	Ala	Leu	Ser	Gly	Ser	Gly	Gly	Pro	Pro	Ala
					35				40					45	
Leu	Asn	His	Ala	Val	Leu	Arg	Ala	Leu	Met	His	Ala	Ala	Ala	Pro	Gly
					50				55					60	

184

Ala	Ala	Asp	Leu	Pro	Cys	Cys	Val	Pro	Ala	Arg	Leu	Ser	Pro	Ile	Ser
65					70				75					80	

Val	Leu	Phe	Phe	Asp	Asn	Ser	Asp	Asn	Val	Val	Leu	Arg	Gln	Tyr	Glu
				85				90				95			

Asp	Met	Val	Val	Asp	Glu	Cys	Gly	Cys	Arg						
				100				105							

## (2) INFORMATION FOR SEQ ID NO:167:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 101 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

Cys	His	Arg	His	Gln	Leu	Phe	Ile	Asn	Phe	Gln	Asp	Leu	Gly	Trp	His
1				5				10					15		

Lys	Trp	Val	Ile	Ala	Pro	Lys	Gly	Phe	Met	Ala	Asn	Tyr	Cys	His	Gly
			20					25				30			

Glu	Cys	Pro	Phe	Ser	Met	Thr	Thr	Tyr	Leu	Asn	Ser	Ser	Asn	Tyr	Ala
			35				40				45				

Phe	Met	Gln	Ala	Leu	Met	His	Met	Ala	Asp	Pro	Lys	Val	Pro	Lys	Ala
	50				55				60						

Val	Cys	Val	Pro	Thr	Lys	Leu	Ser	Pro	Ile	Ser	Met	Leu	Tyr	Gln	Asp
65				70				75			80				

Ser	Asp	Lys	Asn	Val	Ile	Leu	Arg	His	Tyr	Glu	Asp	Met	Val	Val	Asp
	85						90				95				

Glu	Cys	Gly	Cys	Gly											
		100													

## (2) INFORMATION FOR SEQ ID NO:168:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 103 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

Cys	Arg	Arg	Thr	Ser	Leu	His	Val	Asn	Phe	Lys	Glu	Ile	Gly	Trp	Asp
1				5				10				15			

Ser	Trp	Ile	Ile	Ala	Pro	Lys	Asp	Tyr	Glu	Ala	Phe	Glu	Cys	Lys	Gly
			20			25				30					

Gly	Cys	Phe	Phe	Pro	Leu	Thr	Asp	Asn	Val	Thr	Pro	Thr	Lys	His	Ala
	35			40				45							

Ile	Val	Gln	Thr	Leu	Val	His	Leu	Gln	Asn	Pro	Lys	Lys	Ala	Ser	Lys
	50				55			60							

185

Ala	Cys	Cys	Val	Pro	Thr	Lys	Leu	Asp	Ala	Ile	Ser	Ile	Leu	Tyr	Lys
65					70				75					80	
Asp	Asp	Ala	Gly	Val	Pro	Thr	Leu	Ile	Tyr	Asn	Tyr	Glu	Gly	Met	Lys
				85				90					95		
Val	Ala	Glu	Cys	Gly	Cys	Arg									
					100										

## (2) INFORMATION FOR SEQ ID NO:169:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 105 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

Cys	His	Arg	Val	Ala	Leu	Asn	Ile	Ser	Phe	Gln	Glu	Leu	Gly	Trp	Glu
1				5					10					15	
Arg	Trp	Ile	Val	Tyr	Pro	Pro	Ser	Phe	Ile	Phe	His	Tyr	Cys	His	Gly
		20						25			30				
Gly	Cys	Gly	Leu	His	Ile	Pro	Pro	Asn	Leu	Ser	Leu	Pro	Val	Pro	Gly
		35				40			45						
Ala	Pro	Pro	Thr	Pro	Ala	Gln	Pro	Tyr	Ser	Leu	Leu	Pro	Gly	Ala	Gln
			50			55				60					
Pro	Cys	Cys	Ala	Ala	Leu	Pro	Gly	Thr	Met	Arg	Pro	Leu	His	Val	Arg
		65			70			75		80					
Thr	Thr	Ser	Asp	Gly	Gly	Tyr	Ser	Phe	Lys	Tyr	Glu	Thr	Val	Pro	Asn
			85					90			95				
Leu	Leu	Thr	Gln	His	Cys	Ala	Cys	Ile							
			100					105							

## (2) INFORMATION FOR SEQ ID NO:170:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 99 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

Cys	Ala	Leu	Arg	Glu	Leu	Ser	Val	Asp	Leu	Arg	Ala	Glu	Arg	Ser	Val
1			5				10			15					
Leu	Ile	Pro	Glu	Thr	Tyr	Gln	Ala	Asn	Asn	Cys	Gln	Gly	Ala	Cys	Gly
	20					25				30					
Trp	Pro	Gln	Ser	Asp	Arg	Asn	Pro	Arg	Tyr	Gly	Asn	His	Val	Val	Leu
	35				40					45					
Leu	Leu	Lys	Met	Gln	Ala	Arg	Gly	Ala	Thr	Leu	Ala	Arg	Pro	Pro	Cys
		50				55				60					

186

Cys	Val	Pro	Thr	Ala	Tyr	Thr	Gly	Lys	Leu	Leu	Ile	Ser	Leu	Ser	Glu
65															80
Glu	Arg	Ile	Ser	Ala	His	His	Val	Pro	Asn	Met	Val	Ala	Thr	Glu	Cys
															95
Gly	Cys	Arg													

## (2) INFORMATION FOR SEQ ID NO:171:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 102 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

Cys	Glu	Leu	His	Asp	Phe	Ser	Leu	Ser	Phe	Ser	Gln	Leu	Lys	Trp	Asp
1															15
Asn	Trp	Ile	Val	Ala	Pro	His	Ser	Tyr	Asn	Pro	Ser	Tyr	Cys	Lys	Gly
Asp	Cys	Pro	Ser	Ala	Val	Ser	His	Arg	Tyr	Gly	Ser	Pro	Val	His	Thr
35															45
Met	Val	Gln	Asn	Met	Ile	Tyr	Glu	Lys	Leu	Asp	Pro	Ser	Val	Pro	Ser
50															60
Pro	Ser	Cys	Val	Pro	Gly	Lys	Tyr	Ser	Pro	Leu	Ser	Val	Leu	Thr	Ile
															80
65															
Glu	Pro	Asp	Gly	Ser	Ile	Ala	Tyr	Lys	Glu	Tyr	Glu	Asp	Met	Met	Ala
															95
85															
Thr	Ser	Cys	Thr	Cys	Arg										
100															

## (2) INFORMATION FOR SEQ ID NO:172:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 94 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

Cys	Val	Leu	Thr	Ala	Ile	His	Leu	Asn	Val	Thr	Asp	Leu	Gly	Leu	Gly
1															15
Tyr	Glu	Thr	Lys	Glu	Glu	Leu	Ile	Phe	Arg	Tyr	Cys	Ser	Gly	Ser	Cys
															30
Asp	Ala	Ala	Glu	Thr	Thr	Tyr	Asp	Lys	Ile	Leu	Lys	Asn	Leu	Ser	Arg
															45
35															
Asn	Arg	Arg	Leu	Val	Ser	Asp	Lys	Val	Gly	Gln	Ala	Cys	Cys	Arg	Pro
50															60

187

Ile	Ala	Phe	Asp	Asp	Asp	Leu	Ser	Phe	Leu	Asp	Asp	Asn	Leu	Val	Tyr
65						70				75				80	
His	Ile	Leu	Arg	Lys	His	Ser	Ala	Lys	Arg	Cys	Gly	Cys	Cys	Ile	
				85					90						

## (2) INFORMATION FOR SEQ ID NO:173:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 95 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg	Val	Ser	Glu	Leu	Gly	Leu	Gly
1				5				10					15		
Tyr	Ala	Ser	Asp	Glu	Thr	Val	Leu	Phe	Arg	Tyr	Cys	Ala	Gly	Ala	Cys
	20					25				30					
Glu	Ala	Ala	Ala	Arg	Val	Tyr	Asp	Leu	Gly	Leu	Arg	Arg	Leu	Arg	Gln
	35						40				45				
Arg	Arg	Arg	Leu	Arg	Arg	Glu	Arg	Val	Arg	Ala	Gln	Pro	Cys	Cys	Arg
	50					55			60						
Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser	Phe	Leu	Asp	Ala	His	Ser	Arg
	65				70				75				80		
Tyr	His	Thr	Val	His	Glu	Leu	Ser	Ala	Arg	Glu	Cys	Ala	Cys	Val	
	85					90				95					

## (2) INFORMATION FOR SEQ ID NO:174:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 291 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

GCCTTGGCTG	GTTCATGCCG	ACTGTGGAGC	CTGACCCTAC	CAGTGGCTGA	GCTGGGCCTG	60
GGCTATGCCT	CGGAGGAGAA	GGTCATCTTC	CGATACTGTG	CTGGCAGCTG	TCCCCAAGAG	120
GCCC GTACCC	AGCACAGTCT	GGTACTGGCC	CGGCTTCGAG	GGCGGGGTGCG	AGCCCATGGC	180
CGACCCCTGCT	GCCAGCCCAC	CAGCTATGCT	GATGTGACCT	TCCTTGATGA	TCAGCACCAT	240
TGGCAGCAGC	TGCCTCAGCT	CTCAGCTGCA	GCTTGTGGCT	GTGGTGGCTG	A	291

## (2) INFORMATION FOR SEQ ID NO:175:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 405 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

GTAAGAATT	CTGGGGCCT	CCCGACTCCC	CAATTCTTC	TCTCAAAGCC	CTCACTTTGC	60
CTTACAATCC	TACTCTACCT	TGCACTAGGT	AACAACCATG	TCCGTCTTCC	AAGAGCCTTG	120
GCTGGTTCAT	GCCGACTGTG	GAGCCTGACC	CTACCAGTGG	CTGAGCTGGG	CCTGGGCTAT	180
GCCTCGGAGG	AGAAGGTCA	CTTCCGATA	TGTGCTGGCA	GCTGTCCCCA	AGAGGCCGT	240
ACCCAGCACA	GTCTGGTACT	GGCCCGGCTT	CGAGGGCGGG	GTCGAGCCCA	TGGCCGACCC	300
TGCTGCCAGC	CCACCAGCTA	TGCTGATGTG	ACCTTCCTTG	ATGATCAGCA	CCATTGGCAG	360
CAGCTGCCTC	AGCTCTCAGC	TGCAGCTTGT	GGCTGTGGTG	GCTGA		405

(2) INFORMATION FOR SEQ ID NO:176:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 291 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

GCCTTACCTG	GTTTGTGCCG	GCTGTGGAGC	CTGACCCCTAC	CAGTGGCTGA	GCTTGGCCTG	60
GGCTATGCCT	CAGAGGAGAA	GATTATCTTC	CGATACTGTG	CTGGCAGCTG	TCCCCAAGAG	120
GTCCGTACCC	AGCACAGTCT	GGTGCTGGCC	CGTCTTCGAG	GGCAGGGTCG	AGCTCATGGC	180
AGACCTTGCT	GCCAGCCCAC	CAGCTATGCT	GATGTGACCT	TCCCTTGATGA	CCACCACCAT	240
TGGCAGCAGC	TGCCTCAGCT	CTCAGCCGCA	GCTTGTGGCT	GTGGTGGCTG	A	291

(2) INFORMATION FOR SEQ ID NO:177:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 723 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

ATGGCTGCAG	GAAGACTTCG	GATCCTGTGT	CTGCTGCTCC	TGTCCTTGCA	CCCGAGCCTC	60
GGCTGGGTCC	TTGATCTTCA	AGAGGCTTCT	GTGGCAGATA	AGCTCTCATT	TGGGAAGATG	120
GCAGAGACTA	GAGGGACCTG	GACGCCCAT	CAGGGTAAGA	ATTCCTGGGG	GCCTCCGAC	180
TCCCCAATTC	CTTCTCTCAA	AGCCCTCACT	TTGCCTTACA	ATCCTACTCT	ACCTTGCACT	240
AGGTAACAAC	CATGTCCGTC	TTCCAAGAGC	CTTGGCTGGT	TCATGCCGAC	TGTGGAGCCT	300

189

GACCCTACCA	GTGGCTGAGC	TGGGCCTGGG	CTATGCCCTCG	GAGGAGAAGG	TCATCTTCCG	360
ATACTGTGCT	GGCAGCTGTC	CCCAAGAGGC	CCGTACCCAG	CACAGTCTGG	TACTGGCCCG	420
GCTTCGAGGG	CGGGGTCGAG	CCCATGGCCG	ACCCTGCTGC	CAGCCCACCA	GCTATGCTGA	480
TGTGACCTTC	CTTGATGATC	AGCACCATTG	GCAGCAGCTG	CCTCAGCTCT	CAGCTGCAGC	540
TTGTGGCTGT	GGTGGCTGAA	GGAGGCCAGT	CTGGTGTCTC	AGAACACCAA	GCATGAGACA	600
GGCTGGGCTT	TGAAAGGCTC	AGGTGACATT	ACTAGAAATT	TGCATAGGTA	AAGATAAGAA	660
GGGAAAGGAC	CAGGGTTTT	TTGTTCTTT	CTTGCTTGC	TTGTTAGTTT	TTTTTTTTT	720
TTT						723

## (2) INFORMATION FOR SEQ ID NO:178:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 723 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

TACCGACGTC	CTTCTGAAGC	CTAGGACACA	GACGACGAGG	ACAGGAACGT	GGGCTCGGAG	60
CCGACCCAGG	AACTAGAAGT	TCTCCGAAGA	CACCGTCTAT	TCGAGAGTAA	ACCCTTCTAC	120
CGTCTCTGAT	CTCCCTGGAC	CTGCGGGGTA	GTCCCATTCT	TAAGGACCCC	CGGAGGGCTG	180
AGGGGTTAAG	GAAGAGAGTT	TCGGGAGTGA	AACGGAATGT	TAGGATGAGA	TGGAACGTGA	240
TCCATTGTTG	GTACAGGCAG	AAGGTTCTCG	GAACCGACCA	AGTACGGCTG	ACACCTCGGA	300
CTGGGATGGT	CACCGACTCG	ACCCGGACCC	GATA CGGAGC	CTCCTCTTCC	AGTAGAAGGC	360
TATGACACGA	CCGTCGACAG	GGGTTCTCCG	GGCATGGTC	GTGTCAGACC	ATGACCGGGC	420
CGAAGCTCCC	GCCCCAGCTC	GGGTACCGGC	TGGGACGACG	GTCGGGTGGT	CGATACGACT	480
ACACTGGAAG	GAACTACTAG	TCGTGGTAAC	CGTCGTCGAC	GGAGTCGAGA	GTCGACGTCG	540
AACACCGACA	CCACCGACTT	CCTCCGGTCA	GACCACAGAG	TCTTAGTGT	CGTACTCTGT	600
CCGACCCGAA	ACTTCCGAG	TCCACTGTAA	TGATCTTAA	ACGTATCCAT	TTCTATTCTT	660
CCCTTTCCTG	GTCCCCAAAA	AACAAAGAAA	GAAACGAACG	AACAATCAA	AAAAAAAAAA	720
AAA						723

## (2) INFORMATION FOR SEQ ID NO:179:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

190

ATGGCTGCAG	GAAGACTTCG	GATCCTGTGT	CTGCTGCTCC	TGTCCTTGCA	CCCGAGCCTC	60
GGCTGGTCC	TTGATCTTCA	AGAGGCTTCT	GTGGCAGATA	AGCTCTCATT	TGGGAAGATG	120
GCAGAGACTA	GAGGGACCTG	GACGCCCAT	CAGGGTAACA	ACCATGTCCG	TCTTCCAAGA	180
GCCTGGCTG	GTTCATGCCG	ACTGTGGAGC	CTGACCCTAC	CAGTGGCTGA	GCTGGGCCTG	240
GGCTATGCCT	CGGAGGAGAA	GGTCATCTTC	CGATACTGTG	CTGGCAGCTG	TCCCCAAGAG	300
GCCC GTACCC	AGCACAGTCT	GGTACTGGCC	CGGCTTCGAG	GGCGGGGTG	AGCCCATGGC	360
CGACCCCTGCT	GCCAGCCCAC	CAGCTATGCT	GATGTGACCT	TCCTTGATGA	TCAGCACCCT	420
TGGCAGCAGC	TGCCTCAGCT	CTCAGCTGCA	GCTTGTGGCT	GTGGTGGCTG	A	471

## (2) INFORMATION FOR SEQ ID NO:180:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

TACCGACGTC	CTTCTGAAGC	CTAGGACACA	GACGACGAGG	ACAGGAACGT	GGGCTCGGAG	60
CCGACCCAGG	AACTAGAAGT	TCTCCGAAGA	CACCGTCTAT	TCGAGAGTAA	ACCCTTCTAC	120
CGTCTCTGAT	CTCCCTGGAC	CTGCGGGGTA	GTCCCATTGT	TGGTACAGGC	AGAAGGTTCT	180
CGGAACCGAC	CAAGTACGGC	TGACACCTCG	GACTGGGATG	GTCACCGACT	CGACCCGGAC	240
CCGATACGGA	GCCTCCCTTT	CCAGTAGAACG	GCTATGACAC	GACCGTCGAC	AGGGGTTCTC	300
CGGGCATGGG	TCGTGTCAGA	CCATGACCGG	GCCGAAGCTC	CCGGCCCCAGC	TCGGGTACCG	360
GCTGGGACGA	CGGTGGGTG	GTCGATACGA	CTACACTGGA	AGGAACTACT	AGTCGTGGTA	420
ACCGTCGTCG	ACGGAGTCGA	GAGTCGACGT	CGAACACCGA	CACCACCGAC	T	471

## (2) INFORMATION FOR SEQ ID NO:181:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

ATGGCTGCAG	GAAGACTTCG	GATCCTGTGT	CTGCTGCTCC	TGTCCTTGCA	CCCGAGCCTC	60
GGCTGGTCC	TTGATCTTCA	AGAGGCTTCT	GTGGCAGATA	AGCTCTCATT	TGGGAAGATG	120
GCAGAGACTA	GAGGGACCTG	GACGCCCAT	CAGGGTAACA	ACCATGTCCG	TCTTCCAAGA	180

## (2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 180 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

TACCGACGTC CTTCTGAAGC CTAGGACACA GACGACGGAGG ACAGGAACGT GGGCTCGGAG	60
CCGACCCAGG AACTAGAAAGT TCTCCGAAGA CACCGTCTAT TCGAGAGTAA ACCCTTCTAC	120
CGTCTCTGAT CTCCCTGGAC CTGCGGGTA GTCCCATTGT TGGTACAGGC AGAAGGTTCT	180

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

GCCTTGGCTG GTTCATGCCG ACTGTGGAGC CTGACCCCTAC CAGTGGCTGA GCTGGGCTG	60
GGCTATGCCT CGGAGGAGAA GGTCATCTTC CGATACTGTG CTGGCAGCTG TCCCCAAGAG	120
GCCCCGTACCC AGCACAGTCT GGTACTGGCC CGGCTTCGAG GGCGGGGTG AGCCCATGGC	180
CGACCCCTGCT GCCAGCCAC CAGCTATGCT GATGTGACCT TCCTTGATGA TCAGCACCAT	240
TGGCAGCAGC TGCCTCAGCT CTCAGCTGCA GCTTGTGGCT GTGGTGGCTG A	291

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

CGGAACCGAC CAAGTACGGC TGACACCTCG GACTGGGATG GTCACCGACT CGACCCGGAC	60
CCGATACGGA GCCTCCTCTT CCAGTAGAAC GCTATGACAC GACCGTCGAC AGGGGTTCTC	120
CGGGCATGGG TCGTGTCAAGA CCATGACCGG GCCGAAGCTC CGGCCCGAGC TCGGGTACCG	180
GCTGGGACGA CGGTCGGGTG GTCGATAACGA CTACACTGGA AGGAACTACT AGTCGTGGTA	240
ACCGTCGTGACGAGTCGA GAGTCGACGT CGAACACCGA CACCACCGAC T	291

(2) INFORMATION FOR SEQ ID NO:185:

192

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 156 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

```

Met Ala Ala Gly Arg Leu Arg Ile Leu Cys Leu Leu Leu Ser Leu
1           5           10          15

His Pro Ser Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Ser Val Ala
20          25          30

Asp Lys Leu Ser Phe Gly Lys Met Ala Glu Thr Arg Gly Thr Trp Thr
35          40          45

Pro His Gln Gly Asn Asn His Val Arg Leu Pro Arg Ala Leu Ala Gly
50          55          60

Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu
65          70          75          80

Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser
85          90          95

Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu
100         105         110

Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser
115         120         125

Tyr Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln Gln Leu
130         135         140

Pro Gln Leu Ser Ala Ala Cys Gly Cys Gly Gly
145         150

```

## (2) INFORMATION FOR SEQ ID NO:186:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 60 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

```

Met Ala Ala Gly Arg Leu Arg Ile Leu Cys Leu Leu Leu Ser Leu
1           5           10          15

His Pro Ser Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Ser Val Ala
20          25          30

Asp Lys Leu Ser Phe Gly Lys Met Ala Glu Thr Arg Gly Thr Trp Thr
35          40          45

Pro His Gln Gly Asn Asn His Val Arg Leu Pro Arg
50          55          60

```

## (2) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 96 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

Ala	Leu	Ala	Gly	Ser	Cys	Arg	Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala
1										10					15
Glu	Leu	Gly	Leu	Gly	Tyr	Ala	Ser	Glu	Glu	Lys	Val	Ile	Phe	Arg	Tyr
										25					30
Cys	Ala	Gly	Ser	Cys	Pro	Gln	Glu	Ala	Arg	Thr	Gln	His	Ser	Leu	Val
										40					45
Leu	Ala	Arg	Leu	Arg	Gly	Arg	Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys
										55					60
Gln	Pro	Thr	Ser	Tyr	Ala	Asp	Val	Thr	Phe	Leu	Asp	Asp	Gln	His	His
										65					80
Trp	Gln	Gln	Leu	Pro	Gln	Leu	Ser	Ala	Ala	Ala	Cys	Gly	Cys	Gly	Gly
										85					95

(2) INFORMATION FOR SEQ ID NO:188:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 559 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

ATGGCTGCAG	GAAGACTTCG	GATCTTGT	TT CTGCTGCTCC	TGTCC	TGCA CCTGGCCTT	60
GGCTGGGTCC	TTGATCTTCA	AGAGGCTCCT	GC GG CAGATG	AGCTCTCATC	TGGGAAAATG	120
GCAGAGACTG	GAAGGACCTG	GAAGCCCCAT	CAGGTAAGA	ATTCTTGGGG	GCCTCCTAAC	180
TCTACAGTTC	TTCCCTCTCAA	AGCCCTCACT	TTGCC	TACA ATCCTATTCT	ACCTTGC	240
AGGTAACAAAC	AATGTCCGCC	TTCCAAGAGC	CTTACCTGGT	TTGTGCCGGC	TGTGGAGCCT	300
GACCCTACCA	GTGGCTGAGC	TTGGCCTGGG	CTATGCC	TCA GAGGAGA	TTATCTTCCG	360
ATACTGTGCT	GGCAGCTGTC	CCCAAGAGGT	CCGTACCCAG	CACAGTCTGG	TGCTGGCCCG	420
TCTTCGAGGG	CAGGGTCGAG	CTCATGGCAG	ACCTTGCTGC	CAGCCCACCA	GCTATGCTGA	480
TGTGACCTTC	CTTGATGACC	ACCACCATTG	GCAGCAGCTG	CCTCAGCTCT	CAGCCGCAGC	540
TTGTGGCTGT	GGTGGCTGA					559

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 559 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

TACCGACGTC CTTCTGAAGC CTAGAACAAA GACGACGAGG ACAGGAACGT GGACCCGGAA	60
CCGACCCAGG AACTAGAAGT TCTCCGAGGA CGCCGTCTAC TCGAGAGTAG ACCCTTTAC	120
CGTCTCTGAC CTTCTGGAC CTTCGGGGTA GTCCCATTCT TAAGAACCCCC CGGAGGATTG	180
AGATGTCAAG AAGGAGAGTT TCGGGAGTGA AACGGAGTGT TAGGATAAGA TGGAACGTGA	240
TCCATTGTTG TTACAGGCGG AAGGTTCTCG GAATGGACCA AACACGGCCG ACACCTCGGA	300
CTGGGATGGT CACCGACTCG AACCGGACCC GATACTGGAGT CTCCTCTTCT AATAGAACGC	360
TATGACACGA CCGTCGACAG GGGTTCTCCA GGCATGGGTC GTGTCAGACC ACGACCGGGC	420
AGAAGCTCCC GTCCCAGCTC GAGTACCGTC TGGAACGACG GTCGGGTGGT CGATACGACT	480
ACACTGGAAG GAACTACTGG TGGTGGTAAC CGTCGTCGAC GGAGTCGAGA GTCGGGCTCG	540
AACACCGACA CCACCGACT	559

(2) INFORMATION FOR SEQ ID NO:190:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

ATGGCTGCAG GAAGACTTCG GATCTTGTTC CTGCTGCTCC TGTCTTGCA CCTGGGCCTT	60
GGCTGGGTCC TTGATCTTCA AGAGGCTCCT GCGGCAGATG AGCTCTCATC TGGGAAAATG	120
GCAGAGACTG GAAGGACCTG GAAGCCCCAT CAGGGTAACA ACAATGTCCG CCTTCCAAGA	180
GCCTTACCTG GTTGTGCCG GCTGTGGAGC CTGACCCCTAC CAGTGGCTGA GCTTGGCTG	240
GGCTATGCCT CAGAGGAGAA GATTATCTTC CGATACTGTG CTGGCAGCTG TCCCCAAGAG	300
GTCCGTACCC AGCACAGTCT GGTGCTGCC CGTCTTCGAG GGCAGGGTCG AGCTCATGGC	360
AGACCTTGCT GCCAGCCCAC CAGCTATGCT GATGTGACCT TCCTTGATGA CCACCAACCAT	420
TGGCAGCAGC TGCCCTCAGCT CTCAGCCGCA GCTTGTGGCT GTGGTGGCTG A	471

(2) INFORMATION FOR SEQ ID NO:191:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

TACCGACGTC CTTCTGAAGC CTAGAACAAA GACGACGAGG ACAGGAACGT GGACCCGGAA	60
CCGACCCAGG AACTAGAAGT TCTCCGAGGA CGCCGTCTAC TCGAGAGTAG ACCCTTTTAC	120
CGTCTCTGAC CTTCCTGGAC CTTCGGGTA GTCCCATTGT TGTTACAGGC GGAAGGTTCT	180
CGGAATGGAC CAAACACGGC CGACACCTCG GACTGGGATG GTCACCGACT CGAACCGGAC	240
CCGATAACGGA GTCTCCTCTT CTAATAGAAG GCTATGACAC GACCGTCGAC AGGGGTTCTC	300
CAGGCATGGG TCGTGTCAAGA CCACGACCGG GCAGAAGCTC CCGTCCCAGC TCGAGTACCG	360
TCTGGAACGGA CGGTGGGTG GTCGATACGA CTACACTGGA AGGAACTACT GGTGGTGGTA	420
ACCGTCGTCG ACGGAGTCGA GAGTCGGCGT CGAACACCGA CACCACCGAC T	471

## (2) INFORMATION FOR SEQ ID NO:192:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

ATGGCTGCAG GAAGACTTCG GATCTTGTTC CTGCTGCTCC TGTCCCTTGCA CCTGGGCCTT	60
GGCTGGGTCC TTGATCTTCA AGAGGCTCCT GCGGCAGATG AGCTCTCATC TGGGAAAATG	120
GCAGAGACTG GAAGGACCTG GAAGCCCCAT CAGGGTAACA ACAATGTCCG CCTTCCAAGA	180

## (2) INFORMATION FOR SEQ ID NO:193:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

TACCGACGTC CTTCTGAAGC CTAGAACAAA GACGACGAGG ACAGGAACGT GGACCCGGAA	60
CCGACCCAGG AACTAGAAGT TCTCCGAGGA CGCCGTCTAC TCGAGAGTAG ACCCTTTTAC	120
CGTCTCTGAC CTTCCTGGAC CTTCGGGTA GTCCCATTGT TGTTACAGGC GGAAGGTTCT	180

## (2) INFORMATION FOR SEQ ID NO:194:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 291 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

196

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

GCCTTACCTG GTTGTGCCG GCTGTGGAGC CTGACCCCTAC CAGTGGCTGA GCTTGGCCTG	60
GGCTATGCCT CAGAGGAGAA GATTATCTTC CGATACTGTG CTGGCAGCTG TCCCCAAGAG	120
GTCCGTACCC AGCACAGTCT GGTGCTGGCC CGTCTTCGAG GGCAGGGTCG AGCTCATGGC	180
AGACCTTGCT GCCAGCCCAC CAGCTATGCT GATGTGACCT TCCTTGATGA CCACCACCAT	240
TGGCAGCAGC TGCCTCAGCT CTCAGCCGCA GCTTGTGGCT GTGGTGGCTG A	291

(2) INFORMATION FOR SEQ ID NO:195:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 291 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

CGGAATGGAC CAAACACGGC CGACACCTCG GACTGGGATG GTCACCGACT CGAACCGGAC	60
CCGATACGGA GTCTCCTCTT CTAATAGAAG GCTATGACAC GACCGTGCAC AGGGGTTCTC	120
CAGGCATGGG TCGTGTCAAG CCACGACCGG GCAGAAGCTC CCGTCCCAGC TCGAGTACCG	180
TCTGGAACGA CGGTCGGGTG GTCGATAACGA CTACACTGGA AGGAACTACT GGTGGTGGTA	240
ACCGTCGTCG ACGGAGTCGA GAGTCGGCGT CGAACACCGA CACCAACGAC T	291

(2) INFORMATION FOR SEQ ID NO:196:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 156 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

Met Ala Ala Gly Arg Leu Arg Ile Leu Phe Leu Leu Leu Ser Leu	
1 5 10 15	

His Leu Gly Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Pro Ala Ala	
20 25 30	

Asp Glu Leu Ser Ser Gly Lys Met Ala Glu Thr Gly Arg Thr Trp Lys	
35 40 45	

Pro His Gln Gly Asn Asn Asn Val Arg Leu Pro Arg Ala Leu Pro Gly	
50 55 60	

197

Leu	Cys	Arg	Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala	Glu	Leu	Gly	Leu
65						70					75				80
Gly	Tyr	Ala	Ser	Glu	Glu	Lys	Ile	Ile	Phe	Arg	Tyr	Cys	Ala	Gly	Ser
				85						90				95	
Cys	Pro	Gln	Glu	Val	Arg	Thr	Gln	His	Ser	Leu	Val	Leu	Ala	Arg	Leu
				100					105				110		
Arg	Gly	Gln	Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys	Gln	Pro	Thr	Ser
				115					120				125		
Tyr	Ala	Asp	Val	Thr	Phe	Leu	Asp	Asp	His	His	His	Trp	Gln	Gln	Leu
				130			135					140			
Pro	Gln	Leu	Ser	Ala	Ala	Ala	Cys	Gly	Cys	Gly	Gly				
				145			150				155				

## (2) INFORMATION FOR SEQ ID NO:197:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 60 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

Met	Ala	Ala	Gly	Arg	Leu	Arg	Ile	Leu	Phe	Leu	Leu	Leu	Ser	Leu	
1					5				10				15		
His	Leu	Gly	Leu	Gly	Trp	Val	Leu	Asp	Leu	Gln	Glu	Ala	Pro	Ala	Ala
					20			25					30		
Asp	Glu	Leu	Ser	Ser	Gly	Lys	Met	Ala	Glu	Thr	Gly	Arg	Thr	Trp	Lys
					35			40				45			
Pro	His	Gln	Gly	Asn	Asn	Asn	Val	Arg	Leu	Pro	Arg				
				50			55					60			

## (2) INFORMATION FOR SEQ ID NO:198:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 96 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

Ala	Leu	Pro	Gly	Leu	Cys	Arg	Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala
1					5					10				15	
Glu	Leu	Gly	Leu	Gly	Tyr	Ala	Ser	Glu	Glu	Lys	Ile	Ile	Phe	Arg	Tyr
					20			25					30		
Cys	Ala	Gly	Ser	Cys	Pro	Gln	Glu	Val	Arg	Thr	Gln	His	Ser	Leu	Val
					35			40				45			
Leu	Ala	Arg	Leu	Arg	Gly	Gln	Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys
					50			55				60			

198

Gln	Pro	Thr	Ser	Tyr	Ala	Asp	Val	Thr	Phe	Leu	Asp	Asp	His	His	His
65					70					75			80		
Trp	Gln	Gln	Leu	Pro	Gln	Leu	Ser	Ala	Ala	Ala	Cys	Gly	Cys	Gly	Gly
					85					90			95		

## (2) INFORMATION FOR SEQ ID NO:199:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

GCCCTGTCTG	GTCCATGCCA	GCTGTGGAGC	CTGACCCCTGT	CCGTGGCAGA	GCTAGGCCTG	60
GGCTACGCT	CAGAGGAGAA	GGTCATCTTC	CGCTACTGCG	CCGGCAGCTG	CCCCCGTGGT	120
GCCCCGACCC	AGCATGGCCT	GGCGCTGGCC	CGGCTGCAGG	GCCAGGGCCG	AGCCCACGGT	180
GGGGCCCTGCT	GCCGGCCCAC	TCGCTACACC	GACGTGGCCT	TCCTCGATGA	CCGCCACCGC	240
TGGCAGCGGC	TGCCCCAGCT	CTCGGCGGCT	GCCTGCGGCT	GTGGTGGCTG	A	291

## (2) INFORMATION FOR SEQ ID NO:200:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

CGGGGACAGAC	CAGGTACGGT	CGACACCTCG	GACTGGGACA	GGCACCGTCT	CGATCCGGAC	60
CCGATGCGGA	GTCTCCTCTT	CCAGTAGAACG	GCGATGACGC	GGCCGTCGAC	GGGGGCACCA	120
CGGGCGTGGG	TCGTACCGGA	CCGCGACCGG	GCCGACGTCC	CGGTCCCGGC	TGGGGTGCCA	180
CCCGGGACGA	CGGCCGGGTG	AGCGATGTGG	CTGCACCGGA	AGGAGCTACT	GGCGGTGGCG	240
ACCGTCGCCG	ACGGGGTCGA	GAGCCGCCGA	CGGACGCCGA	CACCACCGAC	T	291

## (2) INFORMATION FOR SEQ ID NO:201:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

199

GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCCTGT CCGTGGCAGA GCTAGGCCTG	60
GGCTACGCCT CAGAGGGAGAA GGTCACTCTTC CGCTACTGCG CGGGCAGCTG CCCCCGTGGT	120
GCCCCCACCC AGCATGGCCT GGCGCTGGCC CGGCTGCAGG GCCAGGGCCG AGCCCACGGC	180
GGGCCCTGCT GCCGGCCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC	240
TGGCAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A	291

## (2) INFORMATION FOR SEQ ID NO:202:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 291 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

CGGGACAGAC CAGGTACGGT CGACACCTCG GACTGGGACA GGCACCGTCT CGATCCGGAC	60
CCGATGCAGGA GTCTCCTCTT CCAGTAGAAG GCGATGACGC GGCGTGCAC GGGGGCACCA	120
CGGGCGTGGG TCGTACCGGA CCGCGACCGG GCCGACGTCC CGGTCCCAGG TCGGGTGCCG	180
CCCGGGACGA CGGCCGGGTG AGCGATGTGG CTGCACCGGA AGGAGCTACT GGCGGTGCCG	240
ACCGTCGCCG ACGGGGTCGA GAGCCGCCGA CGGACGCCGA CACCACCGAC T	291

## (2) INFORMATION FOR SEQ ID NO:203:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

ATGGCCGTAG GGAAGTTCTT GCTGGGCTCT CTGCTGCTCC TGTCCCTGCA GCTGGGACAG	60
GGCTGGGCC CCGATGCCCG TGGGGTTCCC GTGGCGATG GAGAGTTCTC GTCTGAACAG	120
GTGGCAAAGG CTGGAGGGAC CTGGCTGGC ACCCACCGCC CCCTTGCCCG CCTGCGCCGA	180
GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCCTGT CCGTGGCAGA GCTAGGCCTG	240
GGCTACGCCT CAGAGGGAGAA GGTCACTCTTC CGCTACTGCG CGGGCAGCTG CCCCCGTGGT	300
GCCCCCACCC AGCATGGCCT GGCGCTGGCC CGGCTGCAGG GCCAGGGCCG AGCCCACGGT	360
GGGCCCTGCT GCCGGCCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC	420
TGGCAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A	471

## (2) INFORMATION FOR SEQ ID NO:204:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid

200

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

TACCGGGCATC CCTTCAAGGA CGACCCGAGA GACGACGAGG ACAGGGACGT CGACCCTGTC	60
CCGACCCCCGG GGCTACGGGC ACCCCAAGGG CACCGGCTAC CTCTCAAGAG CAGACTTGTC	120
CACCGTTTCC GACCTCCCTG GACCGACCCG TGGGTGGCGG GGGAACGGGC GGACCGGGCT	180
CGGGACAGAC CAGGTACGGT CGACACCTCG GACTGGGACA GGCACCGTCT CGATCCGGAC	240
CCGATGCCGA GTCTCCTCTT CCAGTAGAAAG GCGATGACGC GGCGTGCAC GGGGCACCA	300
CGGGCGTGGG TCGTACCGGA CCGCGACCGG GCCGACGTCC CGGTCCCAGG TCGGGTGCCA	360
CCCGGGACGA CGGCCGGGTG AGCGATGTGG CTGCACCGGA AGGAGCTACT GGCGGTGGCG	420
ACCGTCGCCG ACGGGGTCGA GAGCCGCCGA CGGACGCCGA CACCACCGAC T	471

(2) INFORMATION FOR SEQ ID NO:205:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

ATGGCCGTAG GGAAGTTCTT GCTGGGCTCC CTGCTGCTCC TGTCCCTGCA GCTGGGACAG	60
GGCTGGGCC CCGATGCCCG TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTGAACAG	120
GTGGCAAAGG CTGGAGGGAC CTGGCTGGGC ACCCACCGCC CCCTTGCCCG CCTGCGCCGA	180
GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCCTGT CCGTGGCAGA GCTAGGCCTG	240
GGCTACGCCCT CAGAGGAGAA GGTCATCTTC CGCTACTGCG CGGGCAGCTG CCCCGTGGT	300
GCCCCGACCC AGCATGGCCT GGCGCTGCC CGGCTGCAGG GCCAGGGCCG AGCCCACGGC	360
GGGCCCTGCT GCCGGCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC	420
TGGCAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A	471

(2) INFORMATION FOR SEQ ID NO:206:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

201

TACCGGCATC CCTTCAAGGA CGACCCGAGG GACGACGAGG ACAGGGACGT CGACCCTGTC	60
CCGACCCCCGG GGCTACGGGC ACCCCAAGGG CACCGGCTAC CTCTCAAGAG CAGACTTGTC	120
CACCGTTTCC GACCTCCCTG GACCGACCCG TGGGTGGCGG GGGAACGGGC GGACGCGGCT	180
CGGGACAGAC CAGGTACGGT CGACACCTCG GACTGGGACA GGACCGTCT CGATCCGGAC	240
CCGATGCGGA GTCTCCTCTT CCAGTAGAAG GCGATGACGC GGCGTCGAC GGGGGCACCA	300
CGGGCGTGGG TCGTACCGGA CCGCGACCGG GCCGACGTCC CGGTCCCGGC TCGGGTGCCG	360
CCCGGGACGA CGGCCGGGTG AGCGATGTGG CTGCACCGGA AGGAGCTACT GGCGGTGGCG	420
ACCGTCGCCG ACGGGGTCGA GAGCCGCCGA CGGACGCCGA CACCACCGAC T	471

## (2) INFORMATION FOR SEQ ID NO:207:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

ATGGCCGTAG GGAAGTTCTT GCTGGGCTCT CTGCTGCTCC TGTCCCTGCA GCTGGGACAG	60
GGCTGGGGC	69

## (2) INFORMATION FOR SEQ ID NO:208:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

TACCGGCATC CCTTCAAGGA CGACCCGAGA GACGACGAGG ACAGGGACGT CGACCCTGTC	60
CCGACCCCCG	69

## (2) INFORMATION FOR SEQ ID NO:209:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

ATGGCCGTAG GGAAGTTCTT GCTGGGCTCC CTGCTGCTCC TGTCCCTGCA GCTGGGACAG	60
---	----

202

GGCTGGGGC

69

## (2) INFORMATION FOR SEQ ID NO:210:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 69 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

TACCGGCATC CCTTCAAGGA CGACCCGAGG GACGACGAGG ACAGGGACGT CGACCCCTGTC

60

CCGACCCCG

69

## (2) INFORMATION FOR SEQ ID NO:211:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 111 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

CCCGATGCC C GTGGGTTCC CGTGGCCGAT GGAGAGTTCT CGTCTGAACA GGTGGCAAAG

60

GCTGGAGGGA CCTGGCTGGG CACCCACCGC CCCCTTGCCC GCCTGCGCCG A

111

## (2) INFORMATION FOR SEQ ID NO:212:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 111 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

GGGCTACGGG CACCCCAAGG GCACCGGCTA CCTCTCAAGA GCAGACTTGT CCACCGTTTC

60

CGACCTCCCT GGACCGACCC GTGGGTGGCG GGGGAACGGG CGGACGCGGC T

111

## (2) INFORMATION FOR SEQ ID NO:213:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 180 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

203

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

ATGGCCGTAG GGAAGTTCT GCTGGGCTCT CTGCTGCTCC TGTCCCTGCA GCTGGGACAG	60
GGCTGGGGCC CCGATGCCCG TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTAACAG	120
GTGGCAAAGG CTGGAGGGAC CTGGCTGGC ACCCACCGCC CCCTTGCCCCG CCTGCCCGA	180

## (2) INFORMATION FOR SEQ ID NO:214:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

TACCGGCATC CCTTCAAGGA CGACCCGAGA GACGACGAGG ACAGGGACGT CGACCCTGTC	60
CCGACCCCCGG GGCTACGGGC ACCCCAAGGG CACCGGCTAC CTCTCAAGAG CAGACTTGTC	120
CACCGTTTCC GACCTCCCTG GACCGACCCG TGGGTGGCGG GGGAACGGGC GGACGCGGCT	180

## (2) INFORMATION FOR SEQ ID NO:215:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

ATGGCCGTAG GGAAGTTCT GCTGGGCTCC CTGCTGCTCC TGTCCCTGCA GCTGGGACAG	60
GGCTGGGGCC CCGATGCCCG TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTAACAG	120
GTGGCAAAGG CTGGAGGGAC CTGGCTGGC ACCCACCGCC CCCTTGCCCCG CCTGCCCGA	180

## (2) INFORMATION FOR SEQ ID NO:216:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

TACCGGCATC CCTTCAAGGA CGACCCGAGG GACGACGAGG ACAGGGACGT CGACCCTGTC	60
CCGACCCCCGG GGCTACGGGC ACCCCAAGGG CACCGGCTAC CTCTCAAGAG CAGACTTGTC	120

CACCGTTTCC GACCTCCCTG GACCGACCCG TGGGTGGCGG GGGAACGGGC GGACGCGGCT 180

(2) INFORMATION FOR SEQ ID NO:217:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 156 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

Met Ala Val Gly Lys Phe Leu Leu Gly Ser Leu Leu Leu Leu Ser Leu			
1	5	10	15
Gln Leu Gly Gln Gly Trp Gly Pro Asp Ala Arg Gly Val Pro Val Ala			
20	25	30	
Asp Gly Glu Phe Ser Ser Glu Gln Val Ala Lys Ala Gly Gly Thr Trp			
35	40	45	
Leu Gly Thr His Arg Pro Leu Ala Arg Leu Arg Arg Ala Leu Ser Gly			
50	55	60	
Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu			
65	70	75	80
Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser			
85	90	95	
Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu			
100	105	110	
Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg			
115	120	125	
Tyr Thr Asp Val Ala Phe Leu Asp Asp Arg His Arg Trp Gln Arg Leu			
130	135	140	
Pro Gln Leu Ser Ala Ala Cys Gly Cys Gly Gly			
145	150	155	

(2) INFORMATION FOR SEQ ID NO:218:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 60 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

Met Ala Val Gly Lys Phe Leu Leu Gly Ser Leu Leu Leu Ser Leu			
1	5	10	15
Gln Leu Gly Gln Gly Trp Gly Pro Asp Ala Arg Gly Val Pro Val Ala			
20	25	30	
Asp Gly Glu Phe Ser Ser Glu Gln Val Ala Lys Ala Gly Gly Thr Trp			
35	40	45	

205

Leu Gly Thr His Arg Pro Leu Ala Arg Leu Arg Arg  
50 55 60

## (2) INFORMATION FOR SEQ ID NO:219:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

Met Ala Val Gly Lys Phe Leu Leu Gly Ser Leu Leu Leu Ser Leu  
1 5 10 15

Gln Leu Gly Gln Gly Trp Gly  
20

## (2) INFORMATION FOR SEQ ID NO:220:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 37 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

Pro Asp Ala Arg Gly Val Pro Val Ala Asp Gly Glu Phe Ser Ser Glu  
1 5 10 15

Gln Val Ala Lys Ala Gly Gly Thr Trp Leu Gly Thr His Arg Pro Leu  
20 25 30

Ala Arg Leu Arg Arg  
35

## (2) INFORMATION FOR SEQ ID NO:221:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 96 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
1 5 10 15

Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
20 25 30

Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
35 40 45

206

Leu	Ala	Arg	Leu	Gln	Gly	Gln	Gly	Arg	Ala	His	Gly	Gly	Pro	Cys	Cys
50						55					60				
Arg	Pro	Thr	Arg	Tyr	Thr	Asp	Val	Ala	Phe	Leu	Asp	Asp	Arg	His	Arg
65					70					75				80	
Trp	Gln	Arg	Leu	Pro	Gln	Leu	Ser	Ala	Ala	Ala	Cys	Gly	Cys	Gly	Gly
										90				95	

## (2) INFORMATION FOR SEQ ID NO:222:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 91 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

Cys	Gln	Leu	Trp	Ser	Leu	Thr	Leu	Ser	Val	Ala	Glu	Leu	Gly	Leu	Gly
1						5					10			15	
Tyr	Ala	Ser	Glu	Glu	Lys	Val	Ile	Phe	Arg	Tyr	Cys	Ala	Gly	Ser	Cys
						20			25		30				
Pro	Arg	Gly	Ala	Arg	Thr	Gln	His	Gly	Leu	Ala	Leu	Ala	Arg	Leu	Gln
						35			40		45				
Gly	Gln	Gly	Arg	Ala	His	Gly	Gly	Pro	Cys	Cys	Arg	Pro	Thr	Arg	Tyr
					50			55		60					
Thr	Asp	Val	Ala	Phe	Leu	Asp	Asp	Arg	His	Arg	Trp	Gln	Arg	Leu	Pro
						65			70		75		80		
Gln	Leu	Ser	Ala	Ala	Ala	Cys	Gly	Cys	Gly	Gly					
						85			90						

## (2) INFORMATION FOR SEQ ID NO:223:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 89 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

Cys	Gln	Leu	Trp	Ser	Leu	Thr	Leu	Ser	Val	Ala	Glu	Leu	Gly	Leu	Gly
1						5					10			15	
Tyr	Ala	Ser	Glu	Glu	Lys	Val	Ile	Phe	Arg	Tyr	Cys	Ala	Gly	Ser	Cys
						20			25		30				
Pro	Arg	Gly	Ala	Arg	Thr	Gln	His	Gly	Leu	Ala	Leu	Ala	Arg	Leu	Gln
						35			40		45				
Gly	Gln	Gly	Arg	Ala	His	Gly	Gly	Pro	Cys	Cys	Arg	Pro	Thr	Arg	Tyr
					50			55		60					

207

Thr Asp Val Ala Phe Leu Asp Asp Arg His Arg Trp Gln Arg Leu Pro  
65 70 75 80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
85

## (2) INFORMATION FOR SEQ ID NO:224:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:

Ala Leu Ser Gly Pro  
1 5

## (2) INFORMATION FOR SEQ ID NO:225:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

GTSASYGASY TGGGYCTGGG CTAY

24

## (2) INFORMATION FOR SEQ ID NO:226:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

TTYMGSTACT GCRSMGGCKC YTGC

24

## (2) INFORMATION FOR SEQ ID NO:227:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

208

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

RWAGGCSRTS GKGCKGCARC AKGS

24

(2) INFORMATION FOR SEQ ID NO:228:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

MKCRTCYARR AASGACASST C

21

(2) INFORMATION FOR SEQ ID NO:229:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 168 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

CGGCTTGTGA CCGAGCTGGG CCTGGGCTAC GCCTCAGAGG AGAAGGTCA	60
TGCGCCGGCA GCTGCCCG TGCTGCCGC ACCCAGCATG GCCTGGCGCT GGCCCGGCTG	120
CAGGGCCAGG GCCGAGCCCA CGGCGGGCCC TGCTGCCGCC CCATGGCC	168

(2) INFORMATION FOR SEQ ID NO:230:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

GAGGAGAAGG TCATCTTCCG

20

(2) INFORMATION FOR SEQ ID NO:231:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

209

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

CCCGTGGGCT CGGCCCTGGC

20

(2) INFORMATION FOR SEQ ID NO:232:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

AGAGGGAGAAG GTCATCTTCC GCTA

24

(2) INFORMATION FOR SEQ ID NO:233:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

CTCGGCCCCTG GCCCTGCAGC

20

(2) INFORMATION FOR SEQ ID NO:234:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

TGCAGCCGGG CCAGCGCCAG

20

(2) INFORMATION FOR SEQ ID NO:235:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

CGCGGATCCA TGCCTGGATT CGAGGGTGCA G

31

210

## (2) INFORMATION FOR SEQ ID NO:236:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

CGCGGATCCA TGGCCGTAGG GAAGTTCCTG C

31

## (2) INFORMATION FOR SEQ ID NO:237:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 60 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

CTCCCAAGCT TTTACTTGTC ATCGTCGTCC TTGTAGTCGC CACCACAGCC GCAGGCAGCC

60

## (2) INFORMATION FOR SEQ ID NO:238:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 59 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

CTCCCAAGCT TTTACTTGTC ATCGTCGTCC TTGTAGTCGC GAGGAAGGCC ACGTCGGTG

59

## (2) INFORMATION FOR SEQ ID NO:239:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

TCAGCCACCA CAGCCGCAGG CAGCC

25

## (2) INFORMATION FOR SEQ ID NO:240:

211

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 70 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:

CATAAAATAG GTGTGGAGTC GCAAAAAGTT TAAAGAAGAG AAAGGAACCA GAAAAAAA	60
TAGAAAGCGC	70

- (2) INFORMATION FOR SEQ ID NO:241:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 69 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:

CATAAAATAG GTGTGGAGTC GCGAAAAGTT TAAAGAGAGT AAGGAACCAG AAAAAAAAAT	60
AGAAAGCGC	69

- (2) INFORMATION FOR SEQ ID NO:242:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 68 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

CATAAAATAG GTGTGGAGTC GCGAAGTTA AAGAGAGTAA GGAACCAGAA AAAAAAAATA	60
GAAAGCGC	68

What is Claimed is:

1. An isolated and purified growth factor comprising persephin or fragment thereof or conservatively substituted variant thereof.
2. The isolated and purified growth factor of claim 1 comprising a polypeptide sequence which has at least about 75% sequence identity with SEQ ID NO:79, SEQ ID NO:82 or SEQ ID NO:223 or conservatively substituted variants thereof.
3. The isolated and purified growth factor of claim 2 comprising a polypeptide sequence as set forth in SEQ ID NO:187, SEQ ID NO:198, SEQ ID NO:221 or conservatively substituted variants thereof.
4. The isolated and purified growth factor of claim 3 which promotes survival in mesencephalic cells.
5. An isolated and purified polypeptide comprising:
  - (a) a pre-pro persephin as set forth in SEQ ID NO:217, SEQ ID NO:185, or SEQ ID NO:196;
  - 5 (b) a prepro- region of persephin as set forth in SEQ ID NO:218, SEQ ID NO:186, or SEQ ID NO:197;
  - (c) a pre- region of persephin as set forth in SEQ ID NO:219;
  - (d) a pro- region of persephin as set forth in SEQ 10 ID NO:220; or
  - (e) conservatively substituted variants thereof.
6. The isolated and purified growth factor of claim 1 comprising a polypeptide containing a sequence of amino acids having at least about 65% sequence identity with SEQ ID NO:79 or SEQ ID NO:82, or SEQ ID NO:223 5 wherein the growth factor is from a non-mammalian species.
7. A method for obtaining a neuritin-persephin-GDNF family member growth factor comprising:
  - (a) isolating (1) from a human genomic or cDNA library, a clone that hybridizes with a polynucleotide

5 comprising a persephin, neurturin or GDNF sequence or  
fragments thereof or (2) from a human genomic or cDNA  
template, a clone using a polymerase chain reaction  
method with degenerate primers of a conserved region of  
any two of persephin, neurturin or GDNF or fragments of  
10 said conserved regions; and

(b) sequencing said clone.

8. An isolated and purified growth factor that is  
a neurturin-persephin-GDNF family member comprising a  
polypeptide having between about 30% and about 75%  
sequence identity with persephin, between about 30% and  
5 about 75% sequence identity with neurturin and between  
about 30% and about 75% sequence identity with GDNF  
wherein said factor is comprised of a conserved region  
sequence of amino acids having at least a 62.5 percent  
sequence identity with SEQ ID NO:108 or at least a 62.5  
10 percent sequence identity with SEQ ID NO:109 or at least  
a 50 percent sequence identity with SEQ ID NO:110.

13. A pan-growth factor comprising a fragment of  
the persephin polypeptide according to claim 1 and a  
fragment of at least one growth factor from the TGF- $\beta$   
superfamily other than persephin.

14. An isolated and purified nucleic acid molecule  
or nucleic acid molecule complementary thereto comprising  
a nucleotide sequence encoding a growth factor of claim 1  
or a fragment of said nucleotide sequence consisting of  
5 at least 15 contiguous nucleotides.

15. The isolated and purified nucleic acid  
molecule or nucleic acid molecule complementary thereto  
of claim 14 comprising a nucleotide sequence encoding a  
persephin polypeptide that promotes survival in  
5 mesencephalic cells wherein said nucleic acid molecule or  
complement thereto specifically hybridizes to SEQ ID  
NO:183, SEQ ID NO:184, SEQ ID NO:194, SEQ ID NO:195, SEQ  
ID NO:199, SEQ ID NO:200, SEQ ID NO:201, or SEQ ID  
NO:202.

16. The isolated and purified nucleic acid molecule or nucleic acid molecule complementary thereto of claim 15 comprising SEQ ID NO:183, SEQ ID NO:194, SEQ ID NO:199 or SEQ ID NO:201.

17. A vector comprising expression regulatory elements operably linked to a nucleic acid molecule of claim 14.

18. A host cell transformed with the vector of claim 17.

19. An isolated and purified nucleic acid molecule comprising:

(a) a pre-pro persephin nucleotide sequence as set forth in SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ 5 ID NO:191, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, or SEQ ID NO:206 or a polynucleotide that specifically hybridizes to SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, or SEQ ID NO:206;

10 (b) a pre-pro region of a persephin polynucleotide as set forth in SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, or SEQ ID NO:216;

15 (c) a pre- region of a persephin polynucleotide as set forth in SEQ ID NOS:207, SEQ ID NO:208, SEQ ID NO:209, or SEQ ID NO:210;

(d) a pro- region of a persephin polynucleotide as set forth in SEQ ID NO:211, or SEQ ID NO:212; or

20 (e) fragment thereof comprising at least 15 contiguous nucleotides.

20. A recombinant method comprising:

(a) subcloning a polynucleotide encoding the growth factor of claim 1 into an expression vector comprising regulatory elements operably linked to the 5 polynucleotide;

(b) transforming a host cell with the expression vector;

(c) growing the host cell in a host cell culture;  
and

(d) harvesting the growth factor and/or the polynucleotide from the host cell culture.

21. Isolated and purified antibodies which are capable of reacting with a growth factor as defined in claim 1 or an epitope thereof.

22. A method for detecting the presence of a growth factor in a sample from a patient comprising reacting antibodies according to claim 21 with a growth factor present in the sample and detecting a binding of  
5 the antibodies with the growth factor.

23. A kit for detecting the presence of a growth factor in a sample from a patient comprising antibodies of claim 21 which are capable of detectably reacting with said growth factor, packaged in a container.

24. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising administering to the individual a therapeutically effective amount of the growth factor of claim 1 or a  
5 polynucleotide encoding the growth factor of claim 1.

25. The method of claim 24 wherein the cellular degeneration or insufficiency is (a) neuronal degeneration resulting from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease,  
5 Parkinson's disease, Huntington's disease, Ischemic stroke, acute brain injury, acute spinal cord injury, nervous system tumors, multiple sclerosis, or infection;  
(b) hematopoietic cell degeneration or insufficiency resulting from eosinopenia, basopenia, lymphopenia,  
10 moncytopenia, neutropenia, anemias, thrombocytopenia, or stem-cell insufficiencies therefor; or (c) cardiac muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure.

26. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising

implanting into the individual, cells that express the growth factor of claim 1.

27. A method for detecting the presence of a growth factor in a sample from a patient comprising detecting and/or quantitating the presence in the sample of mRNA encoding a growth factor of claim 1.

28. A method for detecting persephin gene alterations comprising detecting the presence of a non-intact persephin gene in a cell wherein presence of the non-intact gene indicates the presence of gene

5 alterations.

29. A method for promoting the growth and/or differentiation of a cell in a culture medium comprising adding to the culture medium the growth factor of claim 1.

30. An isolated and purified persephin antisense polynucleotide comprising a sequence complementary to a nucleic acid sequence of claim 14 and capable of hybridizing to a naturally-occurring DNA or mRNA  
5 polynucleotide sequence encoding persephin to prevent transcription and/or translation of an encoded persephin polypeptide.

31. A method for treating a disease condition mediated by expression of persephin by a population of cells comprising administering to said cells an inhibitory effective amount of the antisense  
5 polynucleotide of claim 30.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/19163

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/399, 387.1; 435/69.4, 69.7, 325, 252.3, 320.1, 6, 7.1, 91.2; 536/23.51, 24.1, 24.31; 514/12, 44; 424/93.21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, IntelliGenetics

search terms: persephin, GDNF, neuritin, glia# derived neurotrophic factor#

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---	WO 93/06116 A1 (SYNTEX-SYNERGEN NEUROSCIENCE JOINT VENTURE) 01 April 1993, see entire document, especially pages 16, 20, 35 and Figures 13-14, 19 and 22.	1, 7-8 and 13-20 ----- 2-6 and 21-31
X ---	WATABE et al. Spontaneously Immortalized Adult Mouse Schwann Cells Secrete Autocrine and Paracrine Growth-Promoting Activities. Journal of Neuroscience Research. 01 June 1995, Vol. 41, No. 2, pages 279-290, especially pages 281-282 and 287.	1, 7-8 and 13-20 ----- 2-6 and 21-31

 Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 DECEMBER 1998

Date of mailing of the international search report

26 JAN 1999


Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT C. HAYES, PH.D.

Telephone No. (703) 308-0196



## INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/19163
---

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- A	SPRINGER et al. CDNA Sequence and Differential mRNA Regulation of Two Forms of Glial Cell Line-Derived Neurotrophic Factor in Schwann Cells and Rat Skeletal Muscle. Experimental Neurology. January 1995, Vol. 131, No. 1, pages 47-52, especially pages 48 and 50.	1, 7-8 and 13-20 ----- 2-6 and 21-31
X --- A	WO 95/17203 A1 (THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY) 29 June 1995, see entire document.	1, 7-8 and 13-20 ----- 2-6 and 21-31
X --- A	KOTZBAUER et al. Neurturin, a Relative of Glial-Cell- Line-Derived Neurotrophic Factor. Nature. 05 December 1996, Vol. 384, No. 6608, pages 467-470, see entire document.	1, 7-8 and 13-20 ----- 2-6 and 21-31
A	TRUPP et al. Peripheral Expression and Biological Activities of GDNF, a New Neurotrophic Factor for Avian and Mammalian Peripheral Neurons. The Journal of Cell Biology. July 1995, Vol. 130, No. 1, pages 137-148, see entire document.	1-8 and 13-31

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US98/19163**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**  

The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US98/19163**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6): C07K 14/475, 16/26; C12N 15/18, 15/85, 15/63; C07H 21/00; A61K 38/18, 48/00; C12Q 1/68; G01N 33/53; C12P 19/34

**A. CLASSIFICATION OF SUBJECT MATTER:**

US CL : 530/399, 387.1; 435/69.4, 69.7, 325, 252.3, 320.1, 6, 7.1, 91.2; 536/23.51, 24.1, 24.31; 514/12, 44; 424/93.21

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-6, 8 and 13, drawn to growth factors that include persephin, neuritin-persephin-GDNF family members, pan-growth factors, and fragments thereof.

Group II, claim(s) 7 and 14-20, drawn to nucleic acids encoding a neuritin-persephin-GDNF family member or pan-growth factor, vectors, host cells, and methods of producing these growth factors.

Group III, claim(s) 21, drawn to antibodies of persephin.

Group IV, claim(s) 22, drawn to methods of detecting persephin in a sample comprising use of antibodies, and kits thereof.

Group V, claim(s) 24-25 and 29, drawn to methods of preventing/treating cellular degeneration comprising administering to a patient a therapeutically effective amount of persephin, and *in vitro* methods of promoting growth using the persephin polypeptide.

Group VI, claim(s) 24-26 and 30-31, drawn to gene and cell therapy methods of preventing/treating cellular degeneration comprising administration of persephin nucleic acid molecules or implanting cells expressing such, as well as the antisense RNA polynucleotides for use in such methods.

Group VII, claim(s) 27-28, drawn to methods of detecting persephin in a sample comprising detecting nucleic acid molecules.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I is directed to growth factors that include persephin, neuritin-persephin-GDNF family members, pan-growth factors, and fragments thereof, which is the first product. However, because SYNTEX-SYNERGEN NEUROSCIENCE JOINT VENTURE (WO 93/06116) teach growth factors that show sufficient homology to anticipate the persephin polypeptide, as claimed, which further possess persephin's ability to increase survival of dopaminergic neurons, no special technical feature exists for Group I as defined by PCT Rule 13.2, because it does not define a contribution over the prior art. Moreover, Groups I-III and VI are drawn to a structurally different products, which do not require each other for their practice and do not share the same or a corresponding technical feature. The technical features of Groups IV-VII are also drawn to methods having different goals, method steps and starting materials, which do not require each other for their practice and do not share the same or a corresponding technical feature. Note that PCT Rule 13 does not provide for multiple products or methods within a single application. Because the technical feature of Group I is not a special technical feature, and because the technical features of the Group II-VII inventions are not present in the Group I claims, unity of invention is lacking.